<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6032166</article-id><article-id pub-id-type="doi">10.3390/ijms19061578</article-id><article-id pub-id-type="publisher-id">ijms-19-01578</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3152-5817</contrib-id><name><surname>Thomford</surname><given-names>Nicholas Ekow</given-names></name><xref ref-type="aff" rid="af1-ijms-19-01578">1</xref><xref ref-type="aff" rid="af2-ijms-19-01578">2</xref><xref ref-type="author-notes" rid="fn1-ijms-19-01578">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Senthebane</surname><given-names>Dimakatso Alice</given-names></name><xref ref-type="aff" rid="af3-ijms-19-01578">3</xref><xref ref-type="aff" rid="af4-ijms-19-01578">4</xref></contrib><contrib contrib-type="author"><name><surname>Rowe</surname><given-names>Arielle</given-names></name><xref ref-type="aff" rid="af3-ijms-19-01578">3</xref></contrib><contrib contrib-type="author"><name><surname>Munro</surname><given-names>Daniella</given-names></name><xref ref-type="aff" rid="af1-ijms-19-01578">1</xref></contrib><contrib contrib-type="author"><name><surname>Seele</surname><given-names>Palesa</given-names></name><xref ref-type="aff" rid="af5-ijms-19-01578">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7965-3415</contrib-id><name><surname>Maroyi</surname><given-names>Alfred</given-names></name><xref ref-type="aff" rid="af6-ijms-19-01578">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1334-4665</contrib-id><name><surname>Dzobo</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="af3-ijms-19-01578">3</xref><xref ref-type="aff" rid="af4-ijms-19-01578">4</xref><xref rid="c1-ijms-19-01578" ref-type="corresp">*</xref><xref ref-type="author-notes" rid="fn1-ijms-19-01578">&#x02020;</xref></contrib></contrib-group><aff id="af1-ijms-19-01578"><label>1</label>Pharmacogenomics and Drug Metabolism Group, Division of Human Genetics, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa; <email>nicholas.thomford@uct.ac.za</email> (N.E.T.); <email>MNRDAN002@myuct.ac.za</email> (D.M.)</aff><aff id="af2-ijms-19-01578"><label>2</label>School of Medical Sciences, University of Cape Coast, PMB, Cape Coast, Ghana</aff><aff id="af3-ijms-19-01578"><label>3</label>International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town Component, Wernher and Beit Building (South), University of Cape Town Medical Campus, Anzio Road, Observatory, Cape Town 7925, South Africa; <email>SNTDIM001@myuct.ac.za</email> (D.A.S.); <email>arielle.rowe@icgeb.org</email> (A.R.)</aff><aff id="af4-ijms-19-01578"><label>4</label>Division of Medical Biochemistry and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa</aff><aff id="af5-ijms-19-01578"><label>5</label>Division of Chemical and Systems Biology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa; <email>SLXPAL001@myuct.ac.za</email></aff><aff id="af6-ijms-19-01578"><label>6</label>Department of Botany, University of Fort Hare, Private Bag, Alice X1314, South Africa; <email>amaroyi@ufh.ac.za</email></aff><author-notes><corresp id="c1-ijms-19-01578"><label>*</label>Correspondence: <email>kd.dzobo@uct.ac.za</email>; Tel.: +27-21-404-7689; Fax: +27-21-406-6060</corresp><fn id="fn1-ijms-19-01578"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>25</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2018</year></pub-date><volume>19</volume><issue>6</issue><elocation-id>1578</elocation-id><history><date date-type="received"><day>27</day><month>4</month><year>2018</year></date><date date-type="accepted"><day>18</day><month>5</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The therapeutic properties of plants have been recognised since time immemorial. Many pathological conditions have been treated using plant-derived medicines. These medicines are used as concoctions or concentrated plant extracts without isolation of active compounds. Modern medicine however, requires the isolation and purification of one or two active compounds. There are however a lot of global health challenges with diseases such as cancer, degenerative diseases, HIV/AIDS and diabetes, of which modern medicine is struggling to provide cures. Many times the isolation of &#x0201c;active compound&#x0201d; has made the compound ineffective. Drug discovery is a multidimensional problem requiring several parameters of both natural and synthetic compounds such as safety, pharmacokinetics and efficacy to be evaluated during drug candidate selection. The advent of latest technologies that enhance drug design hypotheses such as Artificial Intelligence, the use of &#x02018;organ-on chip&#x02019; and microfluidics technologies, means that automation has become part of drug discovery. This has resulted in increased speed in drug discovery and evaluation of the safety, pharmacokinetics and efficacy of candidate compounds whilst allowing novel ways of drug design and synthesis based on natural compounds. Recent advances in analytical and computational techniques have opened new avenues to process complex natural products and to use their structures to derive new and innovative drugs. Indeed, we are in the era of computational molecular design, as applied to natural products. Predictive computational softwares have contributed to the discovery of molecular targets of natural products and their derivatives. In future the use of quantum computing, computational softwares and databases in modelling molecular interactions and predicting features and parameters needed for drug development, such as pharmacokinetic and pharmacodynamics, will result in few false positive leads in drug development. This review discusses plant-based natural product drug discovery and how innovative technologies play a role in next-generation drug discovery.</p></abstract><kwd-group><kwd> natural products</kwd><kwd>drug design and development</kwd><kwd>innovation</kwd><kwd>automation</kwd><kwd>computational softwares</kwd><kwd>bioinformatics</kwd><kwd>precision medicine</kwd><kwd>omics</kwd><kwd>global health</kwd></kwd-group></article-meta></front><body><sec id="sec1-ijms-19-01578"><title>1. Introduction</title><p>The scourge of communicable and non-communicable diseases and the challenges of finding drug candidates that can treat these diseases with little or no side effects is a huge challenge. Despite the development of drugs for treating and managing diseases such as HIV/AIDS, malaria, hypertension, diabetes and cancer, these diseases continue to plague diverse populations worldwide with significant associated-mortalities. There is need for innovative drug discovery strategies that skew from the current &#x0201c;blockbuster&#x0201d; Pharma R&#x00026;D strategies. Currently, a viable approach will be to revert to &#x0201c;nature&#x0201d; for answers since it has worked for drug discovery in the past. Anticancer drugs such as Taxol (<italic>Taxus brevifolia</italic>), Vinblastine (<italic>Catharanthus roseus</italic>) and antimalarial drugs such as quinine (<italic>Cinchona</italic> spp.) and Artemisinin (<italic>Artemisia annua</italic>) were all discovered from natural products and are effective in treating these diseases. In the face of global public health challenges, natural products research and development (R&#x00026;D) potentially plays a pivotal role in innovative drug discovery. </p><p>Plants are found in every habitable environment with most found on land. Faced with many stresses and challenges, coupled with being sedentary, plants have developed many molecules to ward off attacks from animals and environmental insults [<xref rid="B1-ijms-19-01578" ref-type="bibr">1</xref>]. These same molecules give plants their ability to give off fragrances, colours and indeed toxicity. Many historical findings report on early use of plants for medicinal purposes [<xref rid="B2-ijms-19-01578" ref-type="bibr">2</xref>]. The discovery of medicinal plants by early humans must have been a trial and error exercise necessitated by the need to ease disease manifestations. Before the advent of writing and recording of history, such knowledge was passed through generations through word of mouth. Many plants were recorded in the early years of having medicinal properties and were used to treat many pathological conditions [<xref rid="B3-ijms-19-01578" ref-type="bibr">3</xref>,<xref rid="B4-ijms-19-01578" ref-type="bibr">4</xref>,<xref rid="B5-ijms-19-01578" ref-type="bibr">5</xref>,<xref rid="B6-ijms-19-01578" ref-type="bibr">6</xref>,<xref rid="B7-ijms-19-01578" ref-type="bibr">7</xref>,<xref rid="B8-ijms-19-01578" ref-type="bibr">8</xref>]. Natural products from plants and animals have been the go-to source of drugs especially for anticancer and antimicrobial agents [<xref rid="B9-ijms-19-01578" ref-type="bibr">9</xref>,<xref rid="B10-ijms-19-01578" ref-type="bibr">10</xref>,<xref rid="B11-ijms-19-01578" ref-type="bibr">11</xref>,<xref rid="B12-ijms-19-01578" ref-type="bibr">12</xref>,<xref rid="B13-ijms-19-01578" ref-type="bibr">13</xref>]. Traditional medicine has been overshadowed by modern medicine as the means of treatment for human diseases [<xref rid="B14-ijms-19-01578" ref-type="bibr">14</xref>,<xref rid="B15-ijms-19-01578" ref-type="bibr">15</xref>,<xref rid="B16-ijms-19-01578" ref-type="bibr">16</xref>]. However, the past few decades have seen an increase in the use of medicinal plants for health promotion and treatment of diseases in many countries including developed countries [<xref rid="B17-ijms-19-01578" ref-type="bibr">17</xref>,<xref rid="B18-ijms-19-01578" ref-type="bibr">18</xref>,<xref rid="B19-ijms-19-01578" ref-type="bibr">19</xref>,<xref rid="B20-ijms-19-01578" ref-type="bibr">20</xref>,<xref rid="B21-ijms-19-01578" ref-type="bibr">21</xref>,<xref rid="B22-ijms-19-01578" ref-type="bibr">22</xref>]. Indeed, many medicinal plant extracts are now used as prescription drugs in numerous developed countries such as the UK, Germany, China and France [<xref rid="B23-ijms-19-01578" ref-type="bibr">23</xref>,<xref rid="B24-ijms-19-01578" ref-type="bibr">24</xref>].</p><p>About a quarter of all Food and Drug Administration (FDA) and/or the European Medical Agency (EMA) approved drugs are plant based, with well-known drugs such as Paclitaxel and Morphine having been isolated from plants (<xref ref-type="fig" rid="ijms-19-01578-f001">Figure 1</xref>) [<xref rid="B25-ijms-19-01578" ref-type="bibr">25</xref>,<xref rid="B26-ijms-19-01578" ref-type="bibr">26</xref>]. About a third of FDA-approved drugs over the past 20 years are based on natural products or their derivatives [<xref rid="B27-ijms-19-01578" ref-type="bibr">27</xref>,<xref rid="B28-ijms-19-01578" ref-type="bibr">28</xref>]. The discovery of penicillin from fungus led to the screening of many microorganisms for potential antibiotics [<xref rid="B29-ijms-19-01578" ref-type="bibr">29</xref>]. Indeed, drug discovery from natural products revolutionised medicine. These include tetracycline from <italic>Streptomyces aureofaciens</italic>, artemisinin from <italic>Artemisia afra</italic>, doxorubicin from <italic>Streptomyces peucetius</italic> and cyclosporine from <italic>Tolypocladium inflatum</italic> [<xref rid="B27-ijms-19-01578" ref-type="bibr">27</xref>,<xref rid="B29-ijms-19-01578" ref-type="bibr">29</xref>,<xref rid="B30-ijms-19-01578" ref-type="bibr">30</xref>]. Traditionally, plant extracts are used as concoctions made of combinations of different ingredients. Individually some of the ingredients do not have therapeutic activities, but require their synergistic activities [<xref rid="B31-ijms-19-01578" ref-type="bibr">31</xref>]. </p><p>Current challenges to the use of natural products and difficulty in accepting their therapeutic efficacy include: (1) lack of standardization procedures (2) lack of isolation of pure chemical products or compounds (3) lack of elucidation of biological mechanisms and rarely undergoing so-called controlled and (4) documented clinical trials according to &#x0201c;standards&#x0201d;. Historically, there is scientific evidence on the therapeutic efficacy of natural products and as previously mentioned this led to development of some blockbuster conventional medicines. Searching for new drug candidates from natural products is often made difficult by the complexity of the molecular mixtures. The therapeutic activity of plant extracts is usually because of the synergistic and simultaneous action of several chemicals [<xref rid="B30-ijms-19-01578" ref-type="bibr">30</xref>,<xref rid="B32-ijms-19-01578" ref-type="bibr">32</xref>]. Given the complex nature of many diseases including cancer and degenerative diseases, it is not surprising that the reliance on single compound-based drug discovery has failed to provide effective cures. Plant-based drug discovery therefore must start with a combinatorial approach when evaluating candidate compounds. The advent of novel technologies including quantum computing, profiling techniques, computational biology techniques, big data, microfluidics and artificial intelligence will enable scientists to use a combinatorial approach to harness the therapeutic properties of plant-based natural products and simultaneously study their molecular effects in physiological conditions [<xref rid="B33-ijms-19-01578" ref-type="bibr">33</xref>,<xref rid="B34-ijms-19-01578" ref-type="bibr">34</xref>]. </p><p>It is however possible that not all components of plant extracts have measurable effects. It has been suggested that one way to improve screening and simplify extracts is through the removal of possible interfering components such as polyphenolic tannins [<xref rid="B35-ijms-19-01578" ref-type="bibr">35</xref>]. There are several reported innovative strategies which can be used to achieve this and these include pre-fractionation and extraction methods [<xref rid="B36-ijms-19-01578" ref-type="bibr">36</xref>,<xref rid="B37-ijms-19-01578" ref-type="bibr">37</xref>]. Indeed, these extraction strategies have resulted in higher hit leads during drug discovery [<xref rid="B12-ijms-19-01578" ref-type="bibr">12</xref>,<xref rid="B38-ijms-19-01578" ref-type="bibr">38</xref>,<xref rid="B39-ijms-19-01578" ref-type="bibr">39</xref>,<xref rid="B40-ijms-19-01578" ref-type="bibr">40</xref>]. Innovative extraction technologies including semi-bionic extraction [<xref rid="B41-ijms-19-01578" ref-type="bibr">41</xref>], supercritical fluid extraction [<xref rid="B42-ijms-19-01578" ref-type="bibr">42</xref>,<xref rid="B43-ijms-19-01578" ref-type="bibr">43</xref>,<xref rid="B44-ijms-19-01578" ref-type="bibr">44</xref>], microwave-assisted, ultrasonic-assisted and enzyme-assisted extraction [<xref rid="B45-ijms-19-01578" ref-type="bibr">45</xref>], molecular distillation methods [<xref rid="B46-ijms-19-01578" ref-type="bibr">46</xref>,<xref rid="B47-ijms-19-01578" ref-type="bibr">47</xref>] and membrane separation technology [<xref rid="B48-ijms-19-01578" ref-type="bibr">48</xref>,<xref rid="B49-ijms-19-01578" ref-type="bibr">49</xref>] can be used to extract natural compounds efficiently from plants. These extractions strategies have been shown to have similar simulation to traditional methods allowing the extraction process to get most compounds from the natural product.</p><p>Technologies such as high-performance liquid chromatography, nuclear magnetic resonance spectroscopy, mass spectrometry, microfluidics and computational algorithms have seen major advances in the field of medicinal chemistry especially in the 20th century [<xref rid="B50-ijms-19-01578" ref-type="bibr">50</xref>,<xref rid="B51-ijms-19-01578" ref-type="bibr">51</xref>]. This has allowed the determination of chemical components of plants and their utilisation in drug discovery. High throughput assays using bioreactors and microfluidics systems has led to many drug discoveries using plant natural products. Some of these natural products include opium and morphine [<xref rid="B52-ijms-19-01578" ref-type="bibr">52</xref>,<xref rid="B53-ijms-19-01578" ref-type="bibr">53</xref>]. Several structural analogues of these compounds are used in clinics and hospitals today. Several new plant-based compounds are emerging as promising anti-cancer remedies. In one of our studies we investigated the anticancer activities of extracts from African lettuce (<italic>Launaea taraxacifolia</italic>), a plant cultivated extensively in Africa, especially West Africa. <italic>L. taraxacifolia</italic> extract caused WHCO1 cell cycle arrest at the G0/G1 phase by affecting differential expression of genes involved in cell cycle regulation, presenting its potential beneficial effects [<xref rid="B22-ijms-19-01578" ref-type="bibr">22</xref>]. The medicinal plant <italic>Brucea javanica</italic> (L.) Merr. (Simaroubaceae) has been shown to have many properties and activities. Through both phytochemical and biological investigations, it was shown that <italic>Brucea javanica</italic> (L.) Merr. contains many compounds with medicinal properties. For example the seeds of <italic>Brucea javanica</italic> contain several compounds such as quassinoids that show many biological properties, such as antitumour and antimalarial effects [<xref rid="B54-ijms-19-01578" ref-type="bibr">54</xref>]. A well-known malarial drug Artemisinin is a natural product from <italic>Artemisia annua</italic> also known as Sweet Wormwood [<xref rid="B55-ijms-19-01578" ref-type="bibr">55</xref>,<xref rid="B56-ijms-19-01578" ref-type="bibr">56</xref>]. Artemisinin and its structural derivatives are also used for diseases such as type I diabetes and cancer [<xref rid="B57-ijms-19-01578" ref-type="bibr">57</xref>,<xref rid="B58-ijms-19-01578" ref-type="bibr">58</xref>,<xref rid="B59-ijms-19-01578" ref-type="bibr">59</xref>]. High throughput screening assays face many challenges. For example, the Rio Convention on Biodiversity is aimed at limiting the use of natural products and deals with intellectual property rights. This has the effect of limiting access to natural products as there are fears of extinction of natural species [<xref rid="B29-ijms-19-01578" ref-type="bibr">29</xref>,<xref rid="B60-ijms-19-01578" ref-type="bibr">60</xref>,<xref rid="B61-ijms-19-01578" ref-type="bibr">61</xref>,<xref rid="B62-ijms-19-01578" ref-type="bibr">62</xref>,<xref rid="B63-ijms-19-01578" ref-type="bibr">63</xref>,<xref rid="B64-ijms-19-01578" ref-type="bibr">64</xref>,<xref rid="B65-ijms-19-01578" ref-type="bibr">65</xref>].</p><p>Current drug discovery strategies and modern medicine discard the use of whole plant extracts and are driven by single compound-based medicine. Taking the whole plant or extracts with no isolation of components as practised in traditional medicine, produces a better therapeutic effect than individual compounds. This is important as most of the plant metabolites likely work in a synergistic fashion or concurrently to give the plant extract its therapeutic effect. Research into the use of whole plant extracts must be done as this will allow scientists to determine the molecular basis of the therapeutic effect of the plant extracts. For example, anti-asthma herbal medicine made from extracts from <italic>Ganoderma lucidum</italic>, <italic>Glycyrrhiza uralensis</italic> and <italic>Sophora flavescens</italic> alleviates bronchoconstriction in an animal model whilst restoring cytokines balance, contributing to longer lasting anti-asthma benefit after treatment [<xref rid="B66-ijms-19-01578" ref-type="bibr">66</xref>]. The therapeutic effect only emanates from the synergistic effect of chemical components of the three herbal ingredients [<xref rid="B67-ijms-19-01578" ref-type="bibr">67</xref>,<xref rid="B68-ijms-19-01578" ref-type="bibr">68</xref>]. The adoption of Good Manufacturing Practises has allowed the increased use of plant-based medicines and many are now undergoing clinical trial for FDA approval [<xref rid="B69-ijms-19-01578" ref-type="bibr">69</xref>]. Skroza and colleagues showed that catechin and resveratrol have synergistic effects as confirmed by different antioxidant assays [<xref rid="B70-ijms-19-01578" ref-type="bibr">70</xref>]. The same study also showed the synergistic effects of caffeic acid and resveratrol by the ferric reducing ability of plasma (FRAP) antioxidant assay [<xref rid="B70-ijms-19-01578" ref-type="bibr">70</xref>]. Another study showed the synergistic effects of ethnomedicinal plants of the <italic>Apocynaceae</italic> family and antibiotics against clinical isolates of <italic>Acinetobacter baumannii</italic> [<xref rid="B71-ijms-19-01578" ref-type="bibr">71</xref>]. Several other studies showed the synergistic effect of different plant extracts and conventional drugs including doxorubicin [<xref rid="B72-ijms-19-01578" ref-type="bibr">72</xref>]. </p><p>Innovative drug design from natural products is needed to combat global health challenges with the assistance of technological innovation. Most importantly is the need for new and innovative computational and analytical methods to identify chemical components of crude plant extracts in order to identify compounds causing the desired therapeutic effect and optimize extraction to exclude interfering components. Ultimately, more research should be focussing on combinatorial effects of chemicals from plant extracts and not just single compounds. How these combinations affect genes and proteins involved in many cellular processes must be investigated through available &#x0201c;-omics&#x0201d; platforms. Developments in the field of microfluidics and computational analysis have allowed for the designing and testing of plant extract chemicals in drug discovery. Technological advances, such as the development of new analytical and bio-informatic techniques, will aid the design of new structures, the synthesis of these new compounds and the biological testing of such compounds [<xref rid="B73-ijms-19-01578" ref-type="bibr">73</xref>,<xref rid="B74-ijms-19-01578" ref-type="bibr">74</xref>]. Natural products, offer an endless source of compounds to help in the design of pharmacologically important molecular products [<xref rid="B75-ijms-19-01578" ref-type="bibr">75</xref>,<xref rid="B76-ijms-19-01578" ref-type="bibr">76</xref>,<xref rid="B77-ijms-19-01578" ref-type="bibr">77</xref>]. Below we discuss some of the major innovations currently taking place in these areas. We focus on the need for the use of &#x0201c;-omics&#x0201d; technologies, automation and big data during drug design and testing to allow for the rapid production of drugs and computer aided drug design from plant-based natural products. </p></sec><sec id="sec2-ijms-19-01578"><title>2. Multidisciplinary Approach to Natural Products Drug Discovery Using Innovative Technologies</title><p>Innovative drug discovery from natural products requires a multidisciplinary approach utilising available and innovative technologies to package such natural product compounds for medical practice and drug development (<xref ref-type="fig" rid="ijms-19-01578-f002">Figure 2</xref>). The successful use of such an approach will allow the development of next-generation drugs to combat the ever-increasing health challenges of today and the future.</p><p>Most medicinal extract components often work in a synergistic manner to elicit their therapeutic effects so isolating individual components may be counter-productive. Innovative approaches are needed to study and to harness such compounds that can effectively lead to innovative drugs. In addition, a systems biology guided approach provides a different angle in natural products pharma-sciences [<xref rid="B78-ijms-19-01578" ref-type="bibr">78</xref>]. This transcends looking for a specific molecule with a specific target and espousing the complete equilibrium of a physiological system undergoing synchronized mechanisms on multiple molecular targets. A systems biology approach coupled with application of available technologies such as genomics, transcriptomics, proteomics, metabolomics/metabonomics, automation and computational strategies will potentially pave the way for innovative drug design leading to better drug candidates. Molecular libraries of lead compounds from natural products R&#x00026;D will serve as sources of lead compounds/herbal tinctures for innovative drugs. In the application of innovative technologies combined with systems biology, the focus should not be a reductionist approach of trying to source a single active compound but to consider the synergistic effects of compounds. It is important to emphasise that innovative drug discovery from natural products will require a non-reductionist strategy to understand their complex mechanisms of action at the molecular level.</p></sec><sec id="sec3-ijms-19-01578"><title>3. Natural Products Drug Discovery Research and Development and Omics (Genomics Proteomics and Metabolomics/Metabonomics)</title><sec id="sec3dot1-ijms-19-01578"><title>3.1. Genomics in Plant-Based Natural Products Identification and Biomarker Identification</title><p>The quality, precise identification and reliability in the plant species from which the natural product is obtained and to which the therapeutic properties are ascribed is very critical for successful innovative drug discovery. The use of a different or wrong plant species will likely affect the therapeutic properties due to different compounds and quantities that will be found in the species. Genomic methods are important in establishing an accurate identification method for plants and natural product species [<xref rid="B78-ijms-19-01578" ref-type="bibr">78</xref>]. Genomic techniques such as DNA barcoding are established techniques that rely on sequence diversity in short, standard DNA regions (400&#x02013;800 bp) for species-level identification [<xref rid="B79-ijms-19-01578" ref-type="bibr">79</xref>]. DNA barcoding utilising genomics will provide a more robust and precise identification compared to traditional methods of morphological identification and local traditional (vernacular) names [<xref rid="B80-ijms-19-01578" ref-type="bibr">80</xref>]. DNA barcoding of natural products has been applied in biodiversity inventories [<xref rid="B81-ijms-19-01578" ref-type="bibr">81</xref>] and authentication of herbal products [<xref rid="B82-ijms-19-01578" ref-type="bibr">82</xref>,<xref rid="B83-ijms-19-01578" ref-type="bibr">83</xref>,<xref rid="B84-ijms-19-01578" ref-type="bibr">84</xref>]. DNA barcoding was used in an integrative approach for identification of plant species such as <italic>Amaranthus hybridus</italic> L. and crude drugs recorded in the Japanese pharmacopoeia using <italic>ITS2</italic> or <italic>psbA-trnH</italic> sequence amplification [<xref rid="B80-ijms-19-01578" ref-type="bibr">80</xref>,<xref rid="B85-ijms-19-01578" ref-type="bibr">85</xref>]. Genomic-based techniques represent an effective platform for natural product identification but different parts of the same plant with similar sequences may have different qualities, clinical utilities and indications due to the diverse conditions under which they grow. </p><p>To show consistency in the species and pharmacological molecules from natural products, bio-farming can be used to ensure consistency after the traditional species have been authenticated through DNA barcoding [<xref rid="B86-ijms-19-01578" ref-type="bibr">86</xref>]. Markers developed from species through genomic techniques can be incorporated into DNA chips to provide an effective, high-throughput tool for genotyping and also plant species authentication [<xref rid="B78-ijms-19-01578" ref-type="bibr">78</xref>,<xref rid="B87-ijms-19-01578" ref-type="bibr">87</xref>]. Gene expression using microarray analysis is an innovative transcriptomic technology that allows a fast and effective analysis of many transcripts [<xref rid="B78-ijms-19-01578" ref-type="bibr">78</xref>,<xref rid="B88-ijms-19-01578" ref-type="bibr">88</xref>,<xref rid="B89-ijms-19-01578" ref-type="bibr">89</xref>]. This transcriptomic analysis makes it possible to concurrently evaluate variations in multiple gene expressions [<xref rid="B90-ijms-19-01578" ref-type="bibr">90</xref>]. This represents a robust tool for elucidating the molecular mechanisms of therapeutic natural products and biological networks underlying their pharmacological actions. </p><p>Besides its use in natural products identification, genomics can also be used in natural product or compound targeting. Whole genome sequencing combined with transcriptomic analyses has allowed the exploration of drug or compound targeting as never before. Transcription factor binding sites, protein modifications, alterations of the DNA structure as well as methylation patterns can now be analysed and measured at the genome level [<xref rid="B91-ijms-19-01578" ref-type="bibr">91</xref>,<xref rid="B92-ijms-19-01578" ref-type="bibr">92</xref>,<xref rid="B93-ijms-19-01578" ref-type="bibr">93</xref>,<xref rid="B94-ijms-19-01578" ref-type="bibr">94</xref>,<xref rid="B95-ijms-19-01578" ref-type="bibr">95</xref>,<xref rid="B96-ijms-19-01578" ref-type="bibr">96</xref>]. Several studies including our own have identified deletions, insertions, copy number variations, splicing variants and translocations associated with certain cancers, and in so doing identified new drug targets [<xref rid="B97-ijms-19-01578" ref-type="bibr">97</xref>,<xref rid="B98-ijms-19-01578" ref-type="bibr">98</xref>,<xref rid="B99-ijms-19-01578" ref-type="bibr">99</xref>,<xref rid="B100-ijms-19-01578" ref-type="bibr">100</xref>,<xref rid="B101-ijms-19-01578" ref-type="bibr">101</xref>,<xref rid="B102-ijms-19-01578" ref-type="bibr">102</xref>]. The development of novel and unrivalled technologies, allowing genome-wide analysis, has enabled the unbiased discovery of drug targets. These technologies together with the availability of huge databases of chemicals or compounds have enabled the shortening of the time required for the whole process of drug discovery from drug design all the way to clinical trials [<xref rid="B103-ijms-19-01578" ref-type="bibr">103</xref>,<xref rid="B104-ijms-19-01578" ref-type="bibr">104</xref>,<xref rid="B105-ijms-19-01578" ref-type="bibr">105</xref>,<xref rid="B106-ijms-19-01578" ref-type="bibr">106</xref>,<xref rid="B107-ijms-19-01578" ref-type="bibr">107</xref>,<xref rid="B108-ijms-19-01578" ref-type="bibr">108</xref>,<xref rid="B109-ijms-19-01578" ref-type="bibr">109</xref>].</p></sec><sec id="sec3dot2-ijms-19-01578"><title>3.2. Proteomics in Natural Product Validation and Biomarker Identification</title><p>Complimentary to genomic and transcriptomic approaches to quality control and sample variation is the use of proteomic platforms in describing the mechanism of action of many natural products. Proteomic approaches to innovative drug discovery from natural products have the potential to elucidate the protein expression, protein function, metabolic and biosynthetic pathways based on therapeutic effects translating to consistency in quality and profile of the product [<xref rid="B110-ijms-19-01578" ref-type="bibr">110</xref>,<xref rid="B111-ijms-19-01578" ref-type="bibr">111</xref>]. Approaches such as mass-spectrometry utilising isotope tags and two-dimensional electrophoresis will give insight into quantitative protein profiling which generates quantitative data on a scale and sensitivity comparable to what is generated at the genomic level. Proteomics application has been successfully used in identifying species of Chinese herbal medicine, <italic>Panax ginseng</italic> versus <italic>Panax quinquefolium</italic> [<xref rid="B112-ijms-19-01578" ref-type="bibr">112</xref>,<xref rid="B113-ijms-19-01578" ref-type="bibr">113</xref>]. The therapeutic effects of natural products can be elucidated using proteomics and imaging techniques to successfully study the metabolism of natural products and their compounds [<xref rid="B114-ijms-19-01578" ref-type="bibr">114</xref>,<xref rid="B115-ijms-19-01578" ref-type="bibr">115</xref>]. Proteomics is an effective way to elucidate multi-target effects of complex natural product preparations as well as the discovery of multiple compounds and fractions, characterisation of natural products and ultimately a molecular diagnostic platform [<xref rid="B78-ijms-19-01578" ref-type="bibr">78</xref>,<xref rid="B116-ijms-19-01578" ref-type="bibr">116</xref>].</p><p>For natural products to be used as drugs it is crucial that their target proteins be identified. Several methods including affinity chromatography have been in use to identify target proteins with relative success. The advent of technologies allowing for target protein identification without the modification of the natural product has resulted in natural products with increased activity. Such methods include cellular thermal shift assay which is based on the stabilisation of target protein when it binds to its ligand, thermal proteome profiling a method based on the stability of target proteins at high temperatures, bioinformatic-based analysis of connectivity and drug affinity responsive target stability. Due to their many structures and complexity, natural products do show a wide range of biological activities. This is probably due to their abilities to bind to several ligands. Every potential drug will have to be tested for side effects and this is due to its off-target effects. Complex natural compounds with potential target proteins will have to be evaluated properly to identify all its potential target proteins. One of the most utilised methods to identify target proteins and their biological activities is affinity chromatography [<xref rid="B117-ijms-19-01578" ref-type="bibr">117</xref>,<xref rid="B118-ijms-19-01578" ref-type="bibr">118</xref>,<xref rid="B119-ijms-19-01578" ref-type="bibr">119</xref>,<xref rid="B120-ijms-19-01578" ref-type="bibr">120</xref>,<xref rid="B121-ijms-19-01578" ref-type="bibr">121</xref>,<xref rid="B122-ijms-19-01578" ref-type="bibr">122</xref>,<xref rid="B123-ijms-19-01578" ref-type="bibr">123</xref>]. This method is a pull-down method in which the natural product is immobilized on a physical solid support [<xref rid="B124-ijms-19-01578" ref-type="bibr">124</xref>]. The identification of bound proteins is done using mass spectrometry. Modification of natural products however, can lead to reduced or loss of activity. The development of novel and innovative approaches, devoid of any modification, is paramount for the success of target identification [<xref rid="B125-ijms-19-01578" ref-type="bibr">125</xref>,<xref rid="B126-ijms-19-01578" ref-type="bibr">126</xref>]. Of late, several methods have been able to identify target proteins using label-free natural products. These new and improved methods measure the responses of natural product-target protein complex to proteomic and thermal treatment [<xref rid="B127-ijms-19-01578" ref-type="bibr">127</xref>,<xref rid="B128-ijms-19-01578" ref-type="bibr">128</xref>,<xref rid="B129-ijms-19-01578" ref-type="bibr">129</xref>]. Using this new approach, it is possible to identify several target proteins for an individual natural product using proteomic analysis [<xref rid="B13-ijms-19-01578" ref-type="bibr">13</xref>,<xref rid="B130-ijms-19-01578" ref-type="bibr">130</xref>]. </p><sec sec-type="methods"><title>Methods for Target Identification of Label-Free Natural Products</title><p>Drug affinity responsive target stability (DARTS) is one of the direct methods used to identify target proteins using label free natural products [<xref rid="B124-ijms-19-01578" ref-type="bibr">124</xref>]. This methods takes advantage of the changes in stability of a natural product-bound protein versus an unbound protein when subjected to proteolytic treatment [<xref rid="B130-ijms-19-01578" ref-type="bibr">130</xref>]. This method has been used to validate several target proteins for compounds such as resveratrol and rapamycin [<xref rid="B129-ijms-19-01578" ref-type="bibr">129</xref>,<xref rid="B131-ijms-19-01578" ref-type="bibr">131</xref>]. It is however difficult to use DARTS to identify low abundance protein targets in cell lysates [<xref rid="B132-ijms-19-01578" ref-type="bibr">132</xref>]. Another method that takes advantage of ligand-induced changes to target proteins is stability of proteins from rates of oxidation (SPROX) [<xref rid="B124-ijms-19-01578" ref-type="bibr">124</xref>,<xref rid="B133-ijms-19-01578" ref-type="bibr">133</xref>,<xref rid="B134-ijms-19-01578" ref-type="bibr">134</xref>]. This method measures the irreversible oxidation of methionine residues on target proteins [<xref rid="B124-ijms-19-01578" ref-type="bibr">124</xref>]. A mixture of candidate drug compound and proteins is incubated with an oxidising agent and guanidinium hydrochloride in order to oxidise methionine. Generated peptides are then analysed through mass spectrometry to evaluate selective methionine oxidation. Analyses of oxidised and non-oxidised methionine-containing peptides versus the guanidinium hydrochloride concentration reveal that proteins bound to ligands show a larger transition midpoint shift than control samples [<xref rid="B13-ijms-19-01578" ref-type="bibr">13</xref>,<xref rid="B135-ijms-19-01578" ref-type="bibr">135</xref>,<xref rid="B136-ijms-19-01578" ref-type="bibr">136</xref>,<xref rid="B137-ijms-19-01578" ref-type="bibr">137</xref>]. Indeed, several target proteins of compounds such as resveratrol and cyclophilin A were verified using SPROX [<xref rid="B133-ijms-19-01578" ref-type="bibr">133</xref>,<xref rid="B137-ijms-19-01578" ref-type="bibr">137</xref>,<xref rid="B138-ijms-19-01578" ref-type="bibr">138</xref>]. This method however requires highly concentrated proteins for analysis. Modifications of the SPROX method, named stable isotope labelling with amino acids in cell culture (SILAC)-based SPROX is an improvement of the original method and has the advantage of covering more target proteins [<xref rid="B130-ijms-19-01578" ref-type="bibr">130</xref>,<xref rid="B139-ijms-19-01578" ref-type="bibr">139</xref>,<xref rid="B140-ijms-19-01578" ref-type="bibr">140</xref>,<xref rid="B141-ijms-19-01578" ref-type="bibr">141</xref>,<xref rid="B142-ijms-19-01578" ref-type="bibr">142</xref>,<xref rid="B143-ijms-19-01578" ref-type="bibr">143</xref>,<xref rid="B144-ijms-19-01578" ref-type="bibr">144</xref>]. This method is limited to only identifying of methionine containing proteins. </p><p>Cellular Thermal Shift Assay (CETSA) is a recently introduced method based on stabilisation of a target protein by binding to its ligand [<xref rid="B145-ijms-19-01578" ref-type="bibr">145</xref>,<xref rid="B146-ijms-19-01578" ref-type="bibr">146</xref>,<xref rid="B147-ijms-19-01578" ref-type="bibr">147</xref>]. Cell lysates and intact cells are treated with the candidate drug compound and heated to several temperatures and target protein is separated from destabilised protein and analysed by Western blot analysis. Shifts or changes in melting curves are detected when ligand&#x02013;target interactions are plotted against temperature. This method has been useful in identifying target proteins of many anti-cancer therapeutic agents such as raltitrexed and methotrexate [<xref rid="B145-ijms-19-01578" ref-type="bibr">145</xref>]. The advantage of this method is the obvious use of intact cells with no need for treatments or preparations. Due to the use of Western blot step it can be very selective. Some target proteins with unfolded binding sites, however, may not be detected. In addition, due to non-specificity of some antibodies used in Western blot step, off-target proteins may also be identified as false positives. Thermal Proteome Profiling (TPP) is an advanced modification of the CETSA method. This method identifies target proteins displaying thermal stability at high temperatures induced by ligand binding and the use of mass spectrometry to measure ligand&#x02013;target protein interaction at cellular level [<xref rid="B148-ijms-19-01578" ref-type="bibr">148</xref>,<xref rid="B149-ijms-19-01578" ref-type="bibr">149</xref>,<xref rid="B150-ijms-19-01578" ref-type="bibr">150</xref>]. This method uses isobaric mass tagging in for high resolution mass spectrometry. Most expressed soluble proteins will show melting curves resulting in the identification of both target and off-target proteins [<xref rid="B13-ijms-19-01578" ref-type="bibr">13</xref>,<xref rid="B127-ijms-19-01578" ref-type="bibr">127</xref>,<xref rid="B148-ijms-19-01578" ref-type="bibr">148</xref>,<xref rid="B151-ijms-19-01578" ref-type="bibr">151</xref>,<xref rid="B152-ijms-19-01578" ref-type="bibr">152</xref>]. By identifying off-targets TPP can be used to study possible side effects of candidate drug compounds [<xref rid="B150-ijms-19-01578" ref-type="bibr">150</xref>]. This method is very costly and is labour intensive.</p><p>Small interfering RNA and short hairpin RNA are obvious choices for target gene manipulation to functionally validate target protein and natural product interactions [<xref rid="B153-ijms-19-01578" ref-type="bibr">153</xref>,<xref rid="B154-ijms-19-01578" ref-type="bibr">154</xref>]. By knocking down target protein using interfering RNA it is possible to study off-target effects of candidate compounds. Recently clustered regularly interspaced short palindromic repeats-Cas9 (CRISPR-Cas9) genome editing approaches have been used to overcome off-target effects of candidate compounds and to delineate how many natural compounds work [<xref rid="B155-ijms-19-01578" ref-type="bibr">155</xref>,<xref rid="B156-ijms-19-01578" ref-type="bibr">156</xref>]. CRISPR-Cas9 based genome editing combined with high throughput sequencing and computer-based mutation analysis, referred to as DrugTargetSeqR, has been used to study drug resistance and for validation of several anti-cancer therapeutic agents [<xref rid="B157-ijms-19-01578" ref-type="bibr">157</xref>,<xref rid="B158-ijms-19-01578" ref-type="bibr">158</xref>,<xref rid="B159-ijms-19-01578" ref-type="bibr">159</xref>].</p></sec></sec><sec id="sec3dot3-ijms-19-01578"><title>3.3. Metabolomics and Metabonomics Approach to Natural Products Drug Discovery</title><p>Untargeted metabolomics and metabonomics approaches of discovering compounds of therapeutic interest from natural products have the potential to lead to innovative drugs for global health. Metabolomic profiling of natural products seeks to identify and quantify the complete set of its characteristic metabolites [<xref rid="B160-ijms-19-01578" ref-type="bibr">160</xref>,<xref rid="B161-ijms-19-01578" ref-type="bibr">161</xref>] while metabonomics broadly aims to evaluate the global and dynamic metabolic response of living systems to biological stimuli or genetic manipulation [<xref rid="B162-ijms-19-01578" ref-type="bibr">162</xref>,<xref rid="B163-ijms-19-01578" ref-type="bibr">163</xref>,<xref rid="B164-ijms-19-01578" ref-type="bibr">164</xref>,<xref rid="B165-ijms-19-01578" ref-type="bibr">165</xref>]. Drug discovery has traditionally focussed on metabolomics to identify metabolites but recently, the term metabonomics (although used interchangeably) has been reviewed to incorporate a systems biology guided approach to study the functions and perturbations of a biological system following a pharmacological effect. This elucidates a complete biological mechanism of both the natural product and its effect on a living system (<xref ref-type="fig" rid="ijms-19-01578-f003">Figure 3</xref>). </p><p>Metabolomic profiling of natural products using technologies such as ultra-performance high performance liquid chromatography&#x02013;quadruple TOF MS (UPLC&#x02013;MS) has enabled identification of compounds that confer therapeutic properties on herbs such as <italic>Newbouldia laevis</italic>, <italic>Cassia abbreviata</italic>, <italic>Hyptis suaveolens</italic> and <italic>Panax</italic> herbs [<xref rid="B166-ijms-19-01578" ref-type="bibr">166</xref>,<xref rid="B167-ijms-19-01578" ref-type="bibr">167</xref>,<xref rid="B168-ijms-19-01578" ref-type="bibr">168</xref>]. As a quality control measure and to show consistency in species usage, metabolomics has been used in identification of processed <italic>Panax</italic> species (<italic>Panax ginseng</italic> and <italic>Panax quinquefolius</italic>) using Nuclear Magnetic Resonance (NMR) based metabolomics, UPLC&#x02013;QTOF MS and multivariate statistical analysis [<xref rid="B169-ijms-19-01578" ref-type="bibr">169</xref>]. Metabonomics approach to profiling natural products for drug discovery has been hailed as a critical phenotyping tool. The systems biology approach of this technique positions the profiling of natural products in an all-inclusive manner in terms of metabolite and biology systems effect (<xref ref-type="fig" rid="ijms-19-01578-f003">Figure 3</xref>). Metabolomic and metabonomics profiling using NMR, MS and UPLC can potentially elucidate the pharmacodynamic, pharmacokinetic and toxicological value of natural products. </p></sec><sec id="sec3dot4-ijms-19-01578"><title>3.4. Big Data in Drug Development for Natural Product Drug Development and Precision Medicine</title><p>Omics analysis, like genomics, transcriptomics, proteomics, metabolomics and metabolomics, results in a generation of a complex multivariate dataset that requires computational and chemometric tools for interpretation. The use of computational platforms such as bioinformatics and multivariate statistical tools, will allow the application of omics multidata to elucidate pathophysiological effects, target specificity and molecular effects, as well as elucidate the pharmacodynamic, pharmacokinetic and toxicological characterisation of natural products and their compounds. Applications used during the drug discovery process such as docking and virtual screening can make use of novel machine learning algorithms such as deep learning. Machine learning methods can be used for virtual screening of thousands of compounds allowing the utilisation of data from high throughput screening [<xref rid="B170-ijms-19-01578" ref-type="bibr">170</xref>,<xref rid="B171-ijms-19-01578" ref-type="bibr">171</xref>]. </p><p>Computer-based screening of candidate compounds for drug discovery makes use of big databases especially to identify compounds of similar activity. Similarity in structure is equated to similarity in biological activity, with results not always supporting this idea. Knowledge of the chemical structure of candidate compounds together with knowledge about the target protein is utilised to study possible interactions between the two. Transcriptomic data, used as gene signature, can be used to compare differences and similarities in response to candidate compounds [<xref rid="B172-ijms-19-01578" ref-type="bibr">172</xref>,<xref rid="B173-ijms-19-01578" ref-type="bibr">173</xref>,<xref rid="B174-ijms-19-01578" ref-type="bibr">174</xref>,<xref rid="B175-ijms-19-01578" ref-type="bibr">175</xref>,<xref rid="B176-ijms-19-01578" ref-type="bibr">176</xref>]. For example, the connectivity map allows scientists to associate disease-associated gene signatures with drug signatures resulting in the identification of drugs that can potentially reverse the disease gene signature [<xref rid="B177-ijms-19-01578" ref-type="bibr">177</xref>,<xref rid="B178-ijms-19-01578" ref-type="bibr">178</xref>,<xref rid="B179-ijms-19-01578" ref-type="bibr">179</xref>,<xref rid="B180-ijms-19-01578" ref-type="bibr">180</xref>,<xref rid="B181-ijms-19-01578" ref-type="bibr">181</xref>]. Generating a lot of data can have the consequence of losing the ability to understand its meaning. Big data must be useful and put into action. For big data to be useful during drug discovery it must be summarised into a little actionable information [<xref rid="B182-ijms-19-01578" ref-type="bibr">182</xref>,<xref rid="B183-ijms-19-01578" ref-type="bibr">183</xref>,<xref rid="B184-ijms-19-01578" ref-type="bibr">184</xref>]. There are several data sources used for drug identification. These include ChemBank, PubChem, ChEMBL, DrugBank, UniProt, STITCH and the NIH Small Molecule Repository [<xref rid="B185-ijms-19-01578" ref-type="bibr">185</xref>,<xref rid="B186-ijms-19-01578" ref-type="bibr">186</xref>,<xref rid="B187-ijms-19-01578" ref-type="bibr">187</xref>,<xref rid="B188-ijms-19-01578" ref-type="bibr">188</xref>].</p><p>Connectivity Map (CMap) is a bioinformatic application that allows the study of diseases at the molecular level with the help of computers [<xref rid="B189-ijms-19-01578" ref-type="bibr">189</xref>,<xref rid="B190-ijms-19-01578" ref-type="bibr">190</xref>,<xref rid="B191-ijms-19-01578" ref-type="bibr">191</xref>]. Established by the Broad Institute, the CMap is a collection of transcriptional data of many compounds-treated human cells [<xref rid="B172-ijms-19-01578" ref-type="bibr">172</xref>,<xref rid="B173-ijms-19-01578" ref-type="bibr">173</xref>,<xref rid="B174-ijms-19-01578" ref-type="bibr">174</xref>,<xref rid="B175-ijms-19-01578" ref-type="bibr">175</xref>,<xref rid="B192-ijms-19-01578" ref-type="bibr">192</xref>]. The CMap associates gene expression signatures with compounds, genes and disease response allowing for its utilisation to show connections between compounds with the same modes of action and same physiological processes [<xref rid="B172-ijms-19-01578" ref-type="bibr">172</xref>,<xref rid="B173-ijms-19-01578" ref-type="bibr">173</xref>,<xref rid="B174-ijms-19-01578" ref-type="bibr">174</xref>,<xref rid="B192-ijms-19-01578" ref-type="bibr">192</xref>]. The CMap also allows associations to be made between diseases and drugs. The same pattern-matching analysis can be used for natural products, gene expression and diseases [<xref rid="B173-ijms-19-01578" ref-type="bibr">173</xref>,<xref rid="B174-ijms-19-01578" ref-type="bibr">174</xref>,<xref rid="B175-ijms-19-01578" ref-type="bibr">175</xref>,<xref rid="B176-ijms-19-01578" ref-type="bibr">176</xref>]. </p><p>Using electronic databases of chemicals and protein targets and clinical data such as patient to patient variations in response to treatment, several strategies are being employed to reduce the cost of drug development and to increase the speed at which drugs are developed [<xref rid="B193-ijms-19-01578" ref-type="bibr">193</xref>]. There are obvious challenges to the efficient development of drugs and these include the lack of models that can recapitulate the human body properly in terms of response to candidate compounds, the heterogeneity of individuals in terms of their response to candidate compounds and the inability to analyse biological processes properly during testing of candidate compounds [<xref rid="B194-ijms-19-01578" ref-type="bibr">194</xref>,<xref rid="B195-ijms-19-01578" ref-type="bibr">195</xref>,<xref rid="B196-ijms-19-01578" ref-type="bibr">196</xref>]. Despite a heavy investment in research and development, most candidate compounds show weakened efficacy as the stages of drug development move towards clinical trials [<xref rid="B197-ijms-19-01578" ref-type="bibr">197</xref>,<xref rid="B198-ijms-19-01578" ref-type="bibr">198</xref>,<xref rid="B199-ijms-19-01578" ref-type="bibr">199</xref>,<xref rid="B200-ijms-19-01578" ref-type="bibr">200</xref>,<xref rid="B201-ijms-19-01578" ref-type="bibr">201</xref>]. This strategy whereby information is collected without applying a hypothesis or any bias, analysed and then used to come up with new and innovative ideas is called Big Data [<xref rid="B202-ijms-19-01578" ref-type="bibr">202</xref>,<xref rid="B203-ijms-19-01578" ref-type="bibr">203</xref>,<xref rid="B204-ijms-19-01578" ref-type="bibr">204</xref>,<xref rid="B205-ijms-19-01578" ref-type="bibr">205</xref>,<xref rid="B206-ijms-19-01578" ref-type="bibr">206</xref>]. Big data is now integrated with compound chemical structures, protein structures, compound toxicity and clinical trials and this has led to the development of complex algorithms needed for such analysis [<xref rid="B207-ijms-19-01578" ref-type="bibr">207</xref>,<xref rid="B208-ijms-19-01578" ref-type="bibr">208</xref>]. </p><p>One major challenge with the use of big data-driven drug discovery is the relative low presence of similar somatic alterations in cancer patients enrolled in a study. This is caused by tumour heterogeneity, a chief cause of chemoresistance and drug treatment failure. A challenge to scientists using big data to inform drug development and testing is how to integrate a lot of information into a meaningful and manageable unit. For &#x0201c;omics&#x0201d; data to be meaningful and to revolutionise clinical medicine, clinical phenotype data has to be integrated with genomic, transcriptomic, proteomic and epigenomic data [<xref rid="B33-ijms-19-01578" ref-type="bibr">33</xref>,<xref rid="B193-ijms-19-01578" ref-type="bibr">193</xref>,<xref rid="B209-ijms-19-01578" ref-type="bibr">209</xref>]. </p></sec></sec><sec id="sec4-ijms-19-01578"><title>4. Automating Natural Product Drug Discovery</title><p>Automation is usually associated with negative feelings, with many people associating automation with loss of jobs and unfounded consequences such as robots taking over the world. In terms of drugs discovery automation, however, it has been used successfully to speed-up the process. Indeed many pharmaceutical companies already have high-throughput assays robustly used in the drug discovery process [<xref rid="B210-ijms-19-01578" ref-type="bibr">210</xref>]. The design of most synthetic compounds is aided by computers using various softwares, as well as the synthesis of the compounds. Examples of softwares used during drug design include ADAM and EVE, used in target and hit finding [<xref rid="B211-ijms-19-01578" ref-type="bibr">211</xref>,<xref rid="B212-ijms-19-01578" ref-type="bibr">212</xref>]. New softwares and devices are being made to reduce problematic false positives an also to reduce material consumption during compound design, synthesis and biological testing [<xref rid="B213-ijms-19-01578" ref-type="bibr">213</xref>]. For example, integrated microfluidics systems, with the ability to handle liquids and heat necessary for during-synthesis analyses and purification, are being designed by laboratories and pharmaceutical companies, for compound screening and synthesis of compounds [<xref rid="B214-ijms-19-01578" ref-type="bibr">214</xref>,<xref rid="B215-ijms-19-01578" ref-type="bibr">215</xref>]. This has allowed testing of several hypotheses within days. Even more advanced technologies through the use of artificial intelligence (AI) and &#x02018;organ-on-chip&#x02019; technologies are now fully integrated in the drug discovery process, aiding scientists during drug design and optimisation of the drug discovery process [<xref rid="B213-ijms-19-01578" ref-type="bibr">213</xref>,<xref rid="B216-ijms-19-01578" ref-type="bibr">216</xref>,<xref rid="B217-ijms-19-01578" ref-type="bibr">217</xref>,<xref rid="B218-ijms-19-01578" ref-type="bibr">218</xref>,<xref rid="B219-ijms-19-01578" ref-type="bibr">219</xref>]. All these technologies have allowed the reduction of human mistakes and bias commonly made during drug design and optimisation, reduction in the amount of candidate compound needed for the testing, have reduced the time needed for testing of candidate compounds to days and allowed the recapitulation of disease biology more effectively than in vitro assays [<xref rid="B220-ijms-19-01578" ref-type="bibr">220</xref>,<xref rid="B221-ijms-19-01578" ref-type="bibr">221</xref>]. Many times, innovation and technological advances have raised false hopes and never lived up to expectations. Automation and innovation in drug discovery must be fast, but also sustainable in the long run [<xref rid="B33-ijms-19-01578" ref-type="bibr">33</xref>,<xref rid="B222-ijms-19-01578" ref-type="bibr">222</xref>]. </p><p>Several factors are taken into consideration during compound or molecule design. These include absorption, distribution, metabolism, excretion and toxicity (ADMET) properties and the final biological activity of the products. Thus, the optimisation of the drug discovery process is multidimensional. In the end, a balance has to be achieved in order to get the best in terms of compound activity and properties [<xref rid="B213-ijms-19-01578" ref-type="bibr">213</xref>]. Automation will allow scientists to make the best decision regarding the best compound design with relevant biological activity whilst at the same time having desirable ADMET properties. Several concepts such as the diversity-oriented synthesis (DOS) and biology-oriented synthesis (BIOS) have been developed over the past few years to aid compound design and increasing compound collections with new chemical structures and constituents [<xref rid="B223-ijms-19-01578" ref-type="bibr">223</xref>,<xref rid="B224-ijms-19-01578" ref-type="bibr">224</xref>,<xref rid="B225-ijms-19-01578" ref-type="bibr">225</xref>,<xref rid="B226-ijms-19-01578" ref-type="bibr">226</xref>,<xref rid="B227-ijms-19-01578" ref-type="bibr">227</xref>,<xref rid="B228-ijms-19-01578" ref-type="bibr">228</xref>]. An even advanced concept is the function-oriented synthesis which seeks to mimic the function of a promising compound in order to get simple scaffolds and make their synthesis easier and simple [<xref rid="B213-ijms-19-01578" ref-type="bibr">213</xref>,<xref rid="B229-ijms-19-01578" ref-type="bibr">229</xref>,<xref rid="B230-ijms-19-01578" ref-type="bibr">230</xref>]. Several automated compound generators that use deep learning techniques have been made and have allowed automated analysis of generated compounds to obtain even better designs of compounds with desired properties and biological activity [<xref rid="B216-ijms-19-01578" ref-type="bibr">216</xref>,<xref rid="B217-ijms-19-01578" ref-type="bibr">217</xref>,<xref rid="B231-ijms-19-01578" ref-type="bibr">231</xref>,<xref rid="B232-ijms-19-01578" ref-type="bibr">232</xref>]. Although deep learning models are used mainly to predict drug-target interactions and in the generation of new molecules, these models are also useful to predict ADMET properties of novel candidate drugs [<xref rid="B233-ijms-19-01578" ref-type="bibr">233</xref>,<xref rid="B234-ijms-19-01578" ref-type="bibr">234</xref>]. Several deep learning models have also been used to predict the binding affinity for candidate compounds during drug discovery [<xref rid="B234-ijms-19-01578" ref-type="bibr">234</xref>]. Several compounds based on the imidazopyridine scaffold have been synthesised using automated computer-assisted de novo design resulting in the discovery of many ligands for G protein-coupled receptors antagonists [<xref rid="B213-ijms-19-01578" ref-type="bibr">213</xref>,<xref rid="B235-ijms-19-01578" ref-type="bibr">235</xref>,<xref rid="B236-ijms-19-01578" ref-type="bibr">236</xref>]. It is also possible to use a virtual library enumeration parallel to target panel prediction to design a compound library and building block selection. Using integration of computational activity prediction and microfluidics-assisted synthesis enabled scientists to identify ligands with different binding profiles [<xref rid="B236-ijms-19-01578" ref-type="bibr">236</xref>,<xref rid="B237-ijms-19-01578" ref-type="bibr">237</xref>,<xref rid="B238-ijms-19-01578" ref-type="bibr">238</xref>,<xref rid="B239-ijms-19-01578" ref-type="bibr">239</xref>]. Thus, microfluidics synthesis and computer-aided target prediction can be used to generate bioactivity-focussed compound libraries rapidly and efficiently [<xref rid="B235-ijms-19-01578" ref-type="bibr">235</xref>]. </p><p>An important part of automation of compound synthesis is the availability and use of building blocks and chemical reactions that can result in diverse by-products. The use of small volumes of the starting compounds and compact synthesis coupled with in-line purification and analyses ultimately led to the development of novel machines to synthesise complex structures recapitulating the biosynthesis of most natural compounds [<xref rid="B240-ijms-19-01578" ref-type="bibr">240</xref>,<xref rid="B241-ijms-19-01578" ref-type="bibr">241</xref>,<xref rid="B242-ijms-19-01578" ref-type="bibr">242</xref>]. Importantly, 3D printing can allow for the building of different microfluidic devices with several sophisticated and specialised algorithms to monitor product synthesis. 3D printing is very important for microfluidics platforms as most microfluidics systems are custom made for a specific function. Some of the latest approaches using automated robotic synthesis are remotely controlled making it even more efficient [<xref rid="B243-ijms-19-01578" ref-type="bibr">243</xref>,<xref rid="B244-ijms-19-01578" ref-type="bibr">244</xref>]. Some automated compound synthesis approaches are very versatile with only a small set of building blocks being needed to generate a diverse group of by-products [<xref rid="B245-ijms-19-01578" ref-type="bibr">245</xref>]. Microfluidics based synthesis of compounds allows the continuous synthesis of compounds and not batch-wise. Cytochrome P450-catalysed drug oxidation can now be simulated meaning that in future on-chip chemotransformations of compounds can replace in vitro metabolite identification [<xref rid="B246-ijms-19-01578" ref-type="bibr">246</xref>,<xref rid="B247-ijms-19-01578" ref-type="bibr">247</xref>]. Microfluidics synthesis of compounds, coupled with in-process analysis and purification, is revolutionising drug discovery automation [<xref rid="B248-ijms-19-01578" ref-type="bibr">248</xref>]. Besides the obvious avoidance of human exposure to chemicals and dangerous solutions, microfluidics also allows the use of minimum amounts of compounds and reagents [<xref rid="B249-ijms-19-01578" ref-type="bibr">249</xref>,<xref rid="B250-ijms-19-01578" ref-type="bibr">250</xref>,<xref rid="B251-ijms-19-01578" ref-type="bibr">251</xref>]. Given that most animal models are very poor predictors of human response to drugs and biological testing, microfluidic systems can aid in recapitulating human- and species-specific functions by incorporating organoid-based approaches. This allows for the generation of physiological relevant environments within the microfluidic devices and these can be stable over some time [<xref rid="B252-ijms-19-01578" ref-type="bibr">252</xref>,<xref rid="B253-ijms-19-01578" ref-type="bibr">253</xref>]. Several systems incorporating cancer cells or 3D cancer models have been developed and allow for the recapitulation of human tumours and their microenvironments [<xref rid="B254-ijms-19-01578" ref-type="bibr">254</xref>,<xref rid="B255-ijms-19-01578" ref-type="bibr">255</xref>,<xref rid="B256-ijms-19-01578" ref-type="bibr">256</xref>]. Several constraints do exist for continuous flow systems such as microfluidics synthesis of compounds. The synthesis and eventual deposition of reactive reagents and by-products brings about the danger of fluidic surfaces instability as some of the reagents and solutions used in compound synthesis are incompatible with the microfluidic systems. In addition, clogging of channels of the microfluidic system is a major problem. </p><p>Several integrated microfluidics-assisted synthesise and test platforms are now available combining the reagent and compound selection and can adapt based on materials available for the subsequent steps during synthesis and testing of compounds. Several computational tools and networks (containing millions of reactions and pathways for compound synthesis) used for automated compound synthesis have been developed and aid in finding the optimal and innovative route to compound synthesis [<xref rid="B257-ijms-19-01578" ref-type="bibr">257</xref>,<xref rid="B258-ijms-19-01578" ref-type="bibr">258</xref>,<xref rid="B259-ijms-19-01578" ref-type="bibr">259</xref>,<xref rid="B260-ijms-19-01578" ref-type="bibr">260</xref>]. Drug design with the help of artificial intelligence is a requirement to have a sustainable drug discovery process [<xref rid="B261-ijms-19-01578" ref-type="bibr">261</xref>,<xref rid="B262-ijms-19-01578" ref-type="bibr">262</xref>,<xref rid="B263-ijms-19-01578" ref-type="bibr">263</xref>,<xref rid="B264-ijms-19-01578" ref-type="bibr">264</xref>]. Hypothesis generation if done by machines can result in the designing of compounds using several criteria at the same time. Such criteria can be biological activity, side-effects and synthesizability. Machine-guided hypothesis or generation of compound structures is also much faster and can generate different designs at the same time. Artificial intelligence is therefore an enabling technology, aiding the scientist in pattern recognition and can be optimised to do pattern recognition [<xref rid="B265-ijms-19-01578" ref-type="bibr">265</xref>,<xref rid="B266-ijms-19-01578" ref-type="bibr">266</xref>,<xref rid="B267-ijms-19-01578" ref-type="bibr">267</xref>]. </p></sec><sec id="sec5-ijms-19-01578"><title>5. Computer-Aided Drug Design from Natural Products</title><p>Synthetic compounds with structures inspired by natural products can help solve many global health challenges while in many instances some of the new synthetic compounds would have been discarded as not suitable for drug designs. The so called &#x0201c;rule of three&#x0201d; and &#x0201c;rule of five&#x0201d; criteria often used for decision making with regard to drug leads is too strict and some of the new designs would have been failed [<xref rid="B268-ijms-19-01578" ref-type="bibr">268</xref>,<xref rid="B269-ijms-19-01578" ref-type="bibr">269</xref>,<xref rid="B270-ijms-19-01578" ref-type="bibr">270</xref>,<xref rid="B271-ijms-19-01578" ref-type="bibr">271</xref>,<xref rid="B272-ijms-19-01578" ref-type="bibr">272</xref>]. In fact, many of the guidelines used during drug designing show human bias and therefore are limited in their scope and effectiveness, especially when applied to natural products [<xref rid="B269-ijms-19-01578" ref-type="bibr">269</xref>,<xref rid="B270-ijms-19-01578" ref-type="bibr">270</xref>,<xref rid="B271-ijms-19-01578" ref-type="bibr">271</xref>,<xref rid="B272-ijms-19-01578" ref-type="bibr">272</xref>]. Many therapeutic synthetic compounds have been developed using computer-aided designs and these include several anticancer agents [<xref rid="B273-ijms-19-01578" ref-type="bibr">273</xref>,<xref rid="B274-ijms-19-01578" ref-type="bibr">274</xref>,<xref rid="B275-ijms-19-01578" ref-type="bibr">275</xref>,<xref rid="B276-ijms-19-01578" ref-type="bibr">276</xref>]. The Scaffold Hunter software for example was used to simplify complex natural products to generate virtual fragments of small chemically attractive molecules [<xref rid="B277-ijms-19-01578" ref-type="bibr">277</xref>]. The simple molecules visualised by such computational software must retain the same biological activity as the mother compound. Indeed, this method was already used to identify inhibitors and activators of pyruvate kinase [<xref rid="B278-ijms-19-01578" ref-type="bibr">278</xref>]. However, it is also possible that natural-product derived simple molecules will exhibit weaker activities than the parent compound [<xref rid="B275-ijms-19-01578" ref-type="bibr">275</xref>,<xref rid="B276-ijms-19-01578" ref-type="bibr">276</xref>]. The PASS software has been used to predict the biological activities of simple structures or chemical structures obtained from the mother compound with considerable success [<xref rid="B279-ijms-19-01578" ref-type="bibr">279</xref>,<xref rid="B280-ijms-19-01578" ref-type="bibr">280</xref>]. The PASS software has predicted the anti-tumour activities of several marine alkaloids [<xref rid="B278-ijms-19-01578" ref-type="bibr">278</xref>,<xref rid="B279-ijms-19-01578" ref-type="bibr">279</xref>,<xref rid="B280-ijms-19-01578" ref-type="bibr">280</xref>]. </p><p>Indeed several individual compounds from St John&#x02019;s wort were also predicted rightly to have cytochrome P450 modulating effects [<xref rid="B278-ijms-19-01578" ref-type="bibr">278</xref>]. Several computational softwares, databases and web servers have been developed that can predict compound-target associations. Most if not all of these softwares use the similarity of new compound to known drugs to infer target and normal ligand&#x02013;receptor docking. In the absence of any similarity between new compound and any known drug, the SPIDER software can compare computed features between natural products and new compound to predict the target of the new compound [<xref rid="B281-ijms-19-01578" ref-type="bibr">281</xref>,<xref rid="B282-ijms-19-01578" ref-type="bibr">282</xref>]. The identification of G-protein coupled receptor ligands was one of the success stories of the SPIDER software [<xref rid="B282-ijms-19-01578" ref-type="bibr">282</xref>]. The use of computational drug design and target prediction is now tangible and will continue to influence drug development in the near future. However only previously studied targets or proteins can be predicted. Computer based quantitative structure activity approaches can be employed in natural product drug discovery to explain the molecular basis of their therapeutic values and to predict possible derivatives that would improve activity [<xref rid="B283-ijms-19-01578" ref-type="bibr">283</xref>]. The positive aspect of computer-based drug designs is that it guides optimization of lead compounds as to whether to increase their affinity or pharmacodynamic and pharmacokinetic properties. </p><p>New systems are being developed in order to detect candidate or lead compound toxicity at early stages of drug discovery [<xref rid="B284-ijms-19-01578" ref-type="bibr">284</xref>,<xref rid="B285-ijms-19-01578" ref-type="bibr">285</xref>,<xref rid="B286-ijms-19-01578" ref-type="bibr">286</xref>,<xref rid="B287-ijms-19-01578" ref-type="bibr">287</xref>]. Strategies employing in silico methods can be used to detect drug toxicity early on along the drug discovery process. Such approaches if combined with in vitro and in vivo biological testing can drastically decrease the time and cost of drug discovery and improve safety evaluation. Quantitative structure&#x02013;activity relationship models aim to understand the relationship between the structure of a compound and its toxicity [<xref rid="B288-ijms-19-01578" ref-type="bibr">288</xref>,<xref rid="B289-ijms-19-01578" ref-type="bibr">289</xref>,<xref rid="B290-ijms-19-01578" ref-type="bibr">290</xref>,<xref rid="B291-ijms-19-01578" ref-type="bibr">291</xref>]. To understand the possible accumulation of the drug and its metabolism properties such as adsorption, distribution, metabolism and excretion must be evaluated [<xref rid="B292-ijms-19-01578" ref-type="bibr">292</xref>,<xref rid="B293-ijms-19-01578" ref-type="bibr">293</xref>,<xref rid="B294-ijms-19-01578" ref-type="bibr">294</xref>,<xref rid="B295-ijms-19-01578" ref-type="bibr">295</xref>]. To compound the issue of candidate compound toxicity, one has to consider environmental toxicity. So, during drug discovery the potential risk of having a drug in the environment must be addressed. These candidate compounds or lead compounds may have toxic effects on other animals. </p><p>The advent of advanced technologies has allowed scientists to discover the magnitude of tumour heterogeneity and the different patients&#x02019; responses to treatment [<xref rid="B296-ijms-19-01578" ref-type="bibr">296</xref>,<xref rid="B297-ijms-19-01578" ref-type="bibr">297</xref>,<xref rid="B298-ijms-19-01578" ref-type="bibr">298</xref>,<xref rid="B299-ijms-19-01578" ref-type="bibr">299</xref>]. Drug discovery however is based on the &#x0201c;one drug-one target&#x0201d; strategy. It is a fact that combination therapy is the gold standard nowadays. Thus, drug design must take a combinatorial approach, where two or more drugs either target the same pathway or act synergistically to achieve a cure. Conventional chemotherapeutic agents may be combined with targeted therapies such as kinase inhibitors [<xref rid="B300-ijms-19-01578" ref-type="bibr">300</xref>,<xref rid="B301-ijms-19-01578" ref-type="bibr">301</xref>,<xref rid="B302-ijms-19-01578" ref-type="bibr">302</xref>,<xref rid="B303-ijms-19-01578" ref-type="bibr">303</xref>,<xref rid="B304-ijms-19-01578" ref-type="bibr">304</xref>]. Now, a few approaches for computer-based screening for combinatorial drug design and treatment are under development. </p></sec><sec id="sec6-ijms-19-01578"><title>6. Natural Products and Precision Medicine</title><p>The past few years have seen genomics informing drug discovery but overall the clinical efficacy of the resultant drugs has been poor. This is largely due to the complex nature of diseases. Advances in technological and analytical tools used in genomics now allow for the rapid identification and interpretation of genetic differences driving patient specific features of disease (<xref ref-type="fig" rid="ijms-19-01578-f004">Figure 4</xref>) [<xref rid="B33-ijms-19-01578" ref-type="bibr">33</xref>,<xref rid="B222-ijms-19-01578" ref-type="bibr">222</xref>]. Precision medicine would then target these specific features to obtain a cure. At the heart of the Human Genome project lies the need to understand how genetics impacts disease and vice versa. For oncologists and cancer scientists, how genetics can transform drug discovery has generated a lot of excitement. The rapid development of many new techniques now allows the analysis of patients&#x02019; and healthy individuals genomes (<xref ref-type="fig" rid="ijms-19-01578-f004">Figure 4</xref>). Importantly it is possible to link a patient&#x02019;s genome and clinical presentation [<xref rid="B305-ijms-19-01578" ref-type="bibr">305</xref>]. Investigations of whether specific proteins are drug targets culminated in many drugs in use today. Over time however, productivity in terms of drugs produced declined as there were no more definite new drug targets. The &#x0201c;gene to screen&#x0201d; approach was based on the realisation that genes expressed within a cell are the main contributor to the overall cellular phenotype [<xref rid="B306-ijms-19-01578" ref-type="bibr">306</xref>,<xref rid="B307-ijms-19-01578" ref-type="bibr">307</xref>]. Genome-wide association studies (GWAS) is a cost-effective and unbiased way of genotyping and comparison of genomic variations between patients with disease and healthy individuals. GWAS has led to the identification of genetic determinants of diseases and underlying mechanisms driving disease development.</p></sec><sec id="sec7-ijms-19-01578"><title>7. Conclusions</title><p>The low success rate of drug discovery requires a paradigm shift for innovative drug development strategies. Innovative drug discovery starts by deriving inspiration from natural products for effective treatment of disease conditions. The relevance of natural products in providing innovative drugs to find solutions to communicable and non-communicable diseases cannot be over-emphasized. Technological advances have made it possible to understand the profiles of these complex natural products with the potential to discover new drugs for use. An impressive number of blockbuster drugs have been isolated or synthesized from natural product lead compounds. This positions natural product drug discovery as a very successful strategy for the development of novel therapeutic drugs. In this era of advancing scientific technology, innovative drug discovery from natural products will potentially increase the success rate of new therapeutic moieties. Natural product drug discovery stands as a major contributor to solving global health challenges and achieving sustainable development goals on health.</p></sec></body><back><ack><title>Acknowledgments</title><p>The funding for this research was provided by the National Research Foundation (NRF) of South Africa (Grant Number: 91457: RCA13101656402), International Centre for Genetic Engineering and Biotechnology (ICGEB) (Grant Number: 2015/0001), Faculty of Health Sciences, UCT and the University of Cape Town.</p></ack><notes><title>Author Contributions</title><p>N.E.T. and K.D. wrote the main body of the Review manuscript. All authors reviewed and commented the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-19-01578"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>J.K.</given-names></name><name><surname>Philippe</surname><given-names>R.N.</given-names></name><name><surname>Noel</surname><given-names>J.P.</given-names></name></person-group><article-title>The rise of chemodiversity in plants</article-title><source>Science</source><year>2012</year><volume>336</volume><fpage>1667</fpage><lpage>1670</lpage><pub-id pub-id-type="doi">10.1126/science.1217411</pub-id><?supplied-pmid 22745420?><pub-id pub-id-type="pmid">22745420</pub-id></element-citation></ref><ref id="B2-ijms-19-01578"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lietava</surname><given-names>J.</given-names></name></person-group><article-title>Medicinal plants in a Middle Paleolithic grave Shanidar IV?</article-title><source>J. Ethnopharmacol.</source><year>1992</year><volume>35</volume><fpage>263</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/0378-8741(92)90023-K</pub-id><pub-id pub-id-type="pmid">1548898</pub-id></element-citation></ref><ref id="B3-ijms-19-01578"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>M.</given-names></name><name><surname>Grace</surname><given-names>O.M.</given-names></name><name><surname>Saslis-Lagoudakis</surname><given-names>C.H.</given-names></name><name><surname>Nilsson</surname><given-names>N.</given-names></name><name><surname>Simonsen</surname><given-names>H.T.</given-names></name><name><surname>Ronsted</surname><given-names>N.</given-names></name></person-group><article-title>Global medicinal uses of <italic>Euphorbia</italic> L. (<italic>Euphorbiaceae</italic>)</article-title><source>J. Ethnopharmacol.</source><year>2015</year><volume>176</volume><fpage>90</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2015.10.025</pub-id><?supplied-pmid 26485050?><pub-id pub-id-type="pmid">26485050</pub-id></element-citation></ref><ref id="B4-ijms-19-01578"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gozubuyuk</surname><given-names>G.S.</given-names></name><name><surname>Aktas</surname><given-names>E.</given-names></name><name><surname>Yigit</surname><given-names>N.</given-names></name></person-group><article-title>An ancient plant <italic>Lawsonia inermis</italic> (henna): Determination of in vitro antifungal activity against dermatophytes species</article-title><source>J. Mycol. Med.</source><year>2014</year><volume>24</volume><fpage>313</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1016/j.mycmed.2014.07.002</pub-id><?supplied-pmid 25442917?><pub-id pub-id-type="pmid">25442917</pub-id></element-citation></ref><ref id="B5-ijms-19-01578"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotwani</surname><given-names>K.</given-names></name><name><surname>Baliga</surname><given-names>S.</given-names></name><name><surname>Sharma</surname><given-names>K.</given-names></name></person-group><article-title>Phytodentistry: Use of medicinal plants</article-title><source>J. Complement. Integr. Med.</source><year>2014</year><volume>11</volume><fpage>233</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1515/jcim-2013-0015</pub-id><?supplied-pmid 25153610?><pub-id pub-id-type="pmid">25153610</pub-id></element-citation></ref><ref id="B6-ijms-19-01578"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Lawrence</surname><given-names>A.J.</given-names></name><name><surname>Liang</surname><given-names>J.H.</given-names></name></person-group><article-title>Traditional Chinese medicine for treatment of alcoholism: From ancient to modern</article-title><source>Am. J. Chin. Med.</source><year>2011</year><volume>39</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1142/S0192415X11008609</pub-id><?supplied-pmid 21213394?><pub-id pub-id-type="pmid">21213394</pub-id></element-citation></ref><ref id="B7-ijms-19-01578"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannangatti</surname><given-names>P.</given-names></name><name><surname>Naidu</surname><given-names>K.N.</given-names></name></person-group><article-title>Indian herbs for the treatment of neurodegenerative disease</article-title><source>Adv. Neurobiol.</source><year>2016</year><volume>12</volume><fpage>323</fpage><lpage>336</lpage><?supplied-pmid 27651261?><pub-id pub-id-type="pmid">27651261</pub-id></element-citation></ref><ref id="B8-ijms-19-01578"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGovern</surname><given-names>P.E.</given-names></name><name><surname>Mirzoian</surname><given-names>A.</given-names></name><name><surname>Hall</surname><given-names>G.R.</given-names></name></person-group><article-title>Ancient Egyptian herbal wines</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>7361</fpage><lpage>7366</lpage><pub-id pub-id-type="doi">10.1073/pnas.0811578106</pub-id><?supplied-pmid 19365069?><pub-id pub-id-type="pmid">19365069</pub-id></element-citation></ref><ref id="B9-ijms-19-01578"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blunt</surname><given-names>J.W.</given-names></name><name><surname>Carroll</surname><given-names>A.R.</given-names></name><name><surname>Copp</surname><given-names>B.R.</given-names></name><name><surname>Davis</surname><given-names>R.A.</given-names></name><name><surname>Keyzers</surname><given-names>R.A.</given-names></name><name><surname>Prinsep</surname><given-names>M.R.</given-names></name></person-group><article-title>Marine natural products</article-title><source>Nat. Prod. Rep.</source><year>2018</year><volume>35</volume><fpage>8</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1039/C7NP00052A</pub-id><?supplied-pmid 29335692?><pub-id pub-id-type="pmid">29335692</pub-id></element-citation></ref><ref id="B10-ijms-19-01578"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>A.L.</given-names></name></person-group><article-title>Natural products in drug discovery</article-title><source>Drug Discov. Today</source><year>2008</year><volume>13</volume><fpage>894</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2008.07.004</pub-id><?supplied-pmid 18691670?><pub-id pub-id-type="pmid">18691670</pub-id></element-citation></ref><ref id="B11-ijms-19-01578"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>A.L.</given-names></name><name><surname>Clark</surname><given-names>R.L.</given-names></name><name><surname>Mackay</surname><given-names>S.P.</given-names></name><name><surname>Johnston</surname><given-names>B.F.</given-names></name></person-group><article-title>Current strategies for drug discovery through natural products</article-title><source>Expert Opin. Drug Discov.</source><year>2010</year><volume>5</volume><fpage>559</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1517/17460441.2010.488263</pub-id><?supplied-pmid 22823167?><pub-id pub-id-type="pmid">22823167</pub-id></element-citation></ref><ref id="B12-ijms-19-01578"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>A.L.</given-names></name><name><surname>Edrada-Ebel</surname><given-names>R.</given-names></name><name><surname>Quinn</surname><given-names>R.J.</given-names></name></person-group><article-title>The re-emergence of natural products for drug discovery in the genomics era</article-title><source>Nat. Rev. Drug Discov.</source><year>2015</year><volume>14</volume><fpage>111</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1038/nrd4510</pub-id><?supplied-pmid 25614221?><pub-id pub-id-type="pmid">25614221</pub-id></element-citation></ref><ref id="B13-ijms-19-01578"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Kwon</surname><given-names>H.J.</given-names></name></person-group><article-title>Advances in identification and validation of protein targets of natural products without chemical modification</article-title><source>Nat. Prod. Rep.</source><year>2016</year><volume>33</volume><fpage>719</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1039/C5NP00107B</pub-id><?supplied-pmid 26964663?><pub-id pub-id-type="pmid">26964663</pub-id></element-citation></ref><ref id="B14-ijms-19-01578"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tansaz</surname><given-names>M.</given-names></name><name><surname>Tajadini</surname><given-names>H.</given-names></name></person-group><article-title>Comparison of leiomyoma of modern medicine and traditional Persian medicine</article-title><source>J. Evid.-Based Complement. Altern. Med.</source><year>2016</year><volume>21</volume><fpage>160</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1177/2156587215595299</pub-id><?supplied-pmid 26177818?><pub-id pub-id-type="pmid">26177818</pub-id></element-citation></ref><ref id="B15-ijms-19-01578"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Bauer</surname><given-names>R.</given-names></name><name><surname>Hendry</surname><given-names>B.M.</given-names></name><name><surname>Fan</surname><given-names>T.P.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Duez</surname><given-names>P.</given-names></name><name><surname>Simmonds</surname><given-names>M.S.</given-names></name><name><surname>Witt</surname><given-names>C.M.</given-names></name><name><surname>Lu</surname><given-names>A.</given-names></name><name><surname>Robinson</surname><given-names>N.</given-names></name><etal/></person-group><article-title>The quest for modernisation of traditional Chinese medicine</article-title><source>BMC Complement. Altern. Med.</source><year>2013</year><volume>13</volume><elocation-id>132</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6882-13-132</pub-id><?supplied-pmid 23763836?><pub-id pub-id-type="pmid">23763836</pub-id></element-citation></ref><ref id="B16-ijms-19-01578"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name><name><surname>Ye</surname><given-names>L.</given-names></name><name><surname>Piao</surname><given-names>G.</given-names></name></person-group><article-title>The traditional medicine and modern medicine from natural products</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>559</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21050559</pub-id><?supplied-pmid 27136524?><pub-id pub-id-type="pmid">27136524</pub-id></element-citation></ref><ref id="B17-ijms-19-01578"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banjari</surname><given-names>I.</given-names></name><name><surname>Misir</surname><given-names>A.</given-names></name><name><surname>Savikin</surname><given-names>K.</given-names></name><name><surname>Jokic</surname><given-names>S.</given-names></name><name><surname>Molnar</surname><given-names>M.</given-names></name><name><surname>De Zoysa</surname><given-names>H.K.S.</given-names></name><name><surname>Waisundara</surname><given-names>V.Y.</given-names></name></person-group><article-title>Antidiabetic effects of <italic>Aronia melanocarpa</italic> and its other therapeutic properties</article-title><source>Front. Nutr.</source><year>2017</year><volume>4</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.3389/fnut.2017.00053</pub-id><?supplied-pmid 29164127?><pub-id pub-id-type="pmid">29164127</pub-id></element-citation></ref><ref id="B18-ijms-19-01578"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yatoo</surname><given-names>M.I.</given-names></name><name><surname>Dimri</surname><given-names>U.</given-names></name><name><surname>Gopalakrishnan</surname><given-names>A.</given-names></name><name><surname>Karthik</surname><given-names>K.</given-names></name><name><surname>Gopi</surname><given-names>M.</given-names></name><name><surname>Khandia</surname><given-names>R.</given-names></name><name><surname>Saminathan</surname><given-names>M.</given-names></name><name><surname>Saxena</surname><given-names>A.</given-names></name><name><surname>Alagawany</surname><given-names>M.</given-names></name><name><surname>Farag</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Beneficial health applications and medicinal values of pedicularis plants: A review</article-title><source>Biomed. Pharmacother.</source><year>2017</year><volume>95</volume><fpage>1301</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.09.041</pub-id><?supplied-pmid 28938521?><pub-id pub-id-type="pmid">28938521</pub-id></element-citation></ref><ref id="B19-ijms-19-01578"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomford</surname><given-names>N.E.</given-names></name><name><surname>Awortwe</surname><given-names>C.</given-names></name><name><surname>Dzobo</surname><given-names>K.</given-names></name><name><surname>Adu</surname><given-names>F.</given-names></name><name><surname>Chopera</surname><given-names>D.</given-names></name><name><surname>Wonkam</surname><given-names>A.</given-names></name><name><surname>Skelton</surname><given-names>M.</given-names></name><name><surname>Blackhurst</surname><given-names>D.</given-names></name><name><surname>Dandara</surname><given-names>C.</given-names></name></person-group><article-title>Inhibition of cyp2b6 by medicinal plant extracts: Implication for use of efavirenz and nevirapine-based highly active anti-retroviral therapy (HAART) in resource-limited settings</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>211</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21020211</pub-id><?supplied-pmid 26891286?><pub-id pub-id-type="pmid">26891286</pub-id></element-citation></ref><ref id="B20-ijms-19-01578"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomford</surname><given-names>N.E.</given-names></name><name><surname>Dzobo</surname><given-names>K.</given-names></name><name><surname>Chopera</surname><given-names>D.</given-names></name><name><surname>Wonkam</surname><given-names>A.</given-names></name><name><surname>Maroyi</surname><given-names>A.</given-names></name><name><surname>Blackhurst</surname><given-names>D.</given-names></name><name><surname>Dandara</surname><given-names>C.</given-names></name></person-group><article-title>In vitro reversible and time-dependent cyp450 inhibition profiles of medicinal herbal plant extracts <italic>Newbouldia laevis</italic> and <italic>Cassia abbreviata</italic>: Implications for herb-drug interactions</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>891</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21070891</pub-id><?supplied-pmid 27399660?><pub-id pub-id-type="pmid">27399660</pub-id></element-citation></ref><ref id="B21-ijms-19-01578"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomford</surname><given-names>N.E.</given-names></name><name><surname>Dzobo</surname><given-names>K.</given-names></name><name><surname>Chopera</surname><given-names>D.</given-names></name><name><surname>Wonkam</surname><given-names>A.</given-names></name><name><surname>Skelton</surname><given-names>M.</given-names></name><name><surname>Blackhurst</surname><given-names>D.</given-names></name><name><surname>Chirikure</surname><given-names>S.</given-names></name><name><surname>Dandara</surname><given-names>C.</given-names></name></person-group><article-title>Pharmacogenomics implications of using herbal medicinal plants on African populations in health transition</article-title><source>Pharmaceuticals</source><year>2015</year><volume>8</volume><fpage>637</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.3390/ph8030637</pub-id><?supplied-pmid 26402689?><pub-id pub-id-type="pmid">26402689</pub-id></element-citation></ref><ref id="B22-ijms-19-01578"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomford</surname><given-names>N.E.</given-names></name><name><surname>Mkhize</surname><given-names>B.</given-names></name><name><surname>Dzobo</surname><given-names>K.</given-names></name><name><surname>Mpye</surname><given-names>K.</given-names></name><name><surname>Rowe</surname><given-names>A.</given-names></name><name><surname>Parker</surname><given-names>M.I.</given-names></name><name><surname>Wonkam</surname><given-names>A.</given-names></name><name><surname>Skelton</surname><given-names>M.</given-names></name><name><surname>September</surname><given-names>A.V.</given-names></name><name><surname>Dandara</surname><given-names>C.</given-names></name></person-group><article-title>African lettuce (<italic>Launaea taraxacifolia</italic>) displays possible anticancer effects and herb-drug interaction potential by CYP1A2, CYP2C9, and CYP2C19 inhibition</article-title><source>Omics</source><year>2016</year><volume>20</volume><fpage>528</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1089/omi.2016.0117</pub-id><?supplied-pmid 27631192?><pub-id pub-id-type="pmid">27631192</pub-id></element-citation></ref><ref id="B23-ijms-19-01578"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>S.</given-names></name><name><surname>Fattahi</surname><given-names>A.</given-names></name><name><surname>Raffel</surname><given-names>N.</given-names></name><name><surname>Hoffmann</surname><given-names>I.</given-names></name><name><surname>Beckmann</surname><given-names>M.W.</given-names></name><name><surname>Dittrich</surname><given-names>R.</given-names></name><name><surname>Schrauder</surname><given-names>M.</given-names></name></person-group><article-title>Antioxidant effect of aqueous extract of four plants with therapeutic potential on gynecological diseases; semen persicae, <italic>Leonurus cardiaca</italic>, <italic>Hedyotis diffusa</italic>, and <italic>Curcuma zedoaria</italic></article-title><source>Eur. J. Med. Res.</source><year>2017</year><volume>22</volume><fpage>50</fpage><pub-id pub-id-type="doi">10.1186/s40001-017-0293-6</pub-id><?supplied-pmid 29178942?><pub-id pub-id-type="pmid">29178942</pub-id></element-citation></ref><ref id="B24-ijms-19-01578"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruhsam</surname><given-names>M.</given-names></name><name><surname>Hollingsworth</surname><given-names>P.M.</given-names></name></person-group><article-title>Authentication of eleutherococcus and rhodiola herbal supplement products in the United Kingdom</article-title><source>J. Pharm. Biomed. Anal.</source><year>2017</year><volume>149</volume><fpage>403</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2017.11.025</pub-id><?supplied-pmid 29154110?><pub-id pub-id-type="pmid">29154110</pub-id></element-citation></ref><ref id="B25-ijms-19-01578"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patridge</surname><given-names>E.</given-names></name><name><surname>Gareiss</surname><given-names>P.</given-names></name><name><surname>Kinch</surname><given-names>M.S.</given-names></name><name><surname>Hoyer</surname><given-names>D.</given-names></name></person-group><article-title>An analysis of FDA-approved drugs: Natural products and their derivatives</article-title><source>Drug Discov. Today</source><year>2016</year><volume>21</volume><fpage>204</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2015.01.009</pub-id><?supplied-pmid 25617672?><pub-id pub-id-type="pmid">25617672</pub-id></element-citation></ref><ref id="B26-ijms-19-01578"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wani</surname><given-names>M.C.</given-names></name><name><surname>Taylor</surname><given-names>H.L.</given-names></name><name><surname>Wall</surname><given-names>M.E.</given-names></name><name><surname>Coggon</surname><given-names>P.</given-names></name><name><surname>McPhail</surname><given-names>A.T.</given-names></name></person-group><article-title>Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from <italic>Taxus brevifolia</italic></article-title><source>J. Am. Chem. Soc.</source><year>1971</year><volume>93</volume><fpage>2325</fpage><lpage>2327</lpage><pub-id pub-id-type="doi">10.1021/ja00738a045</pub-id><?supplied-pmid 5553076?><pub-id pub-id-type="pmid">5553076</pub-id></element-citation></ref><ref id="B27-ijms-19-01578"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>D.J.</given-names></name><name><surname>Cragg</surname><given-names>G.M.</given-names></name></person-group><article-title>Natural products as sources of new drugs over the 30 years from 1981 to 2010</article-title><source>J. Nat. Prod.</source><year>2012</year><volume>75</volume><fpage>311</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1021/np200906s</pub-id><?supplied-pmid 22316239?><pub-id pub-id-type="pmid">22316239</pub-id></element-citation></ref><ref id="B28-ijms-19-01578"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>G.T.</given-names></name></person-group><article-title>Natural products and Pharma 2011: Strategic changes spur new opportunities</article-title><source>Nat. Prod. Rep.</source><year>2011</year><volume>28</volume><fpage>1783</fpage><lpage>1789</lpage><pub-id pub-id-type="doi">10.1039/c1np00033k</pub-id><?supplied-pmid 21909580?><pub-id pub-id-type="pmid">21909580</pub-id></element-citation></ref><ref id="B29-ijms-19-01578"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.W.</given-names></name><name><surname>Vederas</surname><given-names>J.C.</given-names></name></person-group><article-title>Drug discovery and natural products: End of an era or an endless frontier?</article-title><source>Science</source><year>2009</year><volume>325</volume><fpage>161</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1126/science.1168243</pub-id><?supplied-pmid 19589993?><pub-id pub-id-type="pmid">19589993</pub-id></element-citation></ref><ref id="B30-ijms-19-01578"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.S.</given-names></name><name><surname>Weng</surname><given-names>J.K.</given-names></name></person-group><article-title>Demystifying traditional herbal medicine with modern approach</article-title><source>Nat. Plants</source><year>2017</year><volume>3</volume><fpage>17109</fpage><pub-id pub-id-type="doi">10.1038/nplants.2017.109</pub-id><?supplied-pmid 28758992?><pub-id pub-id-type="pmid">28758992</pub-id></element-citation></ref><ref id="B31-ijms-19-01578"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiyohara</surname><given-names>H.</given-names></name><name><surname>Matsumoto</surname><given-names>T.</given-names></name><name><surname>Yamada</surname><given-names>H.</given-names></name></person-group><article-title>Combination effects of herbs in a multi-herbal formula: Expression of juzen-taiho-to&#x02019;s immuno-modulatory activity on the intestinal immune system</article-title><source>Evid.-Based Complement. Altern. Med.</source><year>2004</year><volume>1</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1093/ecam/neh004</pub-id><?supplied-pmid 15257329?><pub-id pub-id-type="pmid">15257329</pub-id></element-citation></ref><ref id="B32-ijms-19-01578"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonti</surname><given-names>M.</given-names></name><name><surname>Verpoorte</surname><given-names>R.</given-names></name></person-group><article-title>Traditional Mediterranean and European herbal medicines</article-title><source>J. Ethnopharmacol.</source><year>2017</year><volume>199</volume><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2017.01.052</pub-id><?supplied-pmid 28179113?><pub-id pub-id-type="pmid">28179113</pub-id></element-citation></ref><ref id="B33-ijms-19-01578"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozdemir</surname><given-names>V.</given-names></name><name><surname>Hekim</surname><given-names>N.</given-names></name></person-group><article-title>Birth of industry 5.0: Making sense of big data with artificial intelligence, &#x0201c;the internet of things&#x0201d; and next-generation technology policy</article-title><source>Omics</source><year>2018</year><volume>22</volume><fpage>65</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1089/omi.2017.0194</pub-id><?supplied-pmid 29293405?><pub-id pub-id-type="pmid">29293405</pub-id></element-citation></ref><ref id="B34-ijms-19-01578"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zdemir</surname><given-names>V.</given-names></name></person-group><article-title>Omics 2.0: An accelerator for global science, systems medicine and responsible innovation</article-title><source>Omics</source><year>2015</year><volume>19</volume><fpage>579</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1089/omi.2015.0133</pub-id><?supplied-pmid 26484977?><pub-id pub-id-type="pmid">26484977</pub-id></element-citation></ref><ref id="B35-ijms-19-01578"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname><given-names>M.E.</given-names></name><name><surname>Wani</surname><given-names>M.C.</given-names></name><name><surname>Brown</surname><given-names>D.M.</given-names></name><name><surname>Fullas</surname><given-names>F.</given-names></name><name><surname>Olwald</surname><given-names>J.B.</given-names></name><name><surname>Josephson</surname><given-names>F.F.</given-names></name><name><surname>Thornton</surname><given-names>N.M.</given-names></name><name><surname>Pezzuto</surname><given-names>J.M.</given-names></name><name><surname>Beecher</surname><given-names>C.W.</given-names></name><name><surname>Farnsworth</surname><given-names>N.R.</given-names></name><etal/></person-group><article-title>Effect of tannins on screening of plant extracts for enzyme inhibitory activity and techniques for their removal</article-title><source>Phytomedicine</source><year>1996</year><volume>3</volume><fpage>281</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/S0944-7113(96)80067-5</pub-id><pub-id pub-id-type="pmid">23195084</pub-id></element-citation></ref><ref id="B36-ijms-19-01578"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eldridge</surname><given-names>G.R.</given-names></name><name><surname>Vervoort</surname><given-names>H.C.</given-names></name><name><surname>Lee</surname><given-names>C.M.</given-names></name><name><surname>Cremin</surname><given-names>P.A.</given-names></name><name><surname>Williams</surname><given-names>C.T.</given-names></name><name><surname>Hart</surname><given-names>S.M.</given-names></name><name><surname>Goering</surname><given-names>M.G.</given-names></name><name><surname>O&#x02019;Neil-Johnson</surname><given-names>M.</given-names></name><name><surname>Zeng</surname><given-names>L.</given-names></name></person-group><article-title>High-throughput method for the production and analysis of large natural product libraries for drug discovery</article-title><source>Anal. Chem.</source><year>2002</year><volume>74</volume><fpage>3963</fpage><lpage>3971</lpage><pub-id pub-id-type="doi">10.1021/ac025534s</pub-id><?supplied-pmid 12199561?><pub-id pub-id-type="pmid">12199561</pub-id></element-citation></ref><ref id="B37-ijms-19-01578"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name></person-group><article-title>Counter-current chromatography for high throughput analysis of natural products</article-title><source>Comb. Chem. High Throughput Screen.</source><year>2010</year><volume>13</volume><fpage>932</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.2174/138620710793360248</pub-id><?supplied-pmid 20883188?><pub-id pub-id-type="pmid">20883188</pub-id></element-citation></ref><ref id="B38-ijms-19-01578"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugni</surname><given-names>T.S.</given-names></name><name><surname>Richards</surname><given-names>B.</given-names></name><name><surname>Bhoite</surname><given-names>L.</given-names></name><name><surname>Cimbora</surname><given-names>D.</given-names></name><name><surname>Harper</surname><given-names>M.K.</given-names></name><name><surname>Ireland</surname><given-names>C.M.</given-names></name></person-group><article-title>Marine natural product libraries for high-throughput screening and rapid drug discovery</article-title><source>J. Nat. Prod.</source><year>2008</year><volume>71</volume><fpage>1095</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1021/np800184g</pub-id><?supplied-pmid 18505284?><pub-id pub-id-type="pmid">18505284</pub-id></element-citation></ref><ref id="B39-ijms-19-01578"><label>39.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Koehn</surname><given-names>F.E.</given-names></name></person-group><article-title>High impact technologies for natural products screening</article-title><source>Natural Compounds as Drugs Volume I</source><publisher-name>Birkh&#x000e4;user</publisher-name><publisher-loc>Basel, Switzerland</publisher-loc><year>2008</year><volume>Volume 65</volume><fpage>175</fpage><lpage>210</lpage></element-citation></ref><ref id="B40-ijms-19-01578"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>W.R.</given-names></name><name><surname>Oliver</surname><given-names>A.G.</given-names></name><name><surname>Linington</surname><given-names>R.G.</given-names></name></person-group><article-title>Development of antibiotic activity profile screening for the classification and discovery of natural product antibiotics</article-title><source>Chem. Biol.</source><year>2012</year><volume>19</volume><fpage>1483</fpage><lpage>1495</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2012.09.014</pub-id><?supplied-pmid 23177202?><pub-id pub-id-type="pmid">23177202</pub-id></element-citation></ref><ref id="B41-ijms-19-01578"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>G.</given-names></name><name><surname>Yin</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Semi-bionic extraction of effective ingredient from fishbone by high intensity pulsed electric fields</article-title><source>J. Food Process Eng.</source><year>2017</year><volume>40</volume><fpage>e12392</fpage><pub-id pub-id-type="doi">10.1111/jfpe.12392</pub-id></element-citation></ref><ref id="B42-ijms-19-01578"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>T.</given-names></name><name><surname>Nagatomi</surname><given-names>Y.</given-names></name><name><surname>Harayama</surname><given-names>K.</given-names></name><name><surname>Bamba</surname><given-names>T.</given-names></name></person-group><article-title>Development of an analytical method for polycyclic aromatic hydrocarbons in coffee beverages and dark beer using novel high-sensitivity technique of supercritical fluid chromatography/mass spectrometry</article-title><source>J. Biosci. Bioeng.</source><year>2018</year><pub-id pub-id-type="doi">10.1016/j.jbiosc.2018.01.014</pub-id><?supplied-pmid 29499993?><pub-id pub-id-type="pmid">29499993</pub-id></element-citation></ref><ref id="B43-ijms-19-01578"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofstetter</surname><given-names>R.</given-names></name><name><surname>Fassauer</surname><given-names>G.M.</given-names></name><name><surname>Link</surname><given-names>A.</given-names></name></person-group><article-title>Supercritical fluid extraction (SFE) of ketamine metabolites from dried urine and on-line quantification by supercritical fluid chromatography and single mass detection (on-line SFE&#x02013;SFC&#x02013;MS)</article-title><source>J. Chromatogr. B</source><year>2018</year><volume>1076</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2018.01.024</pub-id><?supplied-pmid 29406031?><pub-id pub-id-type="pmid">29406031</pub-id></element-citation></ref><ref id="B44-ijms-19-01578"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>D.</given-names></name><name><surname>Piris</surname><given-names>A.J.</given-names></name><name><surname>Ruiz-Rodriguez</surname><given-names>A.</given-names></name><name><surname>Prodanov</surname><given-names>M.</given-names></name><name><surname>Soler-Rivas</surname><given-names>C.</given-names></name></person-group><article-title>Extraction of bioactive compounds against cardiovascular diseases from <italic>Lentinula edodes</italic> using a sequential extraction method</article-title><source>Biotechnol. Prog.</source><year>2018</year><pub-id pub-id-type="doi">10.1002/btpr.2616</pub-id><?supplied-pmid 29388355?><pub-id pub-id-type="pmid">29388355</pub-id></element-citation></ref><ref id="B45-ijms-19-01578"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joana Gil-Ch&#x000e1;vez</surname><given-names>G.</given-names></name><name><surname>Villa</surname><given-names>J.A.</given-names></name><name><surname>Fernando Ayala-Zavala</surname><given-names>J.</given-names></name><name><surname>Basilio Heredia</surname><given-names>J.</given-names></name><name><surname>Sepulveda</surname><given-names>D.</given-names></name><name><surname>Yahia</surname><given-names>E.M.</given-names></name><name><surname>Gonz&#x000e1;lez-Aguilar</surname><given-names>G.A.</given-names></name></person-group><article-title>Technologies for extraction and production of bioactive compounds to be used as nutraceuticals and food ingredients: An overview</article-title><source>Compr. Rev. Food Sci. Food Saf.</source><year>2013</year><volume>12</volume><fpage>5</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1111/1541-4337.12005</pub-id></element-citation></ref><ref id="B46-ijms-19-01578"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Morais</surname><given-names>S.R.</given-names></name><name><surname>Oliveira</surname><given-names>T.L.</given-names></name><name><surname>de Oliveira</surname><given-names>L.P.</given-names></name><name><surname>Tresvenzol</surname><given-names>L.M.</given-names></name><name><surname>da Conceicao</surname><given-names>E.C.</given-names></name><name><surname>Rezende</surname><given-names>M.H.</given-names></name><name><surname>Fiuza</surname><given-names>T.S.</given-names></name><name><surname>Costa</surname><given-names>E.A.</given-names></name><name><surname>Ferri</surname><given-names>P.H.</given-names></name><name><surname>de Paula</surname><given-names>J.R.</given-names></name></person-group><article-title>Essential oil composition, antimicrobial and pharmacological activities of <italic>Lippia sidoides</italic> cham. (verbenaceae) from Sao Goncalo do Abaete, Minas Gerais, Brazil</article-title><source>Pharmacogn. Mag.</source><year>2016</year><volume>12</volume><fpage>262</fpage><lpage>270</lpage><?supplied-pmid 27867267?><pub-id pub-id-type="pmid">27867267</pub-id></element-citation></ref><ref id="B47-ijms-19-01578"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>Z.</given-names></name><name><surname>Liang</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Wen</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Ni</surname><given-names>Y.</given-names></name></person-group><article-title>Separation and preparation of 6-gingerol from molecular distillation residue of Yunnan ginger rhizomes by high-speed counter-current chromatography and the antioxidant activity of ginger oils in vitro</article-title><source>J. Chromatogr. B Anal. Technol. Biomed. Life Sci.</source><year>2016</year><volume>1011</volume><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2015.12.051</pub-id><?supplied-pmid 26773887?><pub-id pub-id-type="pmid">26773887</pub-id></element-citation></ref><ref id="B48-ijms-19-01578"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Mei</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>He</surname><given-names>C.</given-names></name></person-group><article-title>Application of membrane separation technology in extraction process of Chuanxiong Chatiao granules</article-title><source>Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China J. Chin. Mater. Med.</source><year>2012</year><volume>37</volume><fpage>934</fpage><lpage>936</lpage></element-citation></ref><ref id="B49-ijms-19-01578"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>S.</given-names></name><name><surname>Oatley</surname><given-names>D.</given-names></name><name><surname>Abdrahman</surname><given-names>A.</given-names></name><name><surname>Butt</surname><given-names>T.</given-names></name><name><surname>Nash</surname><given-names>R.</given-names></name></person-group><article-title>Membrane technology for the improved separation of bioactive compounds</article-title><source>Procedia Eng.</source><year>2012</year><volume>44</volume><fpage>2112</fpage><lpage>2114</lpage><pub-id pub-id-type="doi">10.1016/j.proeng.2012.09.064</pub-id></element-citation></ref><ref id="B50-ijms-19-01578"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Ding</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Hao</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>X.M.</given-names></name><name><surname>Chang</surname><given-names>Y.X.</given-names></name></person-group><article-title>Simultaneous determination and qualitative analysis of six types of components in Naoxintong capsule by miniaturized matrix solid-phase dispersion extraction coupled with ultra high-performance liquid chromatography with photodiode array detection and quadrupole time-of-flight mass spectrometry</article-title><source>J. Sep. Sci.</source><year>2018</year><pub-id pub-id-type="doi">10.1002/jssc.201701411</pub-id></element-citation></ref><ref id="B51-ijms-19-01578"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Ge</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Hao</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>X.M.</given-names></name><name><surname>Chang</surname><given-names>Y.X.</given-names></name></person-group><article-title>Simultaneous determination of columbianetin-beta-d-glucopyranoside and columbianetin in a biological sample by high-performance liquid chromatography with fluorescence detection and identification of other columbianetin-beta-d-glucopyranoside metabolites by ultra high-performance liquid chromatography coupled with quadrupole-time of flight mass spectrometry</article-title><source>J. Pharm. Biomed. Anal.</source><year>2018</year><volume>153</volume><fpage>221</fpage><lpage>231</lpage><?supplied-pmid 29506005?><pub-id pub-id-type="pmid">29506005</pub-id></element-citation></ref><ref id="B52-ijms-19-01578"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manglik</surname><given-names>A.</given-names></name><name><surname>Kruse</surname><given-names>A.C.</given-names></name><name><surname>Kobilka</surname><given-names>T.S.</given-names></name><name><surname>Thian</surname><given-names>F.S.</given-names></name><name><surname>Mathiesen</surname><given-names>J.M.</given-names></name><name><surname>Sunahara</surname><given-names>R.K.</given-names></name><name><surname>Pardo</surname><given-names>L.</given-names></name><name><surname>Weis</surname><given-names>W.I.</given-names></name><name><surname>Kobilka</surname><given-names>B.K.</given-names></name><name><surname>Granier</surname><given-names>S.</given-names></name></person-group><article-title>Crystal structure of the micro-opioid receptor bound to a morphinan antagonist</article-title><source>Nature</source><year>2012</year><volume>485</volume><fpage>321</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1038/nature10954</pub-id><?supplied-pmid 22437502?><pub-id pub-id-type="pmid">22437502</pub-id></element-citation></ref><ref id="B53-ijms-19-01578"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>G.</given-names></name></person-group><article-title>Forces of habit: Drugs and the making of the modern world</article-title><source>Addiction</source><year>2002</year><volume>97</volume><fpage>608</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1046/j.1360-0443.2002.t01-9-00166.x</pub-id></element-citation></ref><ref id="B54-ijms-19-01578"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>Q.</given-names></name><name><surname>Ren</surname><given-names>D.</given-names></name></person-group><article-title>Phytochemical and biological activities of an anticancer plant medicine: <italic>Brucea javanica</italic></article-title><source>Anti-Cancer Agents Med. Chem.</source><year>2014</year><volume>14</volume><fpage>440</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.2174/18715206113136660336</pub-id></element-citation></ref><ref id="B55-ijms-19-01578"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>Y.</given-names></name></person-group><article-title>The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine</article-title><source>Nat. Med.</source><year>2011</year><volume>17</volume><fpage>1217</fpage><lpage>1220</lpage><pub-id pub-id-type="doi">10.1038/nm.2471</pub-id><?supplied-pmid 21989013?><pub-id pub-id-type="pmid">21989013</pub-id></element-citation></ref><ref id="B56-ijms-19-01578"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>Y.</given-names></name></person-group><article-title>Artemisinin&#x02014;A gift from traditional Chinese medicine to the world (Nobel lecture)</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2016</year><volume>55</volume><fpage>10210</fpage><lpage>10226</lpage><pub-id pub-id-type="doi">10.1002/anie.201601967</pub-id><?supplied-pmid 27488942?><pub-id pub-id-type="pmid">27488942</pub-id></element-citation></ref><ref id="B57-ijms-19-01578"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Casteels</surname><given-names>T.</given-names></name><name><surname>Frogne</surname><given-names>T.</given-names></name><name><surname>Ingvorsen</surname><given-names>C.</given-names></name><name><surname>Honor&#x000e9;</surname><given-names>C.</given-names></name><name><surname>Courtney</surname><given-names>M.</given-names></name><name><surname>Huber</surname><given-names>K.V.M.</given-names></name><name><surname>Schmitner</surname><given-names>N.</given-names></name><name><surname>Kimmel</surname><given-names>R.A.</given-names></name><name><surname>Romanov</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Artemisinins target GABA<sub>A</sub> receptor signaling and impair &#x003b1; cell identity</article-title><source>Cell</source><year>2017</year><volume>168</volume><fpage>86</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.11.010</pub-id><?supplied-pmid 27916275?><pub-id pub-id-type="pmid">27916275</pub-id></element-citation></ref><ref id="B58-ijms-19-01578"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>H.</given-names></name><name><surname>Singh</surname><given-names>N.P.</given-names></name></person-group><article-title>Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (dmba)-induced breast cancer in the rat</article-title><source>Cancer Lett.</source><year>2006</year><volume>231</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2005.01.019</pub-id><?supplied-pmid 16356830?><pub-id pub-id-type="pmid">16356830</pub-id></element-citation></ref><ref id="B59-ijms-19-01578"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>H.C.</given-names></name><name><surname>Singh</surname><given-names>N.P.</given-names></name><name><surname>Sasaki</surname><given-names>T.</given-names></name></person-group><article-title>Development of artemisinin compounds for cancer treatment</article-title><source>Investig. New Drugs</source><year>2013</year><volume>31</volume><fpage>230</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1007/s10637-012-9873-z</pub-id><?supplied-pmid 22935909?><pub-id pub-id-type="pmid">22935909</pub-id></element-citation></ref><ref id="B60-ijms-19-01578"><label>60.</label><element-citation publication-type="journal"><article-title>Return to Rio: Second chance for the planet</article-title><source>Nature</source><year>2012</year><volume>486</volume><fpage>19</fpage><pub-id pub-id-type="pmid">22678261</pub-id></element-citation></ref><ref id="B61-ijms-19-01578"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbault</surname><given-names>R.</given-names></name></person-group><article-title>2010: A new beginning for biodiversity?</article-title><source>C.R. Biol.</source><year>2011</year><volume>334</volume><fpage>483</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/j.crvi.2011.02.002</pub-id><?supplied-pmid 21640957?><pub-id pub-id-type="pmid">21640957</pub-id></element-citation></ref><ref id="B62-ijms-19-01578"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salazar</surname><given-names>R.</given-names></name><name><surname>Cabrera</surname><given-names>J.A.</given-names></name></person-group><article-title>Intellectual property rights in Costa Rica in the light of the biodiversity convention</article-title><source>J. Ethnopharmacol.</source><year>1996</year><volume>51</volume><fpage>177</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/0378-8741(95)01360-1</pub-id><pub-id pub-id-type="pmid">9213615</pub-id></element-citation></ref><ref id="B63-ijms-19-01578"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samper</surname><given-names>C.</given-names></name></person-group><article-title>Taxonomy and environmental policy</article-title><source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><year>2004</year><volume>359</volume><fpage>721</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1098/rstb.2004.1476</pub-id><?supplied-pmid 15253357?><pub-id pub-id-type="pmid">15253357</pub-id></element-citation></ref><ref id="B64-ijms-19-01578"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seidl</surname><given-names>P.R.</given-names></name></person-group><article-title>Pharmaceuticals from natural products: Current trends</article-title><source>Anais da Academia Brasileira de Ciencias</source><year>2002</year><volume>74</volume><fpage>145</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1590/S0001-37652002000100011</pub-id><?supplied-pmid 11960183?><pub-id pub-id-type="pmid">11960183</pub-id></element-citation></ref><ref id="B65-ijms-19-01578"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tollefson</surname><given-names>J.</given-names></name><name><surname>Gilbert</surname><given-names>N.</given-names></name></person-group><article-title>Earth summit: Rio report card</article-title><source>Nature</source><year>2012</year><volume>486</volume><fpage>20</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/486020a</pub-id><?supplied-pmid 22678262?><pub-id pub-id-type="pmid">22678262</pub-id></element-citation></ref><ref id="B66-ijms-19-01578"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>M.C.</given-names></name><name><surname>Wei</surname><given-names>C.H.</given-names></name><name><surname>Hu</surname><given-names>Z.Q.</given-names></name><name><surname>Srivastava</surname><given-names>K.</given-names></name><name><surname>Ko</surname><given-names>J.</given-names></name><name><surname>Xi</surname><given-names>S.T.</given-names></name><name><surname>Mu</surname><given-names>D.Z.</given-names></name><name><surname>Du</surname><given-names>J.B.</given-names></name><name><surname>Li</surname><given-names>G.H.</given-names></name><name><surname>Wallenstein</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma</article-title><source>J. Allergy Clin. Immunol.</source><year>2005</year><volume>116</volume><fpage>517</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2005.05.029</pub-id><?supplied-pmid 16159618?><pub-id pub-id-type="pmid">16159618</pub-id></element-citation></ref><ref id="B67-ijms-19-01578"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>K.</given-names></name><name><surname>Sampson</surname><given-names>H.A.</given-names></name><name><surname>Charles</surname><given-names>W.</given-names></name><name><surname>Emala</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>X.-M.</given-names></name></person-group><article-title>The anti-asthma herbal medicine ashmi acutely inhibits airway smooth muscle contraction via prostaglandin e2 activation of ep2/ep4 receptors</article-title><source>Am. J. Physiol.-Lung Cell. Mol. Physiol.</source><year>2013</year><volume>305</volume><fpage>L1002</fpage><lpage>L1010</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00423.2012</pub-id><?supplied-pmid 24163140?><pub-id pub-id-type="pmid">24163140</pub-id></element-citation></ref><ref id="B68-ijms-19-01578"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>N.</given-names></name><name><surname>Liang</surname><given-names>B.</given-names></name><name><surname>Srivastava</surname><given-names>K.</given-names></name><name><surname>Zeng</surname><given-names>J.</given-names></name><name><surname>Zhan</surname><given-names>J.</given-names></name><name><surname>Brown</surname><given-names>L.</given-names></name><name><surname>Sampson</surname><given-names>H.</given-names></name><name><surname>Goldfarb</surname><given-names>J.</given-names></name><name><surname>Emala</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>X.M.</given-names></name></person-group><article-title>The <italic>Sophora flavescens</italic> flavonoid compound trifolirhizin inhibits acetylcholine induced airway smooth muscle contraction</article-title><source>Phytochemistry</source><year>2013</year><volume>95</volume><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.phytochem.2013.07.023</pub-id><?supplied-pmid 23993294?><pub-id pub-id-type="pmid">23993294</pub-id></element-citation></ref><ref id="B69-ijms-19-01578"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>K.</given-names></name><name><surname>Shaw</surname><given-names>D.</given-names></name><name><surname>Simmonds</surname><given-names>M.S.</given-names></name><name><surname>Leon</surname><given-names>C.J.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Lu</surname><given-names>A.</given-names></name><name><surname>Sutherland</surname><given-names>I.</given-names></name><name><surname>Ignatova</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>Y.P.</given-names></name><name><surname>Verpoorte</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Good practice in reviewing and publishing studies on herbal medicine, with special emphasis on traditional Chinese medicine and Chinese materia medica</article-title><source>J. Ethnopharmacol.</source><year>2012</year><volume>140</volume><fpage>469</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2012.01.038</pub-id><?supplied-pmid 22330011?><pub-id pub-id-type="pmid">22330011</pub-id></element-citation></ref><ref id="B70-ijms-19-01578"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skroza</surname><given-names>D.</given-names></name><name><surname>Generali&#x00107; Mekini&#x00107;</surname><given-names>I.</given-names></name><name><surname>Svilovi&#x00107;</surname><given-names>S.</given-names></name><name><surname>&#x00160;imat</surname><given-names>V.</given-names></name><name><surname>Katalini&#x00107;</surname><given-names>V.</given-names></name></person-group><article-title>Investigation of the potential synergistic effect of resveratrol with other phenolic compounds: A case of binary phenolic mixtures</article-title><source>J. Food Compos. Anal.</source><year>2015</year><volume>38</volume><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.jfca.2014.06.013</pub-id></element-citation></ref><ref id="B71-ijms-19-01578"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chusri</surname><given-names>S.</given-names></name><name><surname>Siriyong</surname><given-names>T.</given-names></name><name><surname>Na-Phatthalung</surname><given-names>P.</given-names></name><name><surname>Voravuthikunchai</surname><given-names>S.P.</given-names></name></person-group><article-title>Synergistic effects of ethnomedicinal plants of <italic>Apocynaceae</italic> family and antibiotics against clinical isolates of <italic>Acinetobacter baumannii</italic></article-title><source>Asian Pac. J. Trop. Med.</source><year>2014</year><volume>7</volume><fpage>456</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/S1995-7645(14)60074-2</pub-id><pub-id pub-id-type="pmid">25066394</pub-id></element-citation></ref><ref id="B72-ijms-19-01578"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>G.</given-names></name><name><surname>Tyagi</surname><given-names>A.K.</given-names></name><name><surname>Singh</surname><given-names>R.P.</given-names></name><name><surname>Chan</surname><given-names>D.C.</given-names></name><name><surname>Agarwal</surname><given-names>R.</given-names></name></person-group><article-title>Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells</article-title><source>Breast Cancer Res. Treat.</source><year>2004</year><volume>85</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1023/B:BREA.0000020991.55659.59</pub-id><?supplied-pmid 15039593?><pub-id pub-id-type="pmid">15039593</pub-id></element-citation></ref><ref id="B73-ijms-19-01578"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medema</surname><given-names>M.H.</given-names></name><name><surname>Fischbach</surname><given-names>M.A.</given-names></name></person-group><article-title>Computational approaches to natural product discovery</article-title><source>Nat. Chem. Biol.</source><year>2015</year><volume>11</volume><fpage>639</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1884</pub-id><?supplied-pmid 26284671?><pub-id pub-id-type="pmid">26284671</pub-id></element-citation></ref><ref id="B74-ijms-19-01578"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Moore</surname><given-names>B.S.</given-names></name><name><surname>Yoon</surname><given-names>Y.J.</given-names></name></person-group><article-title>Reinvigorating natural product combinatorial biosynthesis with synthetic biology</article-title><source>Nat. Chem. Biol.</source><year>2015</year><volume>11</volume><fpage>649</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1893</pub-id><?supplied-pmid 26284672?><pub-id pub-id-type="pmid">26284672</pub-id></element-citation></ref><ref id="B75-ijms-19-01578"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbulut</surname><given-names>Y.</given-names></name><name><surname>Gaunt</surname><given-names>H.J.</given-names></name><name><surname>Muraki</surname><given-names>K.</given-names></name><name><surname>Ludlow</surname><given-names>M.J.</given-names></name><name><surname>Amer</surname><given-names>M.S.</given-names></name><name><surname>Bruns</surname><given-names>A.</given-names></name><name><surname>Vasudev</surname><given-names>N.S.</given-names></name><name><surname>Radtke</surname><given-names>L.</given-names></name><name><surname>Willot</surname><given-names>M.</given-names></name><name><surname>Hahn</surname><given-names>S.</given-names></name><etal/></person-group><article-title>(-)-Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2015</year><volume>54</volume><fpage>3787</fpage><lpage>3791</lpage><pub-id pub-id-type="doi">10.1002/anie.201411511</pub-id><?supplied-pmid 25707820?><pub-id pub-id-type="pmid">25707820</pub-id></element-citation></ref><ref id="B76-ijms-19-01578"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludlow</surname><given-names>M.J.</given-names></name><name><surname>Gaunt</surname><given-names>H.J.</given-names></name><name><surname>Rubaiy</surname><given-names>H.N.</given-names></name><name><surname>Musialowski</surname><given-names>K.E.</given-names></name><name><surname>Blythe</surname><given-names>N.M.</given-names></name><name><surname>Vasudev</surname><given-names>N.S.</given-names></name><name><surname>Muraki</surname><given-names>K.</given-names></name><name><surname>Beech</surname><given-names>D.J.</given-names></name></person-group><article-title>(-)-Englerin A-evoked cytotoxicity is mediated by Na<sup>+</sup> influx and counteracted by Na<sup>+</sup>/K<sup>+</sup>-atpase</article-title><source>J. Biol. Chem.</source><year>2017</year><volume>292</volume><fpage>723</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.755678</pub-id><?supplied-pmid 27875305?><pub-id pub-id-type="pmid">27875305</pub-id></element-citation></ref><ref id="B77-ijms-19-01578"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muraki</surname><given-names>K.</given-names></name><name><surname>Ohnishi</surname><given-names>K.</given-names></name><name><surname>Takezawa</surname><given-names>A.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>Hatano</surname><given-names>N.</given-names></name><name><surname>Muraki</surname><given-names>Y.</given-names></name><name><surname>Hamzah</surname><given-names>N.</given-names></name><name><surname>Foster</surname><given-names>R.</given-names></name><name><surname>Waldmann</surname><given-names>H.</given-names></name><name><surname>Nussbaumer</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Na(<sup>+</sup>) entry through heteromeric TRPC4/C1 channels mediates (-)Englerin A-induced cytotoxicity in synovial sarcoma cells</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>16988</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-17303-3</pub-id><?supplied-pmid 29209034?><pub-id pub-id-type="pmid">29209034</pub-id></element-citation></ref><ref id="B78-ijms-19-01578"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buriani</surname><given-names>A.</given-names></name><name><surname>Garcia-Bermejo</surname><given-names>M.L.</given-names></name><name><surname>Bosisio</surname><given-names>E.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Simmonds</surname><given-names>M.S.</given-names></name><name><surname>Carrara</surname><given-names>M.</given-names></name><name><surname>Tejedor</surname><given-names>N.</given-names></name><name><surname>Lucio-Cazana</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Omic techniques in systems biology approaches to traditional Chinese medicine research: Present and future</article-title><source>J. Ethnopharmacol.</source><year>2012</year><volume>140</volume><fpage>535</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2012.01.055</pub-id><?supplied-pmid 22342380?><pub-id pub-id-type="pmid">22342380</pub-id></element-citation></ref><ref id="B79-ijms-19-01578"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganie</surname><given-names>S.H.</given-names></name><name><surname>Upadhyay</surname><given-names>P.</given-names></name><name><surname>Das</surname><given-names>S.</given-names></name><name><surname>Prasad Sharma</surname><given-names>M.</given-names></name></person-group><article-title>Authentication of medicinal plants by DNA markers</article-title><source>Plant Gene</source><year>2015</year><volume>4</volume><fpage>83</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.plgene.2015.10.002</pub-id></element-citation></ref><ref id="B80-ijms-19-01578"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghorbani</surname><given-names>A.</given-names></name><name><surname>Saeedi</surname><given-names>Y.</given-names></name><name><surname>de Boer</surname><given-names>H.J.</given-names></name></person-group><article-title>Unidentifiable by morphology: DNA barcoding of plant material in local markets in Iran</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0175722</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0175722</pub-id><?supplied-pmid 28419161?><pub-id pub-id-type="pmid">28419161</pub-id></element-citation></ref><ref id="B81-ijms-19-01578"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>K.A.</given-names></name><name><surname>Newmaster</surname><given-names>S.G.</given-names></name></person-group><article-title>Molecular taxonomic tools provide more accurate estimates of species richness at less cost than traditional morphology-based taxonomic practices in a vegetation survey</article-title><source>Biodivers. Conserv.</source><year>2014</year><volume>23</volume><fpage>1411</fpage><lpage>1424</lpage><pub-id pub-id-type="doi">10.1007/s10531-014-0672-z</pub-id></element-citation></ref><ref id="B82-ijms-19-01578"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Yao</surname><given-names>L.</given-names></name><name><surname>Xie</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name></person-group><article-title>Authentication of animal signatures in traditional Chinese medicine of Lingyang Qingfei Wan using routine molecular diagnostic assays</article-title><source>Mol. Biol. Rep.</source><year>2014</year><volume>41</volume><fpage>2485</fpage><lpage>2491</lpage><pub-id pub-id-type="doi">10.1007/s11033-014-3105-x</pub-id><?supplied-pmid 24445529?><pub-id pub-id-type="pmid">24445529</pub-id></element-citation></ref><ref id="B83-ijms-19-01578"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newmaster</surname><given-names>S.G.</given-names></name><name><surname>Grguric</surname><given-names>M.</given-names></name><name><surname>Shanmughanandhan</surname><given-names>D.</given-names></name><name><surname>Ramalingam</surname><given-names>S.</given-names></name><name><surname>Ragupathy</surname><given-names>S.</given-names></name></person-group><article-title>DNA barcoding detects contamination and substitution in North American herbal products</article-title><source>BMC Med.</source><year>2013</year><volume>11</volume><elocation-id>222</elocation-id><pub-id pub-id-type="doi">10.1186/1741-7015-11-222</pub-id><?supplied-pmid 24120035?><pub-id pub-id-type="pmid">24120035</pub-id></element-citation></ref><ref id="B84-ijms-19-01578"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>P.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Nagireddy</surname><given-names>A.</given-names></name><name><surname>Mani</surname><given-names>D.N.</given-names></name><name><surname>Shukla</surname><given-names>A.K.</given-names></name><name><surname>Tiwari</surname><given-names>R.</given-names></name><name><surname>Sundaresan</surname><given-names>V.</given-names></name></person-group><article-title>DNA barcoding: An efficient tool to overcome authentication challenges in the herbal market</article-title><source>Plant Biotechnol. J.</source><year>2016</year><volume>14</volume><fpage>8</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1111/pbi.12419</pub-id><?supplied-pmid 26079154?><pub-id pub-id-type="pmid">26079154</pub-id></element-citation></ref><ref id="B85-ijms-19-01578"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Xiang</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Yao</surname><given-names>H.</given-names></name><name><surname>Han</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name></person-group><article-title>Identification of crude drugs in the Japanese pharmacopoeia using a DNA barcoding system</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>42325</fpage><pub-id pub-id-type="doi">10.1038/srep42325</pub-id><?supplied-pmid 28186159?><pub-id pub-id-type="pmid">28186159</pub-id></element-citation></ref><ref id="B86-ijms-19-01578"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulice</surname><given-names>G.</given-names></name><name><surname>Pelaz</surname><given-names>S.</given-names></name><name><surname>Mat&#x000ed;as-Hern&#x000e1;ndez</surname><given-names>L.</given-names></name></person-group><article-title>Molecular farming in <italic>Artemisia annua</italic>, a promising approach to improve anti-malarial drug production</article-title><source>Front. Plant Sci.</source><year>2016</year><volume>7</volume><fpage>329</fpage><pub-id pub-id-type="doi">10.3389/fpls.2016.00329</pub-id><?supplied-pmid 27047510?><pub-id pub-id-type="pmid">27047510</pub-id></element-citation></ref><ref id="B87-ijms-19-01578"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gantait</surname><given-names>S.</given-names></name><name><surname>Debnath</surname><given-names>S.</given-names></name><name><surname>Nasim Ali</surname><given-names>M.</given-names></name></person-group><article-title>Genomic profile of the plants with pharmaceutical value</article-title><source>3 Biotech</source><year>2014</year><volume>4</volume><fpage>563</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1007/s13205-014-0218-9</pub-id><?supplied-pmid 28324311?><pub-id pub-id-type="pmid">28324311</pub-id></element-citation></ref><ref id="B88-ijms-19-01578"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Su</surname><given-names>J.</given-names></name><name><surname>Zeng</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group><article-title>The gene expression profiles in response to 102 traditional Chinese medicine (TCM) components: A general template for research on TCMs</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>352</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-00535-8</pub-id><?supplied-pmid 28336967?><pub-id pub-id-type="pmid">28336967</pub-id></element-citation></ref><ref id="B89-ijms-19-01578"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K.-H.</given-names></name><name><surname>Lo</surname><given-names>H.-L.</given-names></name><name><surname>Tang</surname><given-names>W.-C.</given-names></name><name><surname>Hsiao</surname><given-names>H.H.-Y.</given-names></name><name><surname>Yang</surname><given-names>P.-M.</given-names></name></person-group><article-title>A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine Berberine</article-title><source>Sci. Rep.</source><year>2014</year><volume>4</volume><fpage>6394</fpage><pub-id pub-id-type="doi">10.1038/srep06394</pub-id><?supplied-pmid 25227736?><pub-id pub-id-type="pmid">25227736</pub-id></element-citation></ref><ref id="B90-ijms-19-01578"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiyama</surname><given-names>R.</given-names></name></person-group><article-title>DNA microarray-based screening and characterization of traditional Chinese medicine</article-title><source>Microarrays</source><year>2017</year><volume>6</volume><elocation-id>4</elocation-id><pub-id pub-id-type="doi">10.3390/microarrays6010004</pub-id><?supplied-pmid 28146102?><pub-id pub-id-type="pmid">28146102</pub-id></element-citation></ref><ref id="B91-ijms-19-01578"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>M.J.</given-names></name><name><surname>Goodman</surname><given-names>S.J.</given-names></name><name><surname>Kobor</surname><given-names>M.S.</given-names></name></person-group><article-title>DNA methylation and healthy human aging</article-title><source>Aging Cell</source><year>2015</year><volume>14</volume><fpage>924</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1111/acel.12349</pub-id><?supplied-pmid 25913071?><pub-id pub-id-type="pmid">25913071</pub-id></element-citation></ref><ref id="B92-ijms-19-01578"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>T.K.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Lay</surname><given-names>F.D.</given-names></name><name><surname>Liang</surname><given-names>G.</given-names></name><name><surname>Berman</surname><given-names>B.P.</given-names></name><name><surname>Jones</surname><given-names>P.A.</given-names></name></person-group><article-title>Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules</article-title><source>Genome Res.</source><year>2012</year><volume>22</volume><fpage>2497</fpage><lpage>2506</lpage><pub-id pub-id-type="doi">10.1101/gr.143008.112</pub-id><?supplied-pmid 22960375?><pub-id pub-id-type="pmid">22960375</pub-id></element-citation></ref><ref id="B93-ijms-19-01578"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordlund</surname><given-names>J.</given-names></name><name><surname>Backlin</surname><given-names>C.L.</given-names></name><name><surname>Wahlberg</surname><given-names>P.</given-names></name><name><surname>Busche</surname><given-names>S.</given-names></name><name><surname>Berglund</surname><given-names>E.C.</given-names></name><name><surname>Eloranta</surname><given-names>M.L.</given-names></name><name><surname>Flaegstad</surname><given-names>T.</given-names></name><name><surname>Forestier</surname><given-names>E.</given-names></name><name><surname>Frost</surname><given-names>B.M.</given-names></name><name><surname>Harila-Saari</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia</article-title><source>Genome Biol.</source><year>2013</year><volume>14</volume><fpage>r105</fpage><pub-id pub-id-type="doi">10.1186/gb-2013-14-9-r105</pub-id><?supplied-pmid 24063430?><pub-id pub-id-type="pmid">24063430</pub-id></element-citation></ref><ref id="B94-ijms-19-01578"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Xing</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Genome-wide analysis of DNA methylation in bovine placentas</article-title><source>BMC Genom.</source><year>2014</year><volume>15</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-15-12</pub-id><?supplied-pmid 24397284?><pub-id pub-id-type="pmid">24397284</pub-id></element-citation></ref><ref id="B95-ijms-19-01578"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zykovich</surname><given-names>A.</given-names></name><name><surname>Hubbard</surname><given-names>A.</given-names></name><name><surname>Flynn</surname><given-names>J.M.</given-names></name><name><surname>Tarnopolsky</surname><given-names>M.</given-names></name><name><surname>Fraga</surname><given-names>M.F.</given-names></name><name><surname>Kerksick</surname><given-names>C.</given-names></name><name><surname>Ogborn</surname><given-names>D.</given-names></name><name><surname>MacNeil</surname><given-names>L.</given-names></name><name><surname>Mooney</surname><given-names>S.D.</given-names></name><name><surname>Melov</surname><given-names>S.</given-names></name></person-group><article-title>Genome-wide DNA methylation changes with age in disease-free human skeletal muscle</article-title><source>Aging Cell</source><year>2014</year><volume>13</volume><fpage>360</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1111/acel.12180</pub-id><?supplied-pmid 24304487?><pub-id pub-id-type="pmid">24304487</pub-id></element-citation></ref><ref id="B96-ijms-19-01578"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbosa</surname><given-names>S.</given-names></name><name><surname>Carreira</surname><given-names>S.</given-names></name><name><surname>Bailey</surname><given-names>D.</given-names></name><name><surname>Abaitua</surname><given-names>F.</given-names></name><name><surname>O&#x02019;Hare</surname><given-names>P.</given-names></name></person-group><article-title>Phosphorylation and SCF-mediated degradation regulate CREB-H transcription of metabolic targets</article-title><source>Mol. Biol. Cell</source><year>2015</year><volume>26</volume><fpage>2939</fpage><lpage>2954</lpage><pub-id pub-id-type="doi">10.1091/mbc.e15-04-0247</pub-id><?supplied-pmid 26108621?><pub-id pub-id-type="pmid">26108621</pub-id></element-citation></ref><ref id="B97-ijms-19-01578"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>P.</given-names></name><name><surname>Vachhani</surname><given-names>P.</given-names></name><name><surname>Cortes</surname><given-names>J.E.</given-names></name></person-group><article-title>Treatment of relapsed/refractory acute myeloid leukemia</article-title><source>Curr. Treat. Options Oncol.</source><year>2017</year><volume>18</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1007/s11864-017-0456-2</pub-id><?supplied-pmid 28286924?><pub-id pub-id-type="pmid">28286924</pub-id></element-citation></ref><ref id="B98-ijms-19-01578"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>T.J.</given-names></name><name><surname>Miller</surname><given-names>C.</given-names></name><name><surname>Ding</surname><given-names>L.</given-names></name><name><surname>Raphael</surname><given-names>B.J.</given-names></name><name><surname>Mungall</surname><given-names>A.J.</given-names></name><name><surname>Robertson</surname><given-names>A.</given-names></name><name><surname>Hoadley</surname><given-names>K.</given-names></name><name><surname>Triche</surname><given-names>T.J.</given-names><suffix>Jr.</suffix></name><name><surname>Laird</surname><given-names>P.W.</given-names></name><name><surname>Baty</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><fpage>2059</fpage><lpage>2074</lpage><?supplied-pmid 23634996?><pub-id pub-id-type="pmid">23634996</pub-id></element-citation></ref><ref id="B99-ijms-19-01578"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brat</surname><given-names>D.J.</given-names></name><name><surname>Verhaak</surname><given-names>R.G.</given-names></name><name><surname>Aldape</surname><given-names>K.D.</given-names></name><name><surname>Yung</surname><given-names>W.K.</given-names></name><name><surname>Salama</surname><given-names>S.R.</given-names></name><name><surname>Cooper</surname><given-names>L.A.</given-names></name><name><surname>Rheinbay</surname><given-names>E.</given-names></name><name><surname>Miller</surname><given-names>C.R.</given-names></name><name><surname>Vitucci</surname><given-names>M.</given-names></name><name><surname>Morozova</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>2481</fpage><lpage>2498</lpage><?supplied-pmid 26061751?><pub-id pub-id-type="pmid">26061751</pub-id></element-citation></ref><ref id="B100-ijms-19-01578"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckel-Passow</surname><given-names>J.E.</given-names></name><name><surname>Lachance</surname><given-names>D.H.</given-names></name><name><surname>Molinaro</surname><given-names>A.M.</given-names></name><name><surname>Walsh</surname><given-names>K.M.</given-names></name><name><surname>Decker</surname><given-names>P.A.</given-names></name><name><surname>Sicotte</surname><given-names>H.</given-names></name><name><surname>Pekmezci</surname><given-names>M.</given-names></name><name><surname>Rice</surname><given-names>T.</given-names></name><name><surname>Kosel</surname><given-names>M.L.</given-names></name><name><surname>Smirnov</surname><given-names>I.V.</given-names></name><etal/></person-group><article-title>Glioma groups based on 1p/19q, <italic>IDH</italic>, and <italic>TERT</italic> promoter mutations in tumors</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>2499</fpage><lpage>2508</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1407279</pub-id><?supplied-pmid 26061753?><pub-id pub-id-type="pmid">26061753</pub-id></element-citation></ref><ref id="B101-ijms-19-01578"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mwapagha</surname><given-names>L.M.</given-names></name><name><surname>Tiffin</surname><given-names>N.</given-names></name><name><surname>Parker</surname><given-names>M.I.</given-names></name></person-group><article-title>Delineation of the HPV11e6 and HPV18e6 pathways in initiating cellular transformation</article-title><source>Front. Oncol.</source><year>2017</year><volume>7</volume><fpage>258</fpage><pub-id pub-id-type="doi">10.3389/fonc.2017.00258</pub-id><?supplied-pmid 29164058?><pub-id pub-id-type="pmid">29164058</pub-id></element-citation></ref><ref id="B102-ijms-19-01578"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelsang</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Veber</surname><given-names>N.</given-names></name><name><surname>Mwapagha</surname><given-names>L.M.</given-names></name><name><surname>Parker</surname><given-names>M.I.</given-names></name></person-group><article-title>The cumulative effects of polymorphisms in the DNA mismatch repair genes and tobacco smoking in oesophageal cancer risk</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e36962</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0036962</pub-id><?supplied-pmid 22623965?><pub-id pub-id-type="pmid">22623965</pub-id></element-citation></ref><ref id="B103-ijms-19-01578"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fishilevich</surname><given-names>S.</given-names></name><name><surname>Nudel</surname><given-names>R.</given-names></name><name><surname>Rappaport</surname><given-names>N.</given-names></name><name><surname>Hadar</surname><given-names>R.</given-names></name><name><surname>Plaschkes</surname><given-names>I.</given-names></name><name><surname>Iny Stein</surname><given-names>T.</given-names></name><name><surname>Rosen</surname><given-names>N.</given-names></name><name><surname>Kohn</surname><given-names>A.</given-names></name><name><surname>Twik</surname><given-names>M.</given-names></name><name><surname>Safran</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Genehancer: Genome-wide integration of enhancers and target genes in genecards</article-title><source>Database</source><year>2017</year><volume>2017</volume><pub-id pub-id-type="doi">10.1093/database/bax028</pub-id><?supplied-pmid 28605766?><pub-id pub-id-type="pmid">28605766</pub-id></element-citation></ref><ref id="B104-ijms-19-01578"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Long</surname><given-names>J.</given-names></name><name><surname>Zeng</surname><given-names>C.</given-names></name><name><surname>Michailidou</surname><given-names>K.</given-names></name><name><surname>Ghoussaini</surname><given-names>M.</given-names></name><name><surname>Bolla</surname><given-names>M.K.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Milne</surname><given-names>R.L.</given-names></name><name><surname>Shu</surname><given-names>X.O.</given-names></name><name><surname>Cai</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk</article-title><source>Cancer Epidemiol. Biomark. Prev.</source><year>2015</year><volume>24</volume><fpage>1680</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-15-0363</pub-id><?supplied-pmid 26354892?><pub-id pub-id-type="pmid">26354892</pub-id></element-citation></ref><ref id="B105-ijms-19-01578"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ombrello</surname><given-names>M.J.</given-names></name><name><surname>Sikora</surname><given-names>K.A.</given-names></name><name><surname>Kastner</surname><given-names>D.L.</given-names></name></person-group><article-title>Genetics, genomics, and their relevance to pathology and therapy</article-title><source>Best Pract. Res. Clin. Rheumatol.</source><year>2014</year><volume>28</volume><fpage>175</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.berh.2014.05.001</pub-id><?supplied-pmid 24974057?><pub-id pub-id-type="pmid">24974057</pub-id></element-citation></ref><ref id="B106-ijms-19-01578"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmonds</surname><given-names>P.</given-names></name><name><surname>Loomis</surname><given-names>E.</given-names></name><name><surname>Curry</surname><given-names>E.</given-names></name></person-group><article-title>DNA methylation-based chromatin compartments and CHIP-seq profiles reveal transcriptional drivers of prostate carcinogenesis</article-title><source>Genome Med.</source><year>2017</year><volume>9</volume><fpage>54</fpage><pub-id pub-id-type="doi">10.1186/s13073-017-0443-z</pub-id><?supplied-pmid 28592290?><pub-id pub-id-type="pmid">28592290</pub-id></element-citation></ref><ref id="B107-ijms-19-01578"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>T.Y.</given-names></name><name><surname>Hsu</surname><given-names>L.I.</given-names></name><name><surname>Chiu</surname><given-names>A.W.</given-names></name><name><surname>Pu</surname><given-names>Y.S.</given-names></name><name><surname>Wang</surname><given-names>S.H.</given-names></name><name><surname>Liao</surname><given-names>Y.T.</given-names></name><name><surname>Wu</surname><given-names>M.M.</given-names></name><name><surname>Wang</surname><given-names>Y.H.</given-names></name><name><surname>Chang</surname><given-names>C.H.</given-names></name><name><surname>Lee</surname><given-names>T.C.</given-names></name><etal/></person-group><article-title>Comparison of genome-wide DNA methylation in urothelial carcinomas of patients with and without arsenic exposure</article-title><source>Environ. Res.</source><year>2014</year><volume>128</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.envres.2013.10.006</pub-id><?supplied-pmid 24268366?><pub-id pub-id-type="pmid">24268366</pub-id></element-citation></ref><ref id="B108-ijms-19-01578"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>G.</given-names></name><name><surname>Jalan</surname><given-names>R.</given-names></name><name><surname>Mookerjee</surname><given-names>R.P.</given-names></name></person-group><article-title>Cracking the encode: From transcription to therapeutics</article-title><source>Hepatology</source><year>2013</year><volume>57</volume><fpage>2532</fpage><lpage>2535</lpage><pub-id pub-id-type="doi">10.1002/hep.26449</pub-id><?supplied-pmid 23609523?><pub-id pub-id-type="pmid">23609523</pub-id></element-citation></ref><ref id="B109-ijms-19-01578"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tragante</surname><given-names>V.</given-names></name><name><surname>Moore</surname><given-names>J.H.</given-names></name><name><surname>Asselbergs</surname><given-names>F.W.</given-names></name></person-group><article-title>The encode project and perspectives on pathways</article-title><source>Genet. Epidemiol.</source><year>2014</year><volume>38</volume><fpage>275</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1002/gepi.21802</pub-id><?supplied-pmid 24723339?><pub-id pub-id-type="pmid">24723339</pub-id></element-citation></ref><ref id="B110-ijms-19-01578"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bumpus</surname><given-names>S.B.</given-names></name><name><surname>Evans</surname><given-names>B.S.</given-names></name><name><surname>Thomas</surname><given-names>P.M.</given-names></name><name><surname>Ntai</surname><given-names>I.</given-names></name><name><surname>Kelleher</surname><given-names>N.L.</given-names></name></person-group><article-title>A proteomics approach to discovery of natural products and their biosynthetic pathways</article-title><source>Nat. Biotechnol.</source><year>2009</year><volume>27</volume><fpage>951</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1038/nbt.1565</pub-id><?supplied-pmid 19767731?><pub-id pub-id-type="pmid">19767731</pub-id></element-citation></ref><ref id="B111-ijms-19-01578"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez-Esteso</surname><given-names>M.J.</given-names></name><name><surname>Mart&#x000ed;nez-M&#x000e1;rquez</surname><given-names>A.</given-names></name><name><surname>Sell&#x000e9;s-Marchart</surname><given-names>S.</given-names></name><name><surname>Morante-Carriel</surname><given-names>J.A.</given-names></name><name><surname>Bru-Mart&#x000ed;nez</surname><given-names>R.</given-names></name></person-group><article-title>The role of proteomics in progressing insights into plant secondary metabolism</article-title><source>Front. Plant Sci.</source><year>2015</year><volume>6</volume><fpage>504</fpage><pub-id pub-id-type="doi">10.3389/fpls.2015.00504</pub-id><?supplied-pmid 26217358?><pub-id pub-id-type="pmid">26217358</pub-id></element-citation></ref><ref id="B112-ijms-19-01578"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lum</surname><given-names>J.H.</given-names></name><name><surname>Fung</surname><given-names>K.L.</given-names></name><name><surname>Cheung</surname><given-names>P.Y.</given-names></name><name><surname>Wong</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>C.H.</given-names></name><name><surname>Kwok</surname><given-names>F.S.</given-names></name><name><surname>Leung</surname><given-names>M.C.</given-names></name><name><surname>Hui</surname><given-names>P.K.</given-names></name><name><surname>Lo</surname><given-names>S.C.</given-names></name></person-group><article-title>Proteome of oriental ginseng <italic>Panax ginseng C.A. Meyer</italic> and the potential to use it as an identification tool</article-title><source>Proteomics</source><year>2002</year><volume>2</volume><fpage>1123</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1002/1615-9861(200209)2:9&#x0003c;1123::AID-PROT1123&#x0003e;3.0.CO;2-S</pub-id><pub-id pub-id-type="pmid">12362331</pub-id></element-citation></ref><ref id="B113-ijms-19-01578"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.W.</given-names></name><name><surname>Lee</surname><given-names>S.H.</given-names></name><name><surname>Min</surname><given-names>C.W.</given-names></name><name><surname>Jo</surname><given-names>I.H.</given-names></name><name><surname>Bang</surname><given-names>K.H.</given-names></name><name><surname>Hyun</surname><given-names>D.-Y.</given-names></name><name><surname>Agrawal</surname><given-names>G.K.</given-names></name><name><surname>Rakwal</surname><given-names>R.</given-names></name><name><surname>Zargar</surname><given-names>S.M.</given-names></name><name><surname>Gupta</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Ginseng (<italic>Panax</italic> sp.) proteomics: An update</article-title><source>Appl. Biol. Chem.</source><year>2017</year><volume>60</volume><fpage>311</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1007/s13765-017-0283-y</pub-id></element-citation></ref><ref id="B114-ijms-19-01578"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.H.</given-names></name><name><surname>Alex</surname><given-names>D.</given-names></name><name><surname>Siu</surname><given-names>S.O.</given-names></name><name><surname>Chu</surname><given-names>I.K.</given-names></name><name><surname>Renn</surname><given-names>J.</given-names></name><name><surname>Winkler</surname><given-names>C.</given-names></name><name><surname>Lou</surname><given-names>S.</given-names></name><name><surname>Tsui</surname><given-names>S.K.</given-names></name><name><surname>Zhao</surname><given-names>H.Y.</given-names></name><name><surname>Yan</surname><given-names>W.R.</given-names></name><etal/></person-group><article-title>Combined in vivo imaging and omics approaches reveal metabolism of icaritin and its glycosides in zebrafish larvae</article-title><source>Mol. BioSyst.</source><year>2011</year><volume>7</volume><fpage>2128</fpage><lpage>2138</lpage><pub-id pub-id-type="doi">10.1039/c1mb00001b</pub-id><?supplied-pmid 21445457?><pub-id pub-id-type="pmid">21445457</pub-id></element-citation></ref><ref id="B115-ijms-19-01578"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>M.W.</given-names></name><name><surname>Zhang</surname><given-names>Z.J.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Lei</surname><given-names>B.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Cui</surname><given-names>G.Z.</given-names></name><name><surname>Man Hoi</surname><given-names>P.</given-names></name><name><surname>Chan</surname><given-names>K.</given-names></name><name><surname>Lee</surname><given-names>S.M.Y.</given-names></name></person-group><article-title>From omics to drug metabolism and high content screen of natural product in zebrafish: A new model for discovery of neuroactive compound</article-title><source>Evid.-Based Complement. Altern. Med.</source><year>2012</year><volume>2012</volume><fpage>605303</fpage><pub-id pub-id-type="doi">10.1155/2012/605303</pub-id><?supplied-pmid 22919414?><pub-id pub-id-type="pmid">22919414</pub-id></element-citation></ref><ref id="B116-ijms-19-01578"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>Application of proteomics to determine the mechanism of action of traditional Chinese medicine remedies</article-title><source>J. Ethnopharmacol.</source><year>2014</year><volume>155</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2014.05.022</pub-id><?supplied-pmid 24862488?><pub-id pub-id-type="pmid">24862488</pub-id></element-citation></ref><ref id="B117-ijms-19-01578"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>Challenges and recent advances in affinity purification of tag-free proteins</article-title><source>Biotechnol. Lett.</source><year>2014</year><volume>36</volume><fpage>1391</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1007/s10529-014-1509-2</pub-id><?supplied-pmid 24658742?><pub-id pub-id-type="pmid">24658742</pub-id></element-citation></ref><ref id="B118-ijms-19-01578"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novick</surname><given-names>D.</given-names></name><name><surname>Rubinstein</surname><given-names>M.</given-names></name></person-group><article-title>Ligand affinity chromatography, an indispensable method for the purification of soluble cytokine receptors and binding proteins</article-title><source>Methods Mol. Biol.</source><year>2012</year><volume>820</volume><fpage>195</fpage><lpage>214</lpage><?supplied-pmid 22131033?><pub-id pub-id-type="pmid">22131033</pub-id></element-citation></ref><ref id="B119-ijms-19-01578"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaunmiller</surname><given-names>E.L.</given-names></name><name><surname>Paulemond</surname><given-names>M.L.</given-names></name><name><surname>Dupper</surname><given-names>C.M.</given-names></name><name><surname>Hage</surname><given-names>D.S.</given-names></name></person-group><article-title>Affinity monolith chromatography: A review of principles and recent analytical applications</article-title><source>Anal. Bioanal. Chem.</source><year>2013</year><volume>405</volume><fpage>2133</fpage><lpage>2145</lpage><pub-id pub-id-type="doi">10.1007/s00216-012-6568-4</pub-id><?supplied-pmid 23187827?><pub-id pub-id-type="pmid">23187827</pub-id></element-citation></ref><ref id="B120-ijms-19-01578"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rix</surname><given-names>U.</given-names></name><name><surname>Gridling</surname><given-names>M.</given-names></name><name><surname>Superti-Furga</surname><given-names>G.</given-names></name></person-group><article-title>Compound immobilization and drug-affinity chromatography</article-title><source>Methods Mol. Biol.</source><year>2012</year><volume>803</volume><fpage>25</fpage><lpage>38</lpage><?supplied-pmid 22065216?><pub-id pub-id-type="pmid">22065216</pub-id></element-citation></ref><ref id="B121-ijms-19-01578"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.Z.</given-names></name><name><surname>Chu</surname><given-names>Z.Z.</given-names></name><name><surname>Chen</surname><given-names>C.C.</given-names></name><name><surname>Cao</surname><given-names>A.C.</given-names></name><name><surname>Tong</surname><given-names>X.</given-names></name><name><surname>Ouyang</surname><given-names>C.B.</given-names></name><name><surname>Yuan</surname><given-names>Q.H.</given-names></name><name><surname>Wang</surname><given-names>M.N.</given-names></name><name><surname>Wu</surname><given-names>Z.K.</given-names></name><name><surname>Wang</surname><given-names>H.H.</given-names></name><etal/></person-group><article-title>Recombinant passenger proteins can be conveniently purified by one-step affinity chromatography</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0143598</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0143598</pub-id><?supplied-pmid 26641240?><pub-id pub-id-type="pmid">26641240</pub-id></element-citation></ref><ref id="B122-ijms-19-01578"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Han</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Kang</surname><given-names>J.</given-names></name></person-group><article-title>Profiling of drug binding proteins by monolithic affinity chromatography in combination with liquid chromatography-tandem mass spectrometry</article-title><source>J. Chromatogr. A</source><year>2014</year><volume>1359</volume><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.chroma.2014.07.020</pub-id><?supplied-pmid 25064533?><pub-id pub-id-type="pmid">25064533</pub-id></element-citation></ref><ref id="B123-ijms-19-01578"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schenone</surname><given-names>M.</given-names></name><name><surname>Dancik</surname><given-names>V.</given-names></name><name><surname>Wagner</surname><given-names>B.K.</given-names></name><name><surname>Clemons</surname><given-names>P.A.</given-names></name></person-group><article-title>Target identification and mechanism of action in chemical biology and drug discovery</article-title><source>Nat. Chem. Biol.</source><year>2013</year><volume>9</volume><fpage>232</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1199</pub-id><?supplied-pmid 23508189?><pub-id pub-id-type="pmid">23508189</pub-id></element-citation></ref><ref id="B124-ijms-19-01578"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFedries</surname><given-names>A.</given-names></name><name><surname>Schwaid</surname><given-names>A.</given-names></name><name><surname>Saghatelian</surname><given-names>A.</given-names></name></person-group><article-title>Methods for the elucidation of protein-small molecule interactions</article-title><source>Chem. Biol.</source><year>2013</year><volume>20</volume><fpage>667</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2013.04.008</pub-id><?supplied-pmid 23706633?><pub-id pub-id-type="pmid">23706633</pub-id></element-citation></ref><ref id="B125-ijms-19-01578"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rix</surname><given-names>U.</given-names></name><name><surname>Superti-Furga</surname><given-names>G.</given-names></name></person-group><article-title>Target profiling of small molecules by chemical proteomics</article-title><source>Nat. Chem. Biol.</source><year>2009</year><volume>5</volume><fpage>616</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1038/nchembio.216</pub-id><?supplied-pmid 19690537?><pub-id pub-id-type="pmid">19690537</pub-id></element-citation></ref><ref id="B126-ijms-19-01578"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>J.W.</given-names></name></person-group><article-title>Target identification for biologically active small molecules using chemical biology approaches</article-title><source>Arch. Pharm. Res.</source><year>2016</year><volume>39</volume><fpage>1193</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1007/s12272-016-0791-z</pub-id><?supplied-pmid 27387321?><pub-id pub-id-type="pmid">27387321</pub-id></element-citation></ref><ref id="B127-ijms-19-01578"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franken</surname><given-names>H.</given-names></name><name><surname>Mathieson</surname><given-names>T.</given-names></name><name><surname>Childs</surname><given-names>D.</given-names></name><name><surname>Sweetman</surname><given-names>G.M.</given-names></name><name><surname>Werner</surname><given-names>T.</given-names></name><name><surname>Togel</surname><given-names>I.</given-names></name><name><surname>Doce</surname><given-names>C.</given-names></name><name><surname>Gade</surname><given-names>S.</given-names></name><name><surname>Bantscheff</surname><given-names>M.</given-names></name><name><surname>Drewes</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry</article-title><source>Nat. Protoc.</source><year>2015</year><volume>10</volume><fpage>1567</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.1038/nprot.2015.101</pub-id><?supplied-pmid 26379230?><pub-id pub-id-type="pmid">26379230</pub-id></element-citation></ref><ref id="B128-ijms-19-01578"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jafari</surname><given-names>R.</given-names></name><name><surname>Almqvist</surname><given-names>H.</given-names></name><name><surname>Axelsson</surname><given-names>H.</given-names></name><name><surname>Ignatushchenko</surname><given-names>M.</given-names></name><name><surname>Lundback</surname><given-names>T.</given-names></name><name><surname>Nordlund</surname><given-names>P.</given-names></name><name><surname>Martinez Molina</surname><given-names>D.</given-names></name></person-group><article-title>The cellular thermal shift assay for evaluating drug target interactions in cells</article-title><source>Nat. Protoc.</source><year>2014</year><volume>9</volume><fpage>2100</fpage><lpage>2122</lpage><pub-id pub-id-type="doi">10.1038/nprot.2014.138</pub-id><?supplied-pmid 25101824?><pub-id pub-id-type="pmid">25101824</pub-id></element-citation></ref><ref id="B129-ijms-19-01578"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomenick</surname><given-names>B.</given-names></name><name><surname>Hao</surname><given-names>R.</given-names></name><name><surname>Jonai</surname><given-names>N.</given-names></name><name><surname>Chin</surname><given-names>R.M.</given-names></name><name><surname>Aghajan</surname><given-names>M.</given-names></name><name><surname>Warburton</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>R.P.</given-names></name><name><surname>Gomez</surname><given-names>F.</given-names></name><name><surname>Loo</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Target identification using drug affinity responsive target stability (darts)</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>21984</fpage><lpage>21989</lpage><pub-id pub-id-type="doi">10.1073/pnas.0910040106</pub-id><?supplied-pmid 19995983?><pub-id pub-id-type="pmid">19995983</pub-id></element-citation></ref><ref id="B130-ijms-19-01578"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schirle</surname><given-names>M.</given-names></name><name><surname>Bantscheff</surname><given-names>M.</given-names></name><name><surname>Kuster</surname><given-names>B.</given-names></name></person-group><article-title>Mass spectrometry-based proteomics in preclinical drug discovery</article-title><source>Chem. Biol.</source><year>2012</year><volume>19</volume><fpage>72</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2012.01.002</pub-id><?supplied-pmid 22284356?><pub-id pub-id-type="pmid">22284356</pub-id></element-citation></ref><ref id="B131-ijms-19-01578"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomenick</surname><given-names>B.</given-names></name><name><surname>Olsen</surname><given-names>R.W.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name></person-group><article-title>Identification of direct protein targets of small molecules</article-title><source>ACS Chem. Biol.</source><year>2011</year><volume>6</volume><fpage>34</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1021/cb100294v</pub-id><?supplied-pmid 21077692?><pub-id pub-id-type="pmid">21077692</pub-id></element-citation></ref><ref id="B132-ijms-19-01578"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejonghe</surname><given-names>W.</given-names></name><name><surname>Russinova</surname><given-names>E.</given-names></name></person-group><article-title>Target identification strategies in plant chemical biology</article-title><source>Front. Plant Sci.</source><year>2014</year><volume>5</volume><fpage>352</fpage><pub-id pub-id-type="doi">10.3389/fpls.2014.00352</pub-id><?supplied-pmid 25104953?><pub-id pub-id-type="pmid">25104953</pub-id></element-citation></ref><ref id="B133-ijms-19-01578"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>G.M.</given-names></name><name><surname>Tucker</surname><given-names>C.L.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><name><surname>Park</surname><given-names>S.K.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Yates</surname><given-names>J.R.</given-names><suffix>3rd</suffix></name><name><surname>Fitzgerald</surname><given-names>M.C.</given-names></name></person-group><article-title>Quantitative proteomics approach for identifying protein-drug interactions in complex mixtures using protein stability measurements</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>9078</fpage><lpage>9082</lpage><pub-id pub-id-type="doi">10.1073/pnas.1000148107</pub-id><?supplied-pmid 20439767?><pub-id pub-id-type="pmid">20439767</pub-id></element-citation></ref><ref id="B134-ijms-19-01578"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>G.M.</given-names></name><name><surname>Tang</surname><given-names>L.</given-names></name><name><surname>Fitzgerald</surname><given-names>M.C.</given-names></name></person-group><article-title>Thermodynamic analysis of protein stability and ligand binding using a chemical modification- and mass spectrometry-based strategy</article-title><source>Anal. Chem.</source><year>2008</year><volume>80</volume><fpage>4175</fpage><lpage>4185</lpage><pub-id pub-id-type="doi">10.1021/ac702610a</pub-id><?supplied-pmid 18457414?><pub-id pub-id-type="pmid">18457414</pub-id></element-citation></ref><ref id="B135-ijms-19-01578"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Gooden</surname><given-names>D.M.</given-names></name><name><surname>Ball</surname><given-names>C.H.</given-names></name><name><surname>Fitzgerald</surname><given-names>M.C.</given-names></name></person-group><article-title>Targeted mass spectrometry-based approach for protein-ligand binding analyses in complex biological mixtures using a phenacyl bromide modification strategy</article-title><source>Anal. Chem.</source><year>2016</year><volume>88</volume><fpage>10987</fpage><lpage>10993</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.6b02658</pub-id><?supplied-pmid 27740755?><pub-id pub-id-type="pmid">27740755</pub-id></element-citation></ref><ref id="B136-ijms-19-01578"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>C.</given-names></name></person-group><article-title>Identification of protein binding partners of small molecules using label-free methods</article-title><source>Expert Opin. Drug Discov.</source><year>2016</year><volume>11</volume><fpage>1017</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1080/17460441.2016.1227316</pub-id><?supplied-pmid 27554241?><pub-id pub-id-type="pmid">27554241</pub-id></element-citation></ref><ref id="B137-ijms-19-01578"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strickland</surname><given-names>E.C.</given-names></name><name><surname>Geer</surname><given-names>M.A.</given-names></name><name><surname>Hong</surname><given-names>J.</given-names></name><name><surname>Fitzgerald</surname><given-names>M.C.</given-names></name></person-group><article-title>False-positive rate determination of protein target discovery using a covalent modification- and mass spectrometry-based proteomics platform</article-title><source>J. Am. Soc. Mass Spectrom.</source><year>2014</year><volume>25</volume><fpage>132</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1007/s13361-013-0754-2</pub-id><?supplied-pmid 24114261?><pub-id pub-id-type="pmid">24114261</pub-id></element-citation></ref><ref id="B138-ijms-19-01578"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dearmond</surname><given-names>P.D.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Strickland</surname><given-names>E.C.</given-names></name><name><surname>Daniels</surname><given-names>K.G.</given-names></name><name><surname>Fitzgerald</surname><given-names>M.C.</given-names></name></person-group><article-title>Thermodynamic analysis of protein-ligand interactions in complex biological mixtures using a shotgun proteomics approach</article-title><source>J. Proteome Res.</source><year>2011</year><volume>10</volume><fpage>4948</fpage><lpage>4958</lpage><pub-id pub-id-type="doi">10.1021/pr200403c</pub-id><?supplied-pmid 21905665?><pub-id pub-id-type="pmid">21905665</pub-id></element-citation></ref><ref id="B139-ijms-19-01578"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>D.T.</given-names></name><name><surname>Adhikari</surname><given-names>J.</given-names></name><name><surname>Fitzgerald</surname><given-names>M.C.</given-names></name></person-group><article-title>Stableisotope labeling with amino acids in cell culture (SILAC)-based strategy for proteome-wide thermodynamic analysis of protein-ligand binding interactions</article-title><source>Mol. Cell. Proteom.</source><year>2014</year><volume>13</volume><fpage>1800</fpage><lpage>1813</lpage><pub-id pub-id-type="doi">10.1074/mcp.M113.034702</pub-id><?supplied-pmid 24741112?><pub-id pub-id-type="pmid">24741112</pub-id></element-citation></ref><ref id="B140-ijms-19-01578"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geiger</surname><given-names>T.</given-names></name><name><surname>Wisniewski</surname><given-names>J.R.</given-names></name><name><surname>Cox</surname><given-names>J.</given-names></name><name><surname>Zanivan</surname><given-names>S.</given-names></name><name><surname>Kruger</surname><given-names>M.</given-names></name><name><surname>Ishihama</surname><given-names>Y.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name></person-group><article-title>Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in quantitative proteomics</article-title><source>Nat. Protoc.</source><year>2011</year><volume>6</volume><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1038/nprot.2010.192</pub-id><?supplied-pmid 21293456?><pub-id pub-id-type="pmid">21293456</pub-id></element-citation></ref><ref id="B141-ijms-19-01578"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoedt</surname><given-names>E.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Neubert</surname><given-names>T.A.</given-names></name></person-group><article-title>Stable isotope labeling by amino acids in cell culture (SILAC) for quantitative proteomics</article-title><source>Adv. Exp. Med. Biol.</source><year>2014</year><volume>806</volume><fpage>93</fpage><lpage>106</lpage><?supplied-pmid 24952180?><pub-id pub-id-type="pmid">24952180</pub-id></element-citation></ref><ref id="B142-ijms-19-01578"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larance</surname><given-names>M.</given-names></name><name><surname>Bailly</surname><given-names>A.P.</given-names></name><name><surname>Pourkarimi</surname><given-names>E.</given-names></name><name><surname>Hay</surname><given-names>R.T.</given-names></name><name><surname>Buchanan</surname><given-names>G.</given-names></name><name><surname>Coulthurst</surname><given-names>S.</given-names></name><name><surname>Xirodimas</surname><given-names>D.P.</given-names></name><name><surname>Gartner</surname><given-names>A.</given-names></name><name><surname>Lamond</surname><given-names>A.I.</given-names></name></person-group><article-title>Stable-isotope labeling with amino acids in nematodes</article-title><source>Nat. Methods</source><year>2011</year><volume>8</volume><fpage>849</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1679</pub-id><?supplied-pmid 21874007?><pub-id pub-id-type="pmid">21874007</pub-id></element-citation></ref><ref id="B143-ijms-19-01578"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>S.E.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name></person-group><article-title>A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC)</article-title><source>Nat. Protoc.</source><year>2006</year><volume>1</volume><fpage>2650</fpage><lpage>2660</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.427</pub-id><?supplied-pmid 17406521?><pub-id pub-id-type="pmid">17406521</pub-id></element-citation></ref><ref id="B144-ijms-19-01578"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Jin</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>R.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Huo</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Han</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Quantitative analysis of differential protein expression in cervical carcinoma cells after zeylenone treatment by stable isotope labeling with amino acids in cell culture</article-title><source>J. Proteom.</source><year>2015</year><volume>126</volume><fpage>279</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/j.jprot.2015.06.012</pub-id><?supplied-pmid 26130516?><pub-id pub-id-type="pmid">26130516</pub-id></element-citation></ref><ref id="B145-ijms-19-01578"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez Molina</surname><given-names>D.</given-names></name><name><surname>Jafari</surname><given-names>R.</given-names></name><name><surname>Ignatushchenko</surname><given-names>M.</given-names></name><name><surname>Seki</surname><given-names>T.</given-names></name><name><surname>Larsson</surname><given-names>E.A.</given-names></name><name><surname>Dan</surname><given-names>C.</given-names></name><name><surname>Sreekumar</surname><given-names>L.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Nordlund</surname><given-names>P.</given-names></name></person-group><article-title>Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay</article-title><source>Science</source><year>2013</year><volume>341</volume><fpage>84</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1126/science.1233606</pub-id><?supplied-pmid 23828940?><pub-id pub-id-type="pmid">23828940</pub-id></element-citation></ref><ref id="B146-ijms-19-01578"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schirle</surname><given-names>M.</given-names></name><name><surname>Jenkins</surname><given-names>J.L.</given-names></name></person-group><article-title>Identifying compound efficacy targets in phenotypic drug discovery</article-title><source>Drug Discov. Today</source><year>2016</year><volume>21</volume><fpage>82</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2015.08.001</pub-id><?supplied-pmid 26272035?><pub-id pub-id-type="pmid">26272035</pub-id></element-citation></ref><ref id="B147-ijms-19-01578"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H.</given-names></name><name><surname>Duggan</surname><given-names>S.</given-names></name><name><surname>Richardson</surname><given-names>P.L.</given-names></name><name><surname>Marin</surname><given-names>V.</given-names></name><name><surname>Warder</surname><given-names>S.E.</given-names></name><name><surname>McLoughlin</surname><given-names>S.M.</given-names></name></person-group><article-title>Target identification of compounds from a cell viability phenotypic screen using a bead/lysate-based affinity capture platform</article-title><source>J. Biomol. Screen.</source><year>2016</year><volume>21</volume><fpage>201</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1177/1087057115622431</pub-id><?supplied-pmid 26676096?><pub-id pub-id-type="pmid">26676096</pub-id></element-citation></ref><ref id="B148-ijms-19-01578"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>K.V.</given-names></name><name><surname>Olek</surname><given-names>K.M.</given-names></name><name><surname>Muller</surname><given-names>A.C.</given-names></name><name><surname>Tan</surname><given-names>C.S.</given-names></name><name><surname>Bennett</surname><given-names>K.L.</given-names></name><name><surname>Colinge</surname><given-names>J.</given-names></name><name><surname>Superti-Furga</surname><given-names>G.</given-names></name></person-group><article-title>Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling</article-title><source>Nat. Methods</source><year>2015</year><volume>12</volume><fpage>1055</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3590</pub-id><?supplied-pmid 26389571?><pub-id pub-id-type="pmid">26389571</pub-id></element-citation></ref><ref id="B149-ijms-19-01578"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinhard</surname><given-names>F.B.</given-names></name><name><surname>Eberhard</surname><given-names>D.</given-names></name><name><surname>Werner</surname><given-names>T.</given-names></name><name><surname>Franken</surname><given-names>H.</given-names></name><name><surname>Childs</surname><given-names>D.</given-names></name><name><surname>Doce</surname><given-names>C.</given-names></name><name><surname>Savitski</surname><given-names>M.F.</given-names></name><name><surname>Huber</surname><given-names>W.</given-names></name><name><surname>Bantscheff</surname><given-names>M.</given-names></name><name><surname>Savitski</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>Thermal proteome profiling monitors ligand interactions with cellular membrane proteins</article-title><source>Nat. Methods</source><year>2015</year><volume>12</volume><fpage>1129</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3652</pub-id><?supplied-pmid 26524241?><pub-id pub-id-type="pmid">26524241</pub-id></element-citation></ref><ref id="B150-ijms-19-01578"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savitski</surname><given-names>M.M.</given-names></name><name><surname>Reinhard</surname><given-names>F.B.</given-names></name><name><surname>Franken</surname><given-names>H.</given-names></name><name><surname>Werner</surname><given-names>T.</given-names></name><name><surname>Savitski</surname><given-names>M.F.</given-names></name><name><surname>Eberhard</surname><given-names>D.</given-names></name><name><surname>Martinez Molina</surname><given-names>D.</given-names></name><name><surname>Jafari</surname><given-names>R.</given-names></name><name><surname>Dovega</surname><given-names>R.B.</given-names></name><name><surname>Klaeger</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Tracking cancer drugs in living cells by thermal profiling of the proteome</article-title><source>Science</source><year>2014</year><volume>346</volume><fpage>1255784</fpage><pub-id pub-id-type="doi">10.1126/science.1255784</pub-id><?supplied-pmid 25278616?><pub-id pub-id-type="pmid">25278616</pub-id></element-citation></ref><ref id="B151-ijms-19-01578"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becher</surname><given-names>I.</given-names></name><name><surname>Werner</surname><given-names>T.</given-names></name><name><surname>Doce</surname><given-names>C.</given-names></name><name><surname>Zaal</surname><given-names>E.A.</given-names></name><name><surname>Togel</surname><given-names>I.</given-names></name><name><surname>Khan</surname><given-names>C.A.</given-names></name><name><surname>Rueger</surname><given-names>A.</given-names></name><name><surname>Muelbaier</surname><given-names>M.</given-names></name><name><surname>Salzer</surname><given-names>E.</given-names></name><name><surname>Berkers</surname><given-names>C.R.</given-names></name><etal/></person-group><article-title>Thermal profiling reveals phenylalanine hydroxylase as an off-target of panobinostat</article-title><source>Nat. Chem. Biol.</source><year>2016</year><volume>12</volume><fpage>908</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2185</pub-id><?supplied-pmid 27669419?><pub-id pub-id-type="pmid">27669419</pub-id></element-citation></ref><ref id="B152-ijms-19-01578"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateus</surname><given-names>A.</given-names></name><name><surname>Maatta</surname><given-names>T.A.</given-names></name><name><surname>Savitski</surname><given-names>M.M.</given-names></name></person-group><article-title>Thermal proteome profiling: Unbiased assessment of protein state through heat-induced stability changes</article-title><source>Proteome Sci.</source><year>2016</year><volume>15</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.1186/s12953-017-0122-4</pub-id><?supplied-pmid 28652855?><pub-id pub-id-type="pmid">28652855</pub-id></element-citation></ref><ref id="B153-ijms-19-01578"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>C.H.</given-names></name><name><surname>Magtanong</surname><given-names>L.</given-names></name><name><surname>Barker</surname><given-names>S.L.</given-names></name><name><surname>Gresham</surname><given-names>D.</given-names></name><name><surname>Nishimura</surname><given-names>S.</given-names></name><name><surname>Natarajan</surname><given-names>P.</given-names></name><name><surname>Koh</surname><given-names>J.L.Y.</given-names></name><name><surname>Porter</surname><given-names>J.</given-names></name><name><surname>Gray</surname><given-names>C.A.</given-names></name><name><surname>Andersen</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive compounds</article-title><source>Nat. Biotechnol.</source><year>2009</year><volume>27</volume><fpage>369</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1038/nbt.1534</pub-id><?supplied-pmid 19349972?><pub-id pub-id-type="pmid">19349972</pub-id></element-citation></ref><ref id="B154-ijms-19-01578"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>H.J.</given-names></name><name><surname>Kwon</surname><given-names>H.J.</given-names></name></person-group><article-title>Target deconvolution of bioactive small molecules: The heart of chemical biology and drug discovery</article-title><source>Arch. Pharm. Res.</source><year>2015</year><volume>38</volume><fpage>1627</fpage><lpage>1641</lpage><pub-id pub-id-type="doi">10.1007/s12272-015-0618-3</pub-id><?supplied-pmid 26040984?><pub-id pub-id-type="pmid">26040984</pub-id></element-citation></ref><ref id="B155-ijms-19-01578"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassik</surname><given-names>M.C.</given-names></name><name><surname>Kampmann</surname><given-names>M.</given-names></name><name><surname>Lebbink</surname><given-names>R.J.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Hein</surname><given-names>M.Y.</given-names></name><name><surname>Poser</surname><given-names>I.</given-names></name><name><surname>Weibezahn</surname><given-names>J.</given-names></name><name><surname>Horlbeck</surname><given-names>M.A.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility</article-title><source>Cell</source><year>2013</year><volume>152</volume><fpage>909</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.01.030</pub-id><?supplied-pmid 23394947?><pub-id pub-id-type="pmid">23394947</pub-id></element-citation></ref><ref id="B156-ijms-19-01578"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shalem</surname><given-names>O.</given-names></name><name><surname>Sanjana</surname><given-names>N.E.</given-names></name><name><surname>Hartenian</surname><given-names>E.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Scott</surname><given-names>D.A.</given-names></name><name><surname>Mikkelson</surname><given-names>T.</given-names></name><name><surname>Heckl</surname><given-names>D.</given-names></name><name><surname>Ebert</surname><given-names>B.L.</given-names></name><name><surname>Root</surname><given-names>D.E.</given-names></name><name><surname>Doench</surname><given-names>J.G.</given-names></name><etal/></person-group><article-title>Genome-scale crispr-cas9 knockout screening in human cells</article-title><source>Science</source><year>2014</year><volume>343</volume><fpage>84</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1126/science.1247005</pub-id><?supplied-pmid 24336571?><pub-id pub-id-type="pmid">24336571</pub-id></element-citation></ref><ref id="B157-ijms-19-01578"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasap</surname><given-names>C.</given-names></name><name><surname>Elemento</surname><given-names>O.</given-names></name><name><surname>Kapoor</surname><given-names>T.M.</given-names></name></person-group><article-title>Drugtargetseqr: A genomics- and CRISPR-Cas9-based method to analyze drug targets</article-title><source>Nat. Chem. Biol.</source><year>2014</year><volume>10</volume><fpage>626</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1551</pub-id><?supplied-pmid 24929528?><pub-id pub-id-type="pmid">24929528</pub-id></element-citation></ref><ref id="B158-ijms-19-01578"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ipsaro</surname><given-names>J.J.</given-names></name><name><surname>Shen</surname><given-names>C.</given-names></name><name><surname>Arai</surname><given-names>E.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Kinney</surname><given-names>J.B.</given-names></name><name><surname>Joshua-Tor</surname><given-names>L.</given-names></name><name><surname>Vakoc</surname><given-names>C.R.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name></person-group><article-title>Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0172177</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0172177</pub-id><?supplied-pmid 28231254?><pub-id pub-id-type="pmid">28231254</pub-id></element-citation></ref><ref id="B159-ijms-19-01578"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neggers</surname><given-names>J.E.</given-names></name><name><surname>Vercruysse</surname><given-names>T.</given-names></name><name><surname>Jacquemyn</surname><given-names>M.</given-names></name><name><surname>Vanstreels</surname><given-names>E.</given-names></name><name><surname>Baloglu</surname><given-names>E.</given-names></name><name><surname>Shacham</surname><given-names>S.</given-names></name><name><surname>Crochiere</surname><given-names>M.</given-names></name><name><surname>Landesman</surname><given-names>Y.</given-names></name><name><surname>Daelemans</surname><given-names>D.</given-names></name></person-group><article-title>Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing</article-title><source>Chem. Biol.</source><year>2015</year><volume>22</volume><fpage>107</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2014.11.015</pub-id><?supplied-pmid 25579209?><pub-id pub-id-type="pmid">25579209</pub-id></element-citation></ref><ref id="B160-ijms-19-01578"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Locasale</surname><given-names>J.W.</given-names></name></person-group><article-title>Metabolomics: A primer</article-title><source>Trends Biochem. Sci.</source><year>2017</year><volume>42</volume><fpage>274</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2017.01.004</pub-id><?supplied-pmid 28196646?><pub-id pub-id-type="pmid">28196646</pub-id></element-citation></ref><ref id="B161-ijms-19-01578"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clish</surname><given-names>C.B.</given-names></name></person-group><article-title>Metabolomics: An emerging but powerful tool for precision medicine</article-title><source>Cold Spring Harb. Mol. Case Stud.</source><year>2015</year><volume>1</volume><fpage>a000588</fpage><pub-id pub-id-type="doi">10.1101/mcs.a000588</pub-id><?supplied-pmid 27148576?><pub-id pub-id-type="pmid">27148576</pub-id></element-citation></ref><ref id="B162-ijms-19-01578"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>J.K.</given-names></name><name><surname>Lindon</surname><given-names>J.C.</given-names></name></person-group><article-title>Systems biology: Metabonomics</article-title><source>Nature</source><year>2008</year><volume>455</volume><fpage>7216</fpage><pub-id pub-id-type="doi">10.1038/4551054a</pub-id><?supplied-pmid 18948945?><pub-id pub-id-type="pmid">18948945</pub-id></element-citation></ref><ref id="B163-ijms-19-01578"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Pinera</surname><given-names>P.</given-names></name><name><surname>Ousterout</surname><given-names>D.G.</given-names></name><name><surname>Gersbach</surname><given-names>C.A.</given-names></name></person-group><article-title>Advances in targeted genome editing</article-title><source>Curr. Opin. Chem. Biol.</source><year>2012</year><volume>16</volume><fpage>268</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2012.06.007</pub-id><?supplied-pmid 22819644?><pub-id pub-id-type="pmid">22819644</pub-id></element-citation></ref><ref id="B164-ijms-19-01578"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siminovitch</surname><given-names>L.</given-names></name></person-group><article-title>Genetic manipulation: Now is the time to consider controls</article-title><source>Sci. Forum</source><year>1973</year><volume>6</volume><fpage>7</fpage><lpage>11</lpage><?supplied-pmid 11662962?><pub-id pub-id-type="pmid">11662962</pub-id></element-citation></ref><ref id="B165-ijms-19-01578"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarmush</surname><given-names>M.L.</given-names></name><name><surname>Banta</surname><given-names>S.</given-names></name></person-group><article-title>Metabolic engineering: Advances in modeling and intervention in health and disease</article-title><source>Ann. Rev. Biomed. Eng.</source><year>2003</year><volume>5</volume><fpage>349</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1146/annurev.bioeng.5.031003.163247</pub-id><?supplied-pmid 14527316?><pub-id pub-id-type="pmid">14527316</pub-id></element-citation></ref><ref id="B166-ijms-19-01578"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>T.</given-names></name><name><surname>Fu</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name></person-group><article-title>UPLC-MS/MS determination of ephedrine, methylephedrine, amygdalin and glycyrrhizic acid in beagle plasma and its application to a pharmacokinetic study after oral administration of Ma Huang Tang</article-title><source>Drug. Test. Anal.</source><year>2015</year><volume>7</volume><fpage>158</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1002/dta.1635</pub-id><?supplied-pmid 24824649?><pub-id pub-id-type="pmid">24824649</pub-id></element-citation></ref><ref id="B167-ijms-19-01578"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekow Thomford</surname><given-names>N.</given-names></name><name><surname>Dzobo</surname><given-names>K.</given-names></name><name><surname>Adu</surname><given-names>F.</given-names></name><name><surname>Chirikure</surname><given-names>S.</given-names></name><name><surname>Wonkam</surname><given-names>A.</given-names></name><name><surname>Dandara</surname><given-names>C.</given-names></name></person-group><article-title>Bush mint (<italic>Hyptis suaveolens</italic>) and spreading hogweed (<italic>Boerhavia diffusa</italic>) medicinal plant extracts differentially affect activities of CYP1A2, CYP2D6 and CYP3A4 enzymes</article-title><source>J. Ethnopharmacol.</source><year>2018</year><volume>211</volume><fpage>58</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2017.09.023</pub-id><?supplied-pmid 28942133?><pub-id pub-id-type="pmid">28942133</pub-id></element-citation></ref><ref id="B168-ijms-19-01578"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>G.</given-names></name><name><surname>Plumb</surname><given-names>R.</given-names></name><name><surname>Su</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>A.</given-names></name><name><surname>Qiu</surname><given-names>M.</given-names></name><name><surname>Long</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Jia</surname><given-names>W.</given-names></name></person-group><article-title>Ultra-performance LC/TOF MS analysis of medicinal <italic>Panax</italic> herbs for metabolomic research</article-title><source>J. Sep. Sci.</source><year>2008</year><volume>31</volume><fpage>1015</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1002/jssc.200700650</pub-id><?supplied-pmid 18338405?><pub-id pub-id-type="pmid">18338405</pub-id></element-citation></ref><ref id="B169-ijms-19-01578"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H.-W.</given-names></name><name><surname>In</surname><given-names>G.</given-names></name><name><surname>Kim</surname><given-names>J.-H.</given-names></name><name><surname>Cho</surname><given-names>B.-G.</given-names></name><name><surname>Han</surname><given-names>G.-H.</given-names></name><name><surname>Chang</surname><given-names>I.-M.</given-names></name></person-group><article-title>Metabolomic approach for discrimination of processed ginseng genus (<italic>Panax ginseng</italic> and <italic>Panax quinquefolius</italic>) using UPLC-QTOF MS</article-title><source>J. Ginseng Res.</source><year>2014</year><volume>38</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.jgr.2013.11.011</pub-id><?supplied-pmid 24558312?><pub-id pub-id-type="pmid">24558312</pub-id></element-citation></ref><ref id="B170-ijms-19-01578"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korotcov</surname><given-names>A.</given-names></name><name><surname>Tkachenko</surname><given-names>V.</given-names></name><name><surname>Russo</surname><given-names>D.P.</given-names></name><name><surname>Ekins</surname><given-names>S.</given-names></name></person-group><article-title>Comparison of deep learning with multiple machine learning methods and metrics using diverse drug discovery data sets</article-title><source>Mol. Pharm.</source><year>2017</year><volume>14</volume><fpage>4462</fpage><lpage>4475</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00578</pub-id><?supplied-pmid 29096442?><pub-id pub-id-type="pmid">29096442</pub-id></element-citation></ref><ref id="B171-ijms-19-01578"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oprea</surname><given-names>T.I.</given-names></name><name><surname>Matter</surname><given-names>H.</given-names></name></person-group><article-title>Integrating virtual screening in lead discovery</article-title><source>Curr. Opin. Chem. Biol.</source><year>2004</year><volume>8</volume><fpage>349</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2004.06.008</pub-id><?supplied-pmid 15288243?><pub-id pub-id-type="pmid">15288243</pub-id></element-citation></ref><ref id="B172-ijms-19-01578"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>A.</given-names></name><name><surname>Eberherr</surname><given-names>C.</given-names></name><name><surname>Hagemann</surname><given-names>M.</given-names></name><name><surname>Cairo</surname><given-names>S.</given-names></name><name><surname>Haberle</surname><given-names>B.</given-names></name><name><surname>Vokuhl</surname><given-names>C.</given-names></name><name><surname>von Schweinitz</surname><given-names>D.</given-names></name><name><surname>Kappler</surname><given-names>R.</given-names></name></person-group><article-title>Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma</article-title><source>Cancer Biol. Ther.</source><year>2016</year><volume>17</volume><fpage>1168</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1080/15384047.2016.1235664</pub-id><?supplied-pmid 27635950?><pub-id pub-id-type="pmid">27635950</pub-id></element-citation></ref><ref id="B173-ijms-19-01578"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brum</surname><given-names>A.M.</given-names></name><name><surname>van de Peppel</surname><given-names>J.</given-names></name><name><surname>van der Leije</surname><given-names>C.S.</given-names></name><name><surname>Schreuders-Koedam</surname><given-names>M.</given-names></name><name><surname>Eijken</surname><given-names>M.</given-names></name><name><surname>van der Eerden</surname><given-names>B.C.</given-names></name><name><surname>van Leeuwen</surname><given-names>J.P.</given-names></name></person-group><article-title>Connectivity map-based discovery of parbendazole reveals targetable human osteogenic pathway</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>12711</fpage><lpage>12716</lpage><pub-id pub-id-type="doi">10.1073/pnas.1501597112</pub-id><?supplied-pmid 26420877?><pub-id pub-id-type="pmid">26420877</pub-id></element-citation></ref><ref id="B174-ijms-19-01578"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Agarwal</surname><given-names>P.</given-names></name></person-group><article-title>Systematic evaluation of connectivity map for disease indications</article-title><source>Genome Med.</source><year>2014</year><volume>6</volume><fpage>95</fpage><pub-id pub-id-type="doi">10.1186/s13073-014-0095-1</pub-id><?supplied-pmid 25606058?><pub-id pub-id-type="pmid">25606058</pub-id></element-citation></ref><ref id="B175-ijms-19-01578"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>J.</given-names></name></person-group><article-title>The connectivity map: A new tool for biomedical research</article-title><source>Nat. Rev. Cancer</source><year>2007</year><volume>7</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/nrc2044</pub-id><?supplied-pmid 17186018?><pub-id pub-id-type="pmid">17186018</pub-id></element-citation></ref><ref id="B176-ijms-19-01578"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>J.</given-names></name><name><surname>Crawford</surname><given-names>E.D.</given-names></name><name><surname>Peck</surname><given-names>D.</given-names></name><name><surname>Modell</surname><given-names>J.W.</given-names></name><name><surname>Blat</surname><given-names>I.C.</given-names></name><name><surname>Wrobel</surname><given-names>M.J.</given-names></name><name><surname>Lerner</surname><given-names>J.</given-names></name><name><surname>Brunet</surname><given-names>J.P.</given-names></name><name><surname>Subramanian</surname><given-names>A.</given-names></name><name><surname>Ross</surname><given-names>K.N.</given-names></name><etal/></person-group><article-title>The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>1929</fpage><lpage>1935</lpage><pub-id pub-id-type="doi">10.1126/science.1132939</pub-id><?supplied-pmid 17008526?><pub-id pub-id-type="pmid">17008526</pub-id></element-citation></ref><ref id="B177-ijms-19-01578"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>C.K.</given-names></name><name><surname>Berchuck</surname><given-names>J.E.</given-names></name><name><surname>Ross</surname><given-names>K.N.</given-names></name><name><surname>Kakoza</surname><given-names>R.M.</given-names></name><name><surname>Clauser</surname><given-names>K.</given-names></name><name><surname>Schinzel</surname><given-names>A.C.</given-names></name><name><surname>Ross</surname><given-names>L.</given-names></name><name><surname>Galinsky</surname><given-names>I.</given-names></name><name><surname>Davis</surname><given-names>T.N.</given-names></name><name><surname>Silver</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>Proteomic and genetic approaches identify Syk as an AML target</article-title><source>Cancer Cell</source><year>2009</year><volume>16</volume><fpage>281</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.08.018</pub-id><?supplied-pmid 19800574?><pub-id pub-id-type="pmid">19800574</pub-id></element-citation></ref><ref id="B178-ijms-19-01578"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>M.</given-names></name><name><surname>Sandhu</surname><given-names>S.S.</given-names></name><name><surname>Sharma</surname><given-names>A.K.</given-names></name></person-group><article-title>Prognostic and predictive biomarkers in cancer</article-title><source>Curr. Cancer Drug Targets</source><year>2014</year><volume>14</volume><fpage>477</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.2174/1568009614666140506111118</pub-id><?supplied-pmid 24807144?><pub-id pub-id-type="pmid">24807144</pub-id></element-citation></ref><ref id="B179-ijms-19-01578"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayanan</surname><given-names>R.</given-names></name></person-group><article-title>Druggable cancer secretome: Neoplasm-associated traits</article-title><source>Cancer Genom. Proteom.</source><year>2015</year><volume>12</volume><fpage>119</fpage><lpage>131</lpage></element-citation></ref><ref id="B180-ijms-19-01578"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roti</surname><given-names>G.</given-names></name><name><surname>Stegmaier</surname><given-names>K.</given-names></name></person-group><article-title>Genetic and proteomic approaches to identify cancer drug targets</article-title><source>Br. J. Cancer</source><year>2012</year><volume>106</volume><fpage>254</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.543</pub-id><?supplied-pmid 22166799?><pub-id pub-id-type="pmid">22166799</pub-id></element-citation></ref><ref id="B181-ijms-19-01578"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>M.</given-names></name><name><surname>Wright</surname><given-names>G.L.</given-names><suffix>Jr.</suffix></name><name><surname>Hanash</surname><given-names>S.M.</given-names></name><name><surname>Gopal-Srivastava</surname><given-names>R.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name></person-group><article-title>Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2001</year><volume>945</volume><fpage>103</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2001.tb03870.x</pub-id><?supplied-pmid 11708463?><pub-id pub-id-type="pmid">11708463</pub-id></element-citation></ref><ref id="B182-ijms-19-01578"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awale</surname><given-names>M.</given-names></name><name><surname>Visini</surname><given-names>R.</given-names></name><name><surname>Probst</surname><given-names>D.</given-names></name><name><surname>Arus-Pous</surname><given-names>J.</given-names></name><name><surname>Reymond</surname><given-names>J.L.</given-names></name></person-group><article-title>Chemical space: Big data challenge for molecular diversity</article-title><source>Chimia</source><year>2017</year><volume>71</volume><fpage>661</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.2533/chimia.2017.661</pub-id><?supplied-pmid 29070411?><pub-id pub-id-type="pmid">29070411</pub-id></element-citation></ref><ref id="B183-ijms-19-01578"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denny</surname><given-names>J.C.</given-names></name><name><surname>Van Driest</surname><given-names>S.L.</given-names></name><name><surname>Wei</surname><given-names>W.Q.</given-names></name><name><surname>Roden</surname><given-names>D.M.</given-names></name></person-group><article-title>The influence of big (clinical) data and genomics on precision medicine and drug development</article-title><source>Clin. Pharmacol. Ther.</source><year>2018</year><volume>103</volume><fpage>409</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1002/cpt.951</pub-id><?supplied-pmid 29171014?><pub-id pub-id-type="pmid">29171014</pub-id></element-citation></ref><ref id="B184-ijms-19-01578"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>G.</given-names></name><name><surname>Schulthess</surname><given-names>D.</given-names></name><name><surname>Hughes</surname><given-names>N.</given-names></name><name><surname>Vannieuwenhuyse</surname><given-names>B.</given-names></name><name><surname>Kalra</surname><given-names>D.</given-names></name></person-group><article-title>Real world big data for clinical research and drug development</article-title><source>Drug Discov. Today</source><year>2018</year><volume>23</volume><fpage>650</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2017.12.002</pub-id><?supplied-pmid 29294362?><pub-id pub-id-type="pmid">29294362</pub-id></element-citation></ref><ref id="B185-ijms-19-01578"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bento</surname><given-names>A.P.</given-names></name><name><surname>Gaulton</surname><given-names>A.</given-names></name><name><surname>Hersey</surname><given-names>A.</given-names></name><name><surname>Bellis</surname><given-names>L.J.</given-names></name><name><surname>Chambers</surname><given-names>J.</given-names></name><name><surname>Davies</surname><given-names>M.</given-names></name><name><surname>Kruger</surname><given-names>F.A.</given-names></name><name><surname>Light</surname><given-names>Y.</given-names></name><name><surname>Mak</surname><given-names>L.</given-names></name><name><surname>McGlinchey</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The ChEMBL bioactivity database: An update</article-title><source>Nucleic Acids Res.</source><year>2014</year><volume>42</volume><fpage>D1083</fpage><lpage>D1090</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1031</pub-id><?supplied-pmid 24214965?><pub-id pub-id-type="pmid">24214965</pub-id></element-citation></ref><ref id="B186-ijms-19-01578"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaulton</surname><given-names>A.</given-names></name><name><surname>Bellis</surname><given-names>L.J.</given-names></name><name><surname>Bento</surname><given-names>A.P.</given-names></name><name><surname>Chambers</surname><given-names>J.</given-names></name><name><surname>Davies</surname><given-names>M.</given-names></name><name><surname>Hersey</surname><given-names>A.</given-names></name><name><surname>Light</surname><given-names>Y.</given-names></name><name><surname>McGlinchey</surname><given-names>S.</given-names></name><name><surname>Michalovich</surname><given-names>D.</given-names></name><name><surname>Al-Lazikani</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Chembl: A large-scale bioactivity database for drug discovery</article-title><source>Nucleic Acids Res.</source><year>2012</year><volume>40</volume><fpage>D1100</fpage><lpage>D1107</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr777</pub-id><?supplied-pmid 21948594?><pub-id pub-id-type="pmid">21948594</pub-id></element-citation></ref><ref id="B187-ijms-19-01578"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaulton</surname><given-names>A.</given-names></name><name><surname>Hersey</surname><given-names>A.</given-names></name><name><surname>Nowotka</surname><given-names>M.</given-names></name><name><surname>Bento</surname><given-names>A.P.</given-names></name><name><surname>Chambers</surname><given-names>J.</given-names></name><name><surname>Mendez</surname><given-names>D.</given-names></name><name><surname>Mutowo</surname><given-names>P.</given-names></name><name><surname>Atkinson</surname><given-names>F.</given-names></name><name><surname>Bellis</surname><given-names>L.J.</given-names></name><name><surname>Cibrian-Uhalte</surname><given-names>E.</given-names></name><etal/></person-group><article-title>The ChEMBL database in 2017</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>D945</fpage><lpage>D954</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw1074</pub-id><?supplied-pmid 27899562?><pub-id pub-id-type="pmid">27899562</pub-id></element-citation></ref><ref id="B188-ijms-19-01578"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruger</surname><given-names>F.A.</given-names></name><name><surname>Rostom</surname><given-names>R.</given-names></name><name><surname>Overington</surname><given-names>J.P.</given-names></name></person-group><article-title>Mapping small molecule binding data to structural domains</article-title><source>BMC Bioinform.</source><year>2012</year><volume>13</volume><elocation-id>S11</elocation-id></element-citation></ref><ref id="B189-ijms-19-01578"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roos</surname><given-names>D.S.</given-names></name></person-group><article-title>Computational biology. Bioinformatics&#x02014;Trying to swim in a sea of data</article-title><source>Science</source><year>2001</year><volume>291</volume><fpage>1260</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1126/science.291.5507.1260</pub-id><?supplied-pmid 11233452?><pub-id pub-id-type="pmid">11233452</pub-id></element-citation></ref><ref id="B190-ijms-19-01578"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jennings</surname><given-names>A.</given-names></name><name><surname>Tennant</surname><given-names>M.</given-names></name></person-group><article-title>Discovery strategies in a pharmaceutical setting: The application of computational techniques</article-title><source>Expert Opin. Drug Discov.</source><year>2006</year><volume>1</volume><fpage>709</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1517/17460441.1.7.709</pub-id><?supplied-pmid 23495995?><pub-id pub-id-type="pmid">23495995</pub-id></element-citation></ref><ref id="B191-ijms-19-01578"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.P.</given-names></name><name><surname>Chen</surname><given-names>F.</given-names></name></person-group><article-title>Identifying targets for drug discovery using bioinformatics</article-title><source>Expert Opin. Ther. Targets</source><year>2008</year><volume>12</volume><fpage>383</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1517/14728222.12.4.383</pub-id><?supplied-pmid 18348676?><pub-id pub-id-type="pmid">18348676</pub-id></element-citation></ref><ref id="B192-ijms-19-01578"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segal</surname><given-names>M.R.</given-names></name><name><surname>Xiong</surname><given-names>H.</given-names></name><name><surname>Bengtsson</surname><given-names>H.</given-names></name><name><surname>Bourgon</surname><given-names>R.</given-names></name><name><surname>Gentleman</surname><given-names>R.</given-names></name></person-group><article-title>Querying genomic databases: Refining the connectivity map</article-title><source>Stat. Appl. Genet. Mol. Biol.</source><year>2012</year><volume>11</volume><pub-id pub-id-type="doi">10.2202/1544-6115.1715</pub-id><?supplied-pmid 22499690?><pub-id pub-id-type="pmid">22499690</pub-id></element-citation></ref><ref id="B193-ijms-19-01578"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>R.S.</given-names></name><name><surname>Goossens</surname><given-names>N.</given-names></name><name><surname>Hoshida</surname><given-names>Y.</given-names></name></person-group><article-title>Use of big data in drug development for precision medicine</article-title><source>Expert Rev. Precis. Med. Drug Dev.</source><year>2016</year><volume>1</volume><fpage>245</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1080/23808993.2016.1174062</pub-id><?supplied-pmid 27430024?><pub-id pub-id-type="pmid">27430024</pub-id></element-citation></ref><ref id="B194-ijms-19-01578"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cappon</surname><given-names>G.D.</given-names></name></person-group><article-title>Nonclinical support of pediatric drug development in a global context: An industry perspective</article-title><source>Birth Defects Res. Part B Dev. Reprod. Toxicol.</source><year>2011</year><volume>92</volume><fpage>269</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1002/bdrb.20303</pub-id><?supplied-pmid 21594976?><pub-id pub-id-type="pmid">21594976</pub-id></element-citation></ref><ref id="B195-ijms-19-01578"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneko</surname><given-names>T.</given-names></name><name><surname>Cooper</surname><given-names>C.</given-names></name><name><surname>Mdluli</surname><given-names>K.</given-names></name></person-group><article-title>Challenges and opportunities in developing novel drugs for TB</article-title><source>Future Med. Chem.</source><year>2011</year><volume>3</volume><fpage>1373</fpage><lpage>1400</lpage><pub-id pub-id-type="doi">10.4155/fmc.11.115</pub-id><?supplied-pmid 21879843?><pub-id pub-id-type="pmid">21879843</pub-id></element-citation></ref><ref id="B196-ijms-19-01578"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morford</surname><given-names>L.L.</given-names></name><name><surname>Bowman</surname><given-names>C.J.</given-names></name><name><surname>Blanset</surname><given-names>D.L.</given-names></name><name><surname>Bogh</surname><given-names>I.B.</given-names></name><name><surname>Chellman</surname><given-names>G.J.</given-names></name><name><surname>Halpern</surname><given-names>W.G.</given-names></name><name><surname>Weinbauer</surname><given-names>G.F.</given-names></name><name><surname>Coogan</surname><given-names>T.P.</given-names></name></person-group><article-title>Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: Strategy, challenges, current practices</article-title><source>Birth Defects Res. Part B Dev. Reprod. Toxicol.</source><year>2011</year><volume>92</volume><fpage>359</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1002/bdrb.20305</pub-id><?supplied-pmid 21770023?><pub-id pub-id-type="pmid">21770023</pub-id></element-citation></ref><ref id="B197-ijms-19-01578"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beggs</surname><given-names>N.F.</given-names></name><name><surname>Dobrovolny</surname><given-names>H.M.</given-names></name></person-group><article-title>Determining drug efficacy parameters for mathematical models of influenza</article-title><source>J. Biol. Dyn.</source><year>2015</year><volume>9</volume><fpage>332</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1080/17513758.2015.1052764</pub-id><?supplied-pmid 26056712?><pub-id pub-id-type="pmid">26056712</pub-id></element-citation></ref><ref id="B198-ijms-19-01578"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>W.</given-names></name><name><surname>Choi</surname><given-names>J.</given-names></name><name><surname>Kwon</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>D.</given-names></name></person-group><article-title>Context-specific functional module based drug efficacy prediction</article-title><source>BMC Bioinform.</source><year>2016</year><volume>17</volume><issue>Suppl. 6</issue><pub-id pub-id-type="doi">10.1186/s12859-016-1078-6</pub-id><?supplied-pmid 27490093?><pub-id pub-id-type="pmid">27490093</pub-id></element-citation></ref><ref id="B199-ijms-19-01578"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez-Diaz</surname><given-names>M.B.</given-names></name><name><surname>Viera</surname><given-names>S.</given-names></name><name><surname>Fernandez-Alvaro</surname><given-names>E.</given-names></name><name><surname>Angulo-Barturen</surname><given-names>I.</given-names></name></person-group><article-title>Animal models of efficacy to accelerate drug discovery in malaria</article-title><source>Parasitology</source><year>2014</year><volume>141</volume><fpage>93</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1017/S0031182013000991</pub-id><?supplied-pmid 23789594?><pub-id pub-id-type="pmid">23789594</pub-id></element-citation></ref><ref id="B200-ijms-19-01578"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>M.R.</given-names></name><name><surname>Johnson</surname><given-names>T.</given-names></name><name><surname>Warren</surname><given-names>L.</given-names></name><name><surname>Hughes</surname><given-names>A.R.</given-names></name><name><surname>Chissoe</surname><given-names>S.L.</given-names></name><name><surname>Xu</surname><given-names>C.F.</given-names></name><name><surname>Waterworth</surname><given-names>D.M.</given-names></name></person-group><article-title>The genetics of drug efficacy: Opportunities and challenges</article-title><source>Nat. Rev. Genet.</source><year>2016</year><volume>17</volume><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1038/nrg.2016.12</pub-id><?supplied-pmid 26972588?><pub-id pub-id-type="pmid">26972588</pub-id></element-citation></ref><ref id="B201-ijms-19-01578"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsugawa</surname><given-names>J.</given-names></name><name><surname>Onozawa</surname><given-names>R.</given-names></name><name><surname>Fukae</surname><given-names>J.</given-names></name><name><surname>Mishima</surname><given-names>T.</given-names></name><name><surname>Fujioka</surname><given-names>S.</given-names></name><name><surname>Tsuboi</surname><given-names>Y.</given-names></name></person-group><article-title>Impact of insufficient drug efficacy of antiparkinson agents on patient&#x02019;s quality of life: A cross-sectional study</article-title><source>BMC Neurol.</source><year>2015</year><volume>15</volume><elocation-id>105</elocation-id><pub-id pub-id-type="doi">10.1186/s12883-015-0360-y</pub-id><?supplied-pmid 26143184?><pub-id pub-id-type="pmid">26143184</pub-id></element-citation></ref><ref id="B202-ijms-19-01578"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gange</surname><given-names>S.J.</given-names></name><name><surname>Golub</surname><given-names>E.T.</given-names></name></person-group><article-title>From smallpox to big data: The next 100 years of epidemiologic methods</article-title><source>Am. J. Epidemiol.</source><year>2016</year><volume>183</volume><fpage>423</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1093/aje/kwv150</pub-id><?supplied-pmid 26443419?><pub-id pub-id-type="pmid">26443419</pub-id></element-citation></ref><ref id="B203-ijms-19-01578"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Docherty</surname><given-names>A.B.</given-names></name><name><surname>Lone</surname><given-names>N.I.</given-names></name></person-group><article-title>Exploiting big data for critical care research</article-title><source>Curr. Opin. Crit. Care</source><year>2015</year><volume>21</volume><fpage>467</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1097/MCC.0000000000000228</pub-id><?supplied-pmid 26348424?><pub-id pub-id-type="pmid">26348424</pub-id></element-citation></ref><ref id="B204-ijms-19-01578"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greene</surname><given-names>C.S.</given-names></name><name><surname>Tan</surname><given-names>J.</given-names></name><name><surname>Ung</surname><given-names>M.</given-names></name><name><surname>Moore</surname><given-names>J.H.</given-names></name><name><surname>Cheng</surname><given-names>C.</given-names></name></person-group><article-title>Big data bioinformatics</article-title><source>J. Cell. Physiol.</source><year>2014</year><volume>229</volume><fpage>1896</fpage><lpage>1900</lpage><pub-id pub-id-type="doi">10.1002/jcp.24662</pub-id><?supplied-pmid 24799088?><pub-id pub-id-type="pmid">24799088</pub-id></element-citation></ref><ref id="B205-ijms-19-01578"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>S.S.</given-names></name><name><surname>Gao</surname><given-names>G.</given-names></name><name><surname>Koch</surname><given-names>S.</given-names></name></person-group><article-title>Big data and analytics in healthcare</article-title><source>Methods Inf. Med.</source><year>2015</year><volume>54</volume><fpage>546</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.3414/ME15-06-1001</pub-id><?supplied-pmid 26577624?><pub-id pub-id-type="pmid">26577624</pub-id></element-citation></ref><ref id="B206-ijms-19-01578"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wasser</surname><given-names>T.</given-names></name><name><surname>Haynes</surname><given-names>K.</given-names></name><name><surname>Barron</surname><given-names>J.</given-names></name><name><surname>Cziraky</surname><given-names>M.</given-names></name></person-group><article-title>Using &#x02018;big data&#x02019; to validate claims made in the pharmaceutical approval process</article-title><source>J. Med. Econ.</source><year>2015</year><volume>18</volume><fpage>1013</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.3111/13696998.2015.1108919</pub-id><?supplied-pmid 26548546?><pub-id pub-id-type="pmid">26548546</pub-id></element-citation></ref><ref id="B207-ijms-19-01578"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reshef</surname><given-names>D.N.</given-names></name><name><surname>Reshef</surname><given-names>Y.A.</given-names></name><name><surname>Finucane</surname><given-names>H.K.</given-names></name><name><surname>Grossman</surname><given-names>S.R.</given-names></name><name><surname>McVean</surname><given-names>G.</given-names></name><name><surname>Turnbaugh</surname><given-names>P.J.</given-names></name><name><surname>Lander</surname><given-names>E.S.</given-names></name><name><surname>Mitzenmacher</surname><given-names>M.</given-names></name><name><surname>Sabeti</surname><given-names>P.C.</given-names></name></person-group><article-title>Detecting novel associations in large data sets</article-title><source>Science</source><year>2011</year><volume>334</volume><fpage>1518</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1126/science.1205438</pub-id><?supplied-pmid 22174245?><pub-id pub-id-type="pmid">22174245</pub-id></element-citation></ref><ref id="B208-ijms-19-01578"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omberg</surname><given-names>L.</given-names></name><name><surname>Ellrott</surname><given-names>K.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Kandoth</surname><given-names>C.</given-names></name><name><surname>Wong</surname><given-names>C.</given-names></name><name><surname>Kellen</surname><given-names>M.R.</given-names></name><name><surname>Friend</surname><given-names>S.H.</given-names></name><name><surname>Stuart</surname><given-names>J.</given-names></name><name><surname>Liang</surname><given-names>H.</given-names></name><name><surname>Margolin</surname><given-names>A.A.</given-names></name></person-group><article-title>Enabling transparent and collaborative computational analysis of 12 tumor types within the cancer genome atlas</article-title><source>Nat. Genet.</source><year>2013</year><volume>45</volume><fpage>1121</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1038/ng.2761</pub-id><?supplied-pmid 24071850?><pub-id pub-id-type="pmid">24071850</pub-id></element-citation></ref><ref id="B209-ijms-19-01578"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Mias</surname><given-names>G.I.</given-names></name><name><surname>Li-Pook-Than</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Lam</surname><given-names>H.Y.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Miriami</surname><given-names>E.</given-names></name><name><surname>Karczewski</surname><given-names>K.J.</given-names></name><name><surname>Hariharan</surname><given-names>M.</given-names></name><name><surname>Dewey</surname><given-names>F.E.</given-names></name><etal/></person-group><article-title>Personal omics profiling reveals dynamic molecular and medical phenotypes</article-title><source>Cell</source><year>2012</year><volume>148</volume><fpage>1293</fpage><lpage>1307</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.009</pub-id><?supplied-pmid 22424236?><pub-id pub-id-type="pmid">22424236</pub-id></element-citation></ref><ref id="B210-ijms-19-01578"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>T.</given-names></name></person-group><article-title>Lab automation and robotics: Automation on the move</article-title><source>Nature</source><year>2003</year><volume>421</volume><fpage>661</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1038/421661a</pub-id><?supplied-pmid 12571603?><pub-id pub-id-type="pmid">12571603</pub-id></element-citation></ref><ref id="B211-ijms-19-01578"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>R.D.</given-names></name><name><surname>Rowland</surname><given-names>J.</given-names></name><name><surname>Oliver</surname><given-names>S.G.</given-names></name><name><surname>Young</surname><given-names>M.</given-names></name><name><surname>Aubrey</surname><given-names>W.</given-names></name><name><surname>Byrne</surname><given-names>E.</given-names></name><name><surname>Liakata</surname><given-names>M.</given-names></name><name><surname>Markham</surname><given-names>M.</given-names></name><name><surname>Pir</surname><given-names>P.</given-names></name><name><surname>Soldatova</surname><given-names>L.N.</given-names></name><etal/></person-group><article-title>The automation of science</article-title><source>Science</source><year>2009</year><volume>324</volume><fpage>85</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1126/science.1165620</pub-id><?supplied-pmid 19342587?><pub-id pub-id-type="pmid">19342587</pub-id></element-citation></ref><ref id="B212-ijms-19-01578"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sparkes</surname><given-names>A.</given-names></name><name><surname>Aubrey</surname><given-names>W.</given-names></name><name><surname>Byrne</surname><given-names>E.</given-names></name><name><surname>Clare</surname><given-names>A.</given-names></name><name><surname>Khan</surname><given-names>M.N.</given-names></name><name><surname>Liakata</surname><given-names>M.</given-names></name><name><surname>Markham</surname><given-names>M.</given-names></name><name><surname>Rowland</surname><given-names>J.</given-names></name><name><surname>Soldatova</surname><given-names>L.N.</given-names></name><name><surname>Whelan</surname><given-names>K.E.</given-names></name><etal/></person-group><article-title>Towards robot scientists for autonomous scientific discovery</article-title><source>Autom. Exp.</source><year>2010</year><volume>2</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1759-4499-2-1</pub-id><?supplied-pmid 20119518?><pub-id pub-id-type="pmid">20119518</pub-id></element-citation></ref><ref id="B213-ijms-19-01578"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meanwell</surname><given-names>N.A.</given-names></name></person-group><article-title>Improving drug design: An update on recent applications of efficiency metrics, strategies for replacing problematic elements, and compounds in non-traditional drug space</article-title><source>Chem. Res. Toxicol.</source><year>2016</year><volume>29</volume><fpage>564</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrestox.6b00043</pub-id><?supplied-pmid 26974882?><pub-id pub-id-type="pmid">26974882</pub-id></element-citation></ref><ref id="B214-ijms-19-01578"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacConnell</surname><given-names>A.B.</given-names></name><name><surname>Price</surname><given-names>A.K.</given-names></name><name><surname>Paegel</surname><given-names>B.M.</given-names></name></person-group><article-title>An integrated microfluidic processor for DNA-encoded combinatorial library functional screening</article-title><source>ACS Comb. Sci.</source><year>2017</year><volume>19</volume><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1021/acscombsci.6b00192</pub-id><?supplied-pmid 28199790?><pub-id pub-id-type="pmid">28199790</pub-id></element-citation></ref><ref id="B215-ijms-19-01578"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baranczak</surname><given-names>A.</given-names></name><name><surname>Tu</surname><given-names>N.P.</given-names></name><name><surname>Marjanovic</surname><given-names>J.</given-names></name><name><surname>Searle</surname><given-names>P.A.</given-names></name><name><surname>Vasudevan</surname><given-names>A.</given-names></name><name><surname>Djuric</surname><given-names>S.W.</given-names></name></person-group><article-title>Integrated platform for expedited synthesis-purification-testing of small molecule libraries</article-title><source>ACS Med. Chem. Lett.</source><year>2017</year><volume>8</volume><fpage>461</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.7b00054</pub-id><?supplied-pmid 28435537?><pub-id pub-id-type="pmid">28435537</pub-id></element-citation></ref><ref id="B216-ijms-19-01578"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A.</given-names></name><name><surname>Muller</surname><given-names>A.T.</given-names></name><name><surname>Huisman</surname><given-names>B.J.H.</given-names></name><name><surname>Fuchs</surname><given-names>J.A.</given-names></name><name><surname>Schneider</surname><given-names>P.</given-names></name><name><surname>Schneider</surname><given-names>G.</given-names></name></person-group><article-title>Generative recurrent networks for de novo drug design</article-title><source>Mol. Inform.</source><year>2017</year><pub-id pub-id-type="doi">10.1002/minf.201700111</pub-id><?supplied-pmid 29095571?><pub-id pub-id-type="pmid">29095571</pub-id></element-citation></ref><ref id="B217-ijms-19-01578"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merk</surname><given-names>D.</given-names></name><name><surname>Friedrich</surname><given-names>L.</given-names></name><name><surname>Grisoni</surname><given-names>F.</given-names></name><name><surname>Schneider</surname><given-names>G.</given-names></name></person-group><article-title>De novo design of bioactive small molecules by artificial intelligence</article-title><source>Mol. Inform.</source><year>2018</year><pub-id pub-id-type="doi">10.1002/minf.201700153</pub-id><?supplied-pmid 29319225?><pub-id pub-id-type="pmid">29319225</pub-id></element-citation></ref><ref id="B218-ijms-19-01578"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Tan</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>D.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name></person-group><article-title>From machine learning to deep learning: Progress in machine intelligence for rational drug discovery</article-title><source>Drug Discov. Today</source><year>2017</year><volume>22</volume><fpage>1680</fpage><lpage>1685</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2017.08.010</pub-id><?supplied-pmid 28881183?><pub-id pub-id-type="pmid">28881183</pub-id></element-citation></ref><ref id="B219-ijms-19-01578"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duch</surname><given-names>W.</given-names></name><name><surname>Swaminathan</surname><given-names>K.</given-names></name><name><surname>Meller</surname><given-names>J.</given-names></name></person-group><article-title>Artificial intelligence approaches for rational drug design and discovery</article-title><source>Curr. Pharm. Des.</source><year>2007</year><volume>13</volume><fpage>1497</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.2174/138161207780765954</pub-id><?supplied-pmid 17504169?><pub-id pub-id-type="pmid">17504169</pub-id></element-citation></ref><ref id="B220-ijms-19-01578"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esch</surname><given-names>E.W.</given-names></name><name><surname>Bahinski</surname><given-names>A.</given-names></name><name><surname>Huh</surname><given-names>D.</given-names></name></person-group><article-title>Organs-on-chips at the frontiers of drug discovery</article-title><source>Nat. Rev. Drug Discov.</source><year>2015</year><volume>14</volume><fpage>248</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1038/nrd4539</pub-id><?supplied-pmid 25792263?><pub-id pub-id-type="pmid">25792263</pub-id></element-citation></ref><ref id="B221-ijms-19-01578"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eglen</surname><given-names>R.M.</given-names></name><name><surname>Randle</surname><given-names>D.H.</given-names></name></person-group><article-title>Drug discovery goes three-dimensional: Goodbye to flat high-throughput screening?</article-title><source>Assay Drug Dev. Technol.</source><year>2015</year><volume>13</volume><fpage>262</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1089/adt.2015.647</pub-id><?supplied-pmid 26121065?><pub-id pub-id-type="pmid">26121065</pub-id></element-citation></ref><ref id="B222-ijms-19-01578"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozdemir</surname><given-names>V.</given-names></name><name><surname>Patrinos</surname><given-names>G.P.</given-names></name></person-group><article-title>David bowie and the art of slow innovation: A fast-second winner strategy for biotechnology and precision medicine global development</article-title><source>Omics</source><year>2017</year><volume>21</volume><fpage>633</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1089/omi.2017.0148</pub-id><?supplied-pmid 29064337?><pub-id pub-id-type="pmid">29064337</pub-id></element-citation></ref><ref id="B223-ijms-19-01578"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>M.D.</given-names></name><name><surname>Lalic</surname><given-names>G.</given-names></name></person-group><article-title>Teaching target-oriented and diversity-oriented organic synthesis at Harvard University</article-title><source>Chem. Biol.</source><year>2002</year><volume>9</volume><fpage>535</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(02)00143-6</pub-id><pub-id pub-id-type="pmid">12031659</pub-id></element-citation></ref><ref id="B224-ijms-19-01578"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>S.L.</given-names></name></person-group><article-title>Target-oriented and diversity-oriented organic synthesis in drug discovery</article-title><source>Science</source><year>2000</year><volume>287</volume><fpage>1964</fpage><lpage>1969</lpage><pub-id pub-id-type="doi">10.1126/science.287.5460.1964</pub-id><?supplied-pmid 10720315?><pub-id pub-id-type="pmid">10720315</pub-id></element-citation></ref><ref id="B225-ijms-19-01578"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>M.E.</given-names></name></person-group><article-title>Design and synthesis of analogues of natural products</article-title><source>Org. Biomol. Chem.</source><year>2015</year><volume>13</volume><fpage>5302</fpage><lpage>5343</lpage><pub-id pub-id-type="doi">10.1039/C5OB00169B</pub-id><?supplied-pmid 25829247?><pub-id pub-id-type="pmid">25829247</pub-id></element-citation></ref><ref id="B226-ijms-19-01578"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname><given-names>S.</given-names></name><name><surname>Ellinger</surname><given-names>B.</given-names></name><name><surname>Rizzo</surname><given-names>S.</given-names></name><name><surname>Deraeve</surname><given-names>C.</given-names></name><name><surname>Schurmann</surname><given-names>M.</given-names></name><name><surname>Preut</surname><given-names>H.</given-names></name><name><surname>Arndt</surname><given-names>H.D.</given-names></name><name><surname>Waldmann</surname><given-names>H.</given-names></name></person-group><article-title>Biology-oriented synthesis of a natural-product inspired oxepane collection yields a small-molecule activator of the Wnt-pathway</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>6805</fpage><lpage>6810</lpage><pub-id pub-id-type="doi">10.1073/pnas.1015269108</pub-id><?supplied-pmid 21415367?><pub-id pub-id-type="pmid">21415367</pub-id></element-citation></ref><ref id="B227-ijms-19-01578"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>M.</given-names></name><name><surname>Wetzel</surname><given-names>S.</given-names></name><name><surname>Kumar</surname><given-names>K.</given-names></name><name><surname>Waldmann</surname><given-names>H.</given-names></name></person-group><article-title>Biology-inspired synthesis of compound libraries</article-title><source>Cell. Mol. Life Sci.</source><year>2008</year><volume>65</volume><fpage>1186</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1007/s00018-007-7492-1</pub-id><?supplied-pmid 18193390?><pub-id pub-id-type="pmid">18193390</pub-id></element-citation></ref><ref id="B228-ijms-19-01578"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wetzel</surname><given-names>S.</given-names></name><name><surname>Bon</surname><given-names>R.S.</given-names></name><name><surname>Kumar</surname><given-names>K.</given-names></name><name><surname>Waldmann</surname><given-names>H.</given-names></name></person-group><article-title>Biology-oriented synthesis</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2011</year><volume>50</volume><fpage>10800</fpage><lpage>10826</lpage><pub-id pub-id-type="doi">10.1002/anie.201007004</pub-id><?supplied-pmid 22038946?><pub-id pub-id-type="pmid">22038946</pub-id></element-citation></ref><ref id="B229-ijms-19-01578"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wender</surname><given-names>P.A.</given-names></name><name><surname>Quiroz</surname><given-names>R.V.</given-names></name><name><surname>Stevens</surname><given-names>M.C.</given-names></name></person-group><article-title>Function through synthesis-informed design</article-title><source>Acc. Chem. Res.</source><year>2015</year><volume>48</volume><fpage>752</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.5b00004</pub-id><?supplied-pmid 25742599?><pub-id pub-id-type="pmid">25742599</pub-id></element-citation></ref><ref id="B230-ijms-19-01578"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wender</surname><given-names>P.A.</given-names></name><name><surname>Verma</surname><given-names>V.A.</given-names></name><name><surname>Paxton</surname><given-names>T.J.</given-names></name><name><surname>Pillow</surname><given-names>T.H.</given-names></name></person-group><article-title>Function-oriented synthesis, step economy, and drug design</article-title><source>Acc. Chem. Res.</source><year>2008</year><volume>41</volume><fpage>40</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1021/ar700155p</pub-id><?supplied-pmid 18159936?><pub-id pub-id-type="pmid">18159936</pub-id></element-citation></ref><ref id="B231-ijms-19-01578"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Q.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Challa</surname><given-names>S.</given-names></name><name><surname>Ding</surname><given-names>Y.</given-names></name><name><surname>Lajiness</surname><given-names>M.S.</given-names></name><name><surname>Wild</surname><given-names>D.J.</given-names></name></person-group><article-title>Semantic inference using chemogenomics data for drug discovery</article-title><source>BMC Bioinform.</source><year>2011</year><volume>12</volume><elocation-id>256</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-256</pub-id><?supplied-pmid 21699718?><pub-id pub-id-type="pmid">21699718</pub-id></element-citation></ref><ref id="B232-ijms-19-01578"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>D.</given-names></name><name><surname>Wilson</surname><given-names>R.C.</given-names></name></person-group><article-title>Generative models for chemical structures</article-title><source>J. Chem. Inf. Model.</source><year>2010</year><volume>50</volume><fpage>1257</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1021/ci9004089</pub-id><?supplied-pmid 20666408?><pub-id pub-id-type="pmid">20666408</pub-id></element-citation></ref><ref id="B233-ijms-19-01578"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubio</surname><given-names>D.M.</given-names></name><name><surname>Schoenbaum</surname><given-names>E.E.</given-names></name><name><surname>Lee</surname><given-names>L.S.</given-names></name><name><surname>Schteingart</surname><given-names>D.E.</given-names></name><name><surname>Marantz</surname><given-names>P.R.</given-names></name><name><surname>Anderson</surname><given-names>K.E.</given-names></name><name><surname>Platt</surname><given-names>L.D.</given-names></name><name><surname>Baez</surname><given-names>A.</given-names></name><name><surname>Esposito</surname><given-names>K.</given-names></name></person-group><article-title>Defining translational research: Implications for training</article-title><source>Acad. Med.</source><year>2010</year><volume>85</volume><fpage>470</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1097/ACM.0b013e3181ccd618</pub-id><?supplied-pmid 20182120?><pub-id pub-id-type="pmid">20182120</pub-id></element-citation></ref><ref id="B234-ijms-19-01578"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>Y.</given-names></name><name><surname>Bian</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Xie</surname><given-names>X.S.</given-names></name></person-group><article-title>Deep learning for drug design: An artificial intelligence paradigm for drug discovery in the big data era</article-title><source>AAPS J.</source><year>2018</year><volume>20</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1208/s12248-018-0210-0</pub-id><?supplied-pmid 29603063?><pub-id pub-id-type="pmid">29603063</pub-id></element-citation></ref><ref id="B235-ijms-19-01578"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reutlinger</surname><given-names>M.</given-names></name><name><surname>Rodrigues</surname><given-names>T.</given-names></name><name><surname>Schneider</surname><given-names>P.</given-names></name><name><surname>Schneider</surname><given-names>G.</given-names></name></person-group><article-title>Combining on-chip synthesis of a focused combinatorial library with computational target prediction reveals imidazopyridine GPCR ligands</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2014</year><volume>53</volume><fpage>582</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1002/anie.201307786</pub-id><?supplied-pmid 24282133?><pub-id pub-id-type="pmid">24282133</pub-id></element-citation></ref><ref id="B236-ijms-19-01578"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>G.</given-names></name></person-group><article-title>Automating drug discovery</article-title><source>Nat. Rev. Drug Discov.</source><year>2018</year><volume>17</volume><fpage>97</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.232</pub-id><?supplied-pmid 29242609?><pub-id pub-id-type="pmid">29242609</pub-id></element-citation></ref><ref id="B237-ijms-19-01578"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reutlinger</surname><given-names>M.</given-names></name><name><surname>Rodrigues</surname><given-names>T.</given-names></name><name><surname>Schneider</surname><given-names>P.</given-names></name><name><surname>Schneider</surname><given-names>G.</given-names></name></person-group><article-title>Multi-objective molecular de novo design by adaptive fragment prioritization</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2014</year><volume>53</volume><fpage>4244</fpage><lpage>4248</lpage><pub-id pub-id-type="doi">10.1002/anie.201310864</pub-id><?supplied-pmid 24623390?><pub-id pub-id-type="pmid">24623390</pub-id></element-citation></ref><ref id="B238-ijms-19-01578"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>P.</given-names></name><name><surname>Rothlisberger</surname><given-names>M.</given-names></name><name><surname>Reker</surname><given-names>D.</given-names></name><name><surname>Schneider</surname><given-names>G.</given-names></name></person-group><article-title>Spotting and designing promiscuous ligands for drug discovery</article-title><source>Chem. Commun.</source><year>2016</year><volume>52</volume><fpage>1135</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.1039/C5CC07506H</pub-id><?supplied-pmid 26602698?><pub-id pub-id-type="pmid">26602698</pub-id></element-citation></ref><ref id="B239-ijms-19-01578"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>B.</given-names></name><name><surname>Pierce</surname><given-names>L.</given-names></name><name><surname>Krilov</surname><given-names>G.</given-names></name><name><surname>Lupyan</surname><given-names>D.</given-names></name><name><surname>Robinson</surname><given-names>S.</given-names></name><name><surname>Dahlgren</surname><given-names>M.K.</given-names></name><name><surname>Greenwood</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field</article-title><source>J. Am. Chem. Soc.</source><year>2015</year><volume>137</volume><fpage>2695</fpage><lpage>2703</lpage><pub-id pub-id-type="doi">10.1021/ja512751q</pub-id><?supplied-pmid 25625324?><pub-id pub-id-type="pmid">25625324</pub-id></element-citation></ref><ref id="B240-ijms-19-01578"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besnard</surname><given-names>J.</given-names></name><name><surname>Ruda</surname><given-names>G.F.</given-names></name><name><surname>Setola</surname><given-names>V.</given-names></name><name><surname>Abecassis</surname><given-names>K.</given-names></name><name><surname>Rodriguiz</surname><given-names>R.M.</given-names></name><name><surname>Huang</surname><given-names>X.P.</given-names></name><name><surname>Norval</surname><given-names>S.</given-names></name><name><surname>Sassano</surname><given-names>M.F.</given-names></name><name><surname>Shin</surname><given-names>A.I.</given-names></name><name><surname>Webster</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>Automated design of ligands to polypharmacological profiles</article-title><source>Nature</source><year>2012</year><volume>492</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/nature11691</pub-id><?supplied-pmid 23235874?><pub-id pub-id-type="pmid">23235874</pub-id></element-citation></ref><ref id="B241-ijms-19-01578"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koppitz</surname><given-names>M.</given-names></name><name><surname>Eis</surname><given-names>K.</given-names></name></person-group><article-title>Automated medicinal chemistry</article-title><source>Drug Discov. Today</source><year>2006</year><volume>11</volume><fpage>561</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2006.04.005</pub-id><?supplied-pmid 16713909?><pub-id pub-id-type="pmid">16713909</pub-id></element-citation></ref><ref id="B242-ijms-19-01578"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>J.D.</given-names></name><name><surname>Tu</surname><given-names>N.P.</given-names></name><name><surname>Nemcek</surname><given-names>T.A.</given-names></name><name><surname>Searle</surname><given-names>P.A.</given-names></name><name><surname>Hochlowski</surname><given-names>J.E.</given-names></name><name><surname>Djuric</surname><given-names>S.W.</given-names></name><name><surname>Pan</surname><given-names>J.Y.</given-names></name></person-group><article-title>An automated synthesis-purification-sample-management platform for the accelerated generation of pharmaceutical candidates</article-title><source>J. Lab. Autom.</source><year>2014</year><volume>19</volume><fpage>176</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1177/2211068213516325</pub-id><?supplied-pmid 24352687?><pub-id pub-id-type="pmid">24352687</pub-id></element-citation></ref><ref id="B243-ijms-19-01578"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godfrey</surname><given-names>A.G.</given-names></name><name><surname>Masquelin</surname><given-names>T.</given-names></name><name><surname>Hemmerle</surname><given-names>H.</given-names></name></person-group><article-title>A remote-controlled adaptive medchem lab: An innovative approach to enable drug discovery in the 21st century</article-title><source>Drug Discov. Today</source><year>2013</year><volume>18</volume><fpage>795</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2013.03.001</pub-id><?supplied-pmid 23523957?><pub-id pub-id-type="pmid">23523957</pub-id></element-citation></ref><ref id="B244-ijms-19-01578"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolaou</surname><given-names>C.A.</given-names></name><name><surname>Watson</surname><given-names>I.A.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>The proximal lilly collection: Mapping, exploring and exploiting feasible chemical space</article-title><source>J. Chem. Inf. Model.</source><year>2016</year><volume>56</volume><fpage>1253</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.6b00173</pub-id><?supplied-pmid 27286472?><pub-id pub-id-type="pmid">27286472</pub-id></element-citation></ref><ref id="B245-ijms-19-01578"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Ballmer</surname><given-names>S.G.</given-names></name><name><surname>Gillis</surname><given-names>E.P.</given-names></name><name><surname>Fujii</surname><given-names>S.</given-names></name><name><surname>Schmidt</surname><given-names>M.J.</given-names></name><name><surname>Palazzolo</surname><given-names>A.M.</given-names></name><name><surname>Lehmann</surname><given-names>J.W.</given-names></name><name><surname>Morehouse</surname><given-names>G.F.</given-names></name><name><surname>Burke</surname><given-names>M.D.</given-names></name></person-group><article-title>Synthesis of many different types of organic small molecules using one automated process</article-title><source>Science</source><year>2015</year><volume>347</volume><fpage>1221</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1126/science.aaa5414</pub-id><?supplied-pmid 25766227?><pub-id pub-id-type="pmid">25766227</pub-id></element-citation></ref><ref id="B246-ijms-19-01578"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stalder</surname><given-names>R.</given-names></name><name><surname>Roth</surname><given-names>G.P.</given-names></name></person-group><article-title>Preparative microfluidic electrosynthesis of drug metabolites</article-title><source>ACS Med. Chem. Lett.</source><year>2013</year><volume>4</volume><fpage>1119</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1021/ml400316p</pub-id><?supplied-pmid 24900614?><pub-id pub-id-type="pmid">24900614</pub-id></element-citation></ref><ref id="B247-ijms-19-01578"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genovino</surname><given-names>J.</given-names></name><name><surname>Sames</surname><given-names>D.</given-names></name><name><surname>Hamann</surname><given-names>L.G.</given-names></name><name><surname>Toure</surname><given-names>B.B.</given-names></name></person-group><article-title>Accessing drug metabolites via transition-metal catalyzed c-h oxidation: The liver as synthetic inspiration</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2016</year><volume>55</volume><fpage>14218</fpage><lpage>14238</lpage><pub-id pub-id-type="doi">10.1002/anie.201602644</pub-id><?supplied-pmid 27723189?><pub-id pub-id-type="pmid">27723189</pub-id></element-citation></ref><ref id="B248-ijms-19-01578"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaPorte</surname><given-names>T.L.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>Continuous processes for the production of pharmaceutical intermediates and active pharmaceutical ingredients</article-title><source>Curr. Opin. Drug Discov. Dev.</source><year>2007</year><volume>10</volume><fpage>738</fpage><lpage>745</lpage></element-citation></ref><ref id="B249-ijms-19-01578"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>P.</given-names></name><name><surname>Barney</surname><given-names>W.S.</given-names></name><name><surname>Pindzola</surname><given-names>B.A.</given-names></name></person-group><article-title>Microstructured reactors as tools for the intensification of pharmaceutical reactions and processes</article-title><source>Curr. Opin. Drug Discov. Dev.</source><year>2009</year><volume>12</volume><fpage>848</fpage><lpage>861</lpage></element-citation></ref><ref id="B250-ijms-19-01578"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saaby</surname><given-names>S.</given-names></name><name><surname>Knudsen</surname><given-names>K.R.</given-names></name><name><surname>Ladlow</surname><given-names>M.</given-names></name><name><surname>Ley</surname><given-names>S.V.</given-names></name></person-group><article-title>The use of a continuous flow-reactor employing a mixed hydrogen-liquid flow stream for the efficient reduction of imines to amines</article-title><source>Chem. Commun.</source><year>2005</year><fpage>2909</fpage><lpage>2911</lpage><pub-id pub-id-type="doi">10.1039/b504854k</pub-id><?supplied-pmid 15957022?><pub-id pub-id-type="pmid">15957022</pub-id></element-citation></ref><ref id="B251-ijms-19-01578"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brzozowski</surname><given-names>M.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>M.</given-names></name><name><surname>Ley</surname><given-names>S.V.</given-names></name><name><surname>Polyzos</surname><given-names>A.</given-names></name></person-group><article-title>Flow chemistry: Intelligent processing of gas-liquid transformations using a tube-in-tube reactor</article-title><source>Acc. Chem. Res.</source><year>2015</year><volume>48</volume><fpage>349</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1021/ar500359m</pub-id><?supplied-pmid 25611216?><pub-id pub-id-type="pmid">25611216</pub-id></element-citation></ref><ref id="B252-ijms-19-01578"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loskill</surname><given-names>P.</given-names></name><name><surname>Sezhian</surname><given-names>T.</given-names></name><name><surname>Tharp</surname><given-names>K.M.</given-names></name><name><surname>Lee-Montiel</surname><given-names>F.T.</given-names></name><name><surname>Jeeawoody</surname><given-names>S.</given-names></name><name><surname>Reese</surname><given-names>W.M.</given-names></name><name><surname>Zushin</surname><given-names>P.H.</given-names></name><name><surname>Stahl</surname><given-names>A.</given-names></name><name><surname>Healy</surname><given-names>K.E.</given-names></name></person-group><article-title>Wat-on-a-chip: A physiologically relevant microfluidic system incorporating white adipose tissue</article-title><source>Lab Chip</source><year>2017</year><volume>17</volume><fpage>1645</fpage><lpage>1654</lpage><pub-id pub-id-type="doi">10.1039/C6LC01590E</pub-id><?supplied-pmid 28418430?><pub-id pub-id-type="pmid">28418430</pub-id></element-citation></ref><ref id="B253-ijms-19-01578"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyer</surname><given-names>K.</given-names></name><name><surname>Stratz</surname><given-names>S.</given-names></name><name><surname>Kuhn</surname><given-names>P.</given-names></name><name><surname>Kuster</surname><given-names>S.K.</given-names></name><name><surname>Dittrich</surname><given-names>P.S.</given-names></name></person-group><article-title>Implementing enzyme-linked immunosorbent assays on a microfluidic chip to quantify intracellular molecules in single cells</article-title><source>Anal. Chem.</source><year>2013</year><volume>85</volume><fpage>3280</fpage><lpage>3287</lpage><pub-id pub-id-type="doi">10.1021/ac303628j</pub-id><?supplied-pmid 23388050?><pub-id pub-id-type="pmid">23388050</pub-id></element-citation></ref><ref id="B254-ijms-19-01578"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>M.</given-names></name></person-group><article-title>Frontiers in cancer nanomedicine: Directing mass transport through biological barriers</article-title><source>Trends Biotechnol.</source><year>2010</year><volume>28</volume><fpage>181</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2009.12.007</pub-id><?supplied-pmid 20079548?><pub-id pub-id-type="pmid">20079548</pub-id></element-citation></ref><ref id="B255-ijms-19-01578"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.S.</given-names></name><name><surname>Zhang</surname><given-names>Y.N.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>Cancer-on-a-chip systems at the frontier of nanomedicine</article-title><source>Drug Discov. Today</source><year>2017</year><volume>22</volume><fpage>1392</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2017.03.011</pub-id><?supplied-pmid 28390929?><pub-id pub-id-type="pmid">28390929</pub-id></element-citation></ref><ref id="B256-ijms-19-01578"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galler</surname><given-names>K.</given-names></name><name><surname>Brautigam</surname><given-names>K.</given-names></name><name><surname>Grosse</surname><given-names>C.</given-names></name><name><surname>Popp</surname><given-names>J.</given-names></name><name><surname>Neugebauer</surname><given-names>U.</given-names></name></person-group><article-title>Making a big thing of a small cell&#x02013;recent advances in single cell analysis</article-title><source>Analyst</source><year>2014</year><volume>139</volume><fpage>1237</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1039/C3AN01939J</pub-id><?supplied-pmid 24495980?><pub-id pub-id-type="pmid">24495980</pub-id></element-citation></ref><ref id="B257-ijms-19-01578"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kayala</surname><given-names>M.A.</given-names></name><name><surname>Azencott</surname><given-names>C.A.</given-names></name><name><surname>Chen</surname><given-names>J.H.</given-names></name><name><surname>Baldi</surname><given-names>P.</given-names></name></person-group><article-title>Learning to predict chemical reactions</article-title><source>J. Chem. Inf. Model.</source><year>2011</year><volume>51</volume><fpage>2209</fpage><lpage>2222</lpage><pub-id pub-id-type="doi">10.1021/ci200207y</pub-id><?supplied-pmid 21819139?><pub-id pub-id-type="pmid">21819139</pub-id></element-citation></ref><ref id="B258-ijms-19-01578"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>C.R.</given-names></name><name><surname>Muggleton</surname><given-names>S.H.</given-names></name><name><surname>Sternberg</surname><given-names>M.J.</given-names></name></person-group><article-title>Incorporating virtual reactions into a logic-based ligand-based virtual screening method to discover new leads</article-title><source>Mol. Inform.</source><year>2015</year><volume>34</volume><fpage>615</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1002/minf.201400162</pub-id><?supplied-pmid 26583052?><pub-id pub-id-type="pmid">26583052</pub-id></element-citation></ref><ref id="B259-ijms-19-01578"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kowalik</surname><given-names>M.</given-names></name><name><surname>Gothard</surname><given-names>C.M.</given-names></name><name><surname>Drews</surname><given-names>A.M.</given-names></name><name><surname>Gothard</surname><given-names>N.A.</given-names></name><name><surname>Weckiewicz</surname><given-names>A.</given-names></name><name><surname>Fuller</surname><given-names>P.E.</given-names></name><name><surname>Grzybowski</surname><given-names>B.A.</given-names></name><name><surname>Bishop</surname><given-names>K.J.</given-names></name></person-group><article-title>Parallel optimization of synthetic pathways within the network of organic chemistry</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2012</year><volume>51</volume><fpage>7928</fpage><lpage>7932</lpage><pub-id pub-id-type="doi">10.1002/anie.201202209</pub-id><?supplied-pmid 22807100?><pub-id pub-id-type="pmid">22807100</pub-id></element-citation></ref><ref id="B260-ijms-19-01578"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szymkuc</surname><given-names>S.</given-names></name><name><surname>Gajewska</surname><given-names>E.P.</given-names></name><name><surname>Klucznik</surname><given-names>T.</given-names></name><name><surname>Molga</surname><given-names>K.</given-names></name><name><surname>Dittwald</surname><given-names>P.</given-names></name><name><surname>Startek</surname><given-names>M.</given-names></name><name><surname>Bajczyk</surname><given-names>M.</given-names></name><name><surname>Grzybowski</surname><given-names>B.A.</given-names></name></person-group><article-title>Computer-assisted synthetic planning: The end of the beginning</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2016</year><volume>55</volume><fpage>5904</fpage><lpage>5937</lpage><pub-id pub-id-type="doi">10.1002/anie.201506101</pub-id><?supplied-pmid 27062365?><pub-id pub-id-type="pmid">27062365</pub-id></element-citation></ref><ref id="B261-ijms-19-01578"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>M.</given-names></name></person-group><article-title>Europe bets on drug discovery</article-title><source>Nature</source><year>2013</year><volume>494</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1038/494020a</pub-id><?supplied-pmid 23393658?><pub-id pub-id-type="pmid">23393658</pub-id></element-citation></ref><ref id="B262-ijms-19-01578"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Rubio</surname><given-names>E.</given-names></name><name><surname>Elizondo</surname><given-names>D.A.</given-names></name><name><surname>Grootveld</surname><given-names>M.</given-names></name><name><surname>Jerez</surname><given-names>J.M.</given-names></name><name><surname>Luque-Baena</surname><given-names>R.M.</given-names></name></person-group><article-title>Computational intelligence techniques in medicine</article-title><source>Comput. Math. Methods Med.</source><year>2015</year><volume>2015</volume><fpage>196976</fpage><pub-id pub-id-type="doi">10.1155/2015/196976</pub-id><?supplied-pmid 25834633?><pub-id pub-id-type="pmid">25834633</pub-id></element-citation></ref><ref id="B263-ijms-19-01578"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montanez-Godinez</surname><given-names>N.</given-names></name><name><surname>Martinez-Olguin</surname><given-names>A.C.</given-names></name><name><surname>Deeb</surname><given-names>O.</given-names></name><name><surname>Garduno-Juarez</surname><given-names>R.</given-names></name><name><surname>Ramirez-Galicia</surname><given-names>G.</given-names></name></person-group><article-title>QSAR/QSPR as an application of artificial neural networks</article-title><source>Methods Mol. Biol.</source><year>2015</year><volume>1260</volume><fpage>319</fpage><lpage>333</lpage><?supplied-pmid 25502390?><pub-id pub-id-type="pmid">25502390</pub-id></element-citation></ref><ref id="B264-ijms-19-01578"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wesolowski</surname><given-names>M.</given-names></name><name><surname>Suchacz</surname><given-names>B.</given-names></name></person-group><article-title>Artificial neural networks: Theoretical background and pharmaceutical applications: A review</article-title><source>J. AOAC Int.</source><year>2012</year><volume>95</volume><fpage>652</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.5740/jaoacint.SGE_Wesolowski_ANN</pub-id><?supplied-pmid 22816255?><pub-id pub-id-type="pmid">22816255</pub-id></element-citation></ref><ref id="B265-ijms-19-01578"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baskin</surname><given-names>I.I.</given-names></name><name><surname>Winkler</surname><given-names>D.</given-names></name><name><surname>Tetko</surname><given-names>I.V.</given-names></name></person-group><article-title>A renaissance of neural networks in drug discovery</article-title><source>Expert Opin. Drug Discov.</source><year>2016</year><volume>11</volume><fpage>785</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1080/17460441.2016.1201262</pub-id><?supplied-pmid 27295548?><pub-id pub-id-type="pmid">27295548</pub-id></element-citation></ref><ref id="B266-ijms-19-01578"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolsky</surname><given-names>Y.</given-names></name><name><surname>Nikolskaya</surname><given-names>T.</given-names></name><name><surname>Bugrim</surname><given-names>A.</given-names></name></person-group><article-title>Biological networks and analysis of experimental data in drug discovery</article-title><source>Drug Discov. Today</source><year>2005</year><volume>10</volume><fpage>653</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1016/S1359-6446(05)03420-3</pub-id><pub-id pub-id-type="pmid">15894230</pub-id></element-citation></ref><ref id="B267-ijms-19-01578"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeCun</surname><given-names>Y.</given-names></name><name><surname>Bengio</surname><given-names>Y.</given-names></name><name><surname>Hinton</surname><given-names>G.</given-names></name></person-group><article-title>Deep learning</article-title><source>Nature</source><year>2015</year><volume>521</volume><fpage>436</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1038/nature14539</pub-id><?supplied-pmid 26017442?><pub-id pub-id-type="pmid">26017442</pub-id></element-citation></ref><ref id="B268-ijms-19-01578"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>C.A.</given-names></name></person-group><article-title>Drug-like properties and the causes of poor solubility and poor permeability</article-title><source>J. Pharmacol. Toxicol. Methods</source><year>2000</year><volume>44</volume><fpage>235</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/S1056-8719(00)00107-6</pub-id><pub-id pub-id-type="pmid">11274893</pub-id></element-citation></ref><ref id="B269-ijms-19-01578"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Congreve</surname><given-names>M.</given-names></name><name><surname>Carr</surname><given-names>R.</given-names></name><name><surname>Murray</surname><given-names>C.</given-names></name><name><surname>Jhoti</surname><given-names>H.</given-names></name></person-group><article-title>A &#x02018;rule of three&#x02019; for fragment-based lead discovery?</article-title><source>Drug Discov. Today</source><year>2003</year><volume>8</volume><fpage>876</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1016/S1359-6446(03)02831-9</pub-id></element-citation></ref><ref id="B270-ijms-19-01578"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Molle</surname><given-names>I.</given-names></name><name><surname>Thomann</surname><given-names>A.</given-names></name><name><surname>Buckley</surname><given-names>D.L.</given-names></name><name><surname>So</surname><given-names>E.C.</given-names></name><name><surname>Lang</surname><given-names>S.</given-names></name><name><surname>Crews</surname><given-names>C.M.</given-names></name><name><surname>Ciulli</surname><given-names>A.</given-names></name></person-group><article-title>Dissecting fragment-based lead discovery at the von Hippel-Lindau protein: Hypoxia inducible factor 1alpha protein-protein interface</article-title><source>Chem. Biol.</source><year>2012</year><volume>19</volume><fpage>1300</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2012.08.015</pub-id><?supplied-pmid 23102223?><pub-id pub-id-type="pmid">23102223</pub-id></element-citation></ref><ref id="B271-ijms-19-01578"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuegg</surname><given-names>J.</given-names></name><name><surname>Cooper</surname><given-names>M.A.</given-names></name></person-group><article-title>Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening</article-title><source>Curr. Top. Med. Chem.</source><year>2012</year><volume>12</volume><fpage>1500</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.2174/156802612802652466</pub-id><?supplied-pmid 22827520?><pub-id pub-id-type="pmid">22827520</pub-id></element-citation></ref><ref id="B272-ijms-19-01578"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ntie-Kang</surname><given-names>F.</given-names></name><name><surname>Lifongo</surname><given-names>L.L.</given-names></name><name><surname>Judson</surname><given-names>P.N.</given-names></name><name><surname>Sippl</surname><given-names>W.</given-names></name><name><surname>Efange</surname><given-names>S.M.</given-names></name></person-group><article-title>How &#x0201c;drug-like&#x0201d; are naturally occurring anti-cancer compounds?</article-title><source>J. Mol. Model.</source><year>2014</year><volume>20</volume><fpage>2069</fpage><pub-id pub-id-type="doi">10.1007/s00894-014-2069-z</pub-id><?supplied-pmid 24452907?><pub-id pub-id-type="pmid">24452907</pub-id></element-citation></ref><ref id="B273-ijms-19-01578"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabowski</surname><given-names>K.</given-names></name><name><surname>Baringhaus</surname><given-names>K.H.</given-names></name><name><surname>Schneider</surname><given-names>G.</given-names></name></person-group><article-title>Scaffold diversity of natural products: Inspiration for combinatorial library design</article-title><source>Nat. Prod. Rep.</source><year>2008</year><volume>25</volume><fpage>892</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1039/b715668p</pub-id><?supplied-pmid 18820757?><pub-id pub-id-type="pmid">18820757</pub-id></element-citation></ref><ref id="B274-ijms-19-01578"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elumalai</surname><given-names>N.</given-names></name><name><surname>Berg</surname><given-names>A.</given-names></name><name><surname>Natarajan</surname><given-names>K.</given-names></name><name><surname>Scharow</surname><given-names>A.</given-names></name><name><surname>Berg</surname><given-names>T.</given-names></name></person-group><article-title>Nanomolar inhibitors of the transcription factor STAT5b with high selectivity over STAT5a</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2015</year><volume>54</volume><fpage>4758</fpage><lpage>4763</lpage><pub-id pub-id-type="doi">10.1002/anie.201410672</pub-id><?supplied-pmid 25702814?><pub-id pub-id-type="pmid">25702814</pub-id></element-citation></ref><ref id="B275-ijms-19-01578"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bon</surname><given-names>R.S.</given-names></name><name><surname>Waldmann</surname><given-names>H.</given-names></name></person-group><article-title>Bioactivity-guided navigation of chemical space</article-title><source>Acc. Chem. Res.</source><year>2010</year><volume>43</volume><fpage>1103</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1021/ar100014h</pub-id><?supplied-pmid 20481515?><pub-id pub-id-type="pmid">20481515</pub-id></element-citation></ref><ref id="B276-ijms-19-01578"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renner</surname><given-names>S.</given-names></name><name><surname>van Otterlo</surname><given-names>W.A.</given-names></name><name><surname>Dominguez Seoane</surname><given-names>M.</given-names></name><name><surname>Mocklinghoff</surname><given-names>S.</given-names></name><name><surname>Hofmann</surname><given-names>B.</given-names></name><name><surname>Wetzel</surname><given-names>S.</given-names></name><name><surname>Schuffenhauer</surname><given-names>A.</given-names></name><name><surname>Ertl</surname><given-names>P.</given-names></name><name><surname>Oprea</surname><given-names>T.I.</given-names></name><name><surname>Steinhilber</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Bioactivity-guided mapping and navigation of chemical space</article-title><source>Nat. Chem. Biol.</source><year>2009</year><volume>5</volume><fpage>585</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1038/nchembio.188</pub-id><?supplied-pmid 19561619?><pub-id pub-id-type="pmid">19561619</pub-id></element-citation></ref><ref id="B277-ijms-19-01578"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wetzel</surname><given-names>S.</given-names></name><name><surname>Klein</surname><given-names>K.</given-names></name><name><surname>Renner</surname><given-names>S.</given-names></name><name><surname>Rauh</surname><given-names>D.</given-names></name><name><surname>Oprea</surname><given-names>T.I.</given-names></name><name><surname>Mutzel</surname><given-names>P.</given-names></name><name><surname>Waldmann</surname><given-names>H.</given-names></name></person-group><article-title>Interactive exploration of chemical space with scaffold hunter</article-title><source>Nat. Chem. Biol.</source><year>2009</year><volume>5</volume><fpage>581</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1038/nchembio.187</pub-id><?supplied-pmid 19561620?><pub-id pub-id-type="pmid">19561620</pub-id></element-citation></ref><ref id="B278-ijms-19-01578"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>T.</given-names></name><name><surname>Reker</surname><given-names>D.</given-names></name><name><surname>Schneider</surname><given-names>P.</given-names></name><name><surname>Schneider</surname><given-names>G.</given-names></name></person-group><article-title>Counting on natural products for drug design</article-title><source>Nat. Chem.</source><year>2016</year><volume>8</volume><fpage>531</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1038/nchem.2479</pub-id><?supplied-pmid 27219696?><pub-id pub-id-type="pmid">27219696</pub-id></element-citation></ref><ref id="B279-ijms-19-01578"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagunin</surname><given-names>A.</given-names></name><name><surname>Stepanchikova</surname><given-names>A.</given-names></name><name><surname>Filimonov</surname><given-names>D.</given-names></name><name><surname>Poroikov</surname><given-names>V.</given-names></name></person-group><article-title>Pass: Prediction of activity spectra for biologically active substances</article-title><source>Bioinformatics</source><year>2000</year><volume>16</volume><fpage>747</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/16.8.747</pub-id><?supplied-pmid 11099264?><pub-id pub-id-type="pmid">11099264</pub-id></element-citation></ref><ref id="B280-ijms-19-01578"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stepanchikova</surname><given-names>A.V.</given-names></name><name><surname>Lagunin</surname><given-names>A.A.</given-names></name><name><surname>Filimonov</surname><given-names>D.A.</given-names></name><name><surname>Poroikov</surname><given-names>V.V.</given-names></name></person-group><article-title>Prediction of biological activity spectra for substances: Evaluation on the diverse sets of drug-like structures</article-title><source>Curr. Med. Chem.</source><year>2003</year><volume>10</volume><fpage>225</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.2174/0929867033368510</pub-id><?supplied-pmid 12570709?><pub-id pub-id-type="pmid">12570709</pub-id></element-citation></ref><ref id="B281-ijms-19-01578"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reker</surname><given-names>D.</given-names></name><name><surname>Rodrigues</surname><given-names>T.</given-names></name><name><surname>Schneider</surname><given-names>P.</given-names></name><name><surname>Schneider</surname><given-names>G.</given-names></name></person-group><article-title>Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>4067</fpage><lpage>4072</lpage><pub-id pub-id-type="doi">10.1073/pnas.1320001111</pub-id><?supplied-pmid 24591595?><pub-id pub-id-type="pmid">24591595</pub-id></element-citation></ref><ref id="B282-ijms-19-01578"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>G.</given-names></name><name><surname>Reker</surname><given-names>D.</given-names></name><name><surname>Rodrigues</surname><given-names>T.</given-names></name><name><surname>Schneider</surname><given-names>P.</given-names></name></person-group><article-title>Coping with polypharmacology by computational medicinal chemistry</article-title><source>Chimia</source><year>2014</year><volume>68</volume><fpage>648</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.2533/chimia.2014.648</pub-id><?supplied-pmid 25437786?><pub-id pub-id-type="pmid">25437786</pub-id></element-citation></ref><ref id="B283-ijms-19-01578"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sliwoski</surname><given-names>G.</given-names></name><name><surname>Kothiwale</surname><given-names>S.</given-names></name><name><surname>Meiler</surname><given-names>J.</given-names></name><name><surname>Lowe</surname><given-names>E.W.</given-names></name></person-group><article-title>Computational methods in drug discovery</article-title><source>Pharmacol. Rev.</source><year>2014</year><volume>66</volume><fpage>334</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1124/pr.112.007336</pub-id><?supplied-pmid 24381236?><pub-id pub-id-type="pmid">24381236</pub-id></element-citation></ref><ref id="B284-ijms-19-01578"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiMasi</surname><given-names>J.A.</given-names></name><name><surname>Feldman</surname><given-names>L.</given-names></name><name><surname>Seckler</surname><given-names>A.</given-names></name><name><surname>Wilson</surname><given-names>A.</given-names></name></person-group><article-title>Trends in risks associated with new drug development: Success rates for investigational drugs</article-title><source>Clin. Pharmacol. Ther.</source><year>2010</year><volume>87</volume><fpage>272</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1038/clpt.2009.295</pub-id><?supplied-pmid 20130567?><pub-id pub-id-type="pmid">20130567</pub-id></element-citation></ref><ref id="B285-ijms-19-01578"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiMasi</surname><given-names>J.A.</given-names></name><name><surname>Reichert</surname><given-names>J.M.</given-names></name><name><surname>Feldman</surname><given-names>L.</given-names></name><name><surname>Malins</surname><given-names>A.</given-names></name></person-group><article-title>Clinical approval success rates for investigational cancer drugs</article-title><source>Clin. Pharmacol. Ther.</source><year>2013</year><volume>94</volume><fpage>329</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1038/clpt.2013.117</pub-id><?supplied-pmid 23739536?><pub-id pub-id-type="pmid">23739536</pub-id></element-citation></ref><ref id="B286-ijms-19-01578"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>M.</given-names></name><name><surname>Thomas</surname><given-names>D.W.</given-names></name><name><surname>Craighead</surname><given-names>J.L.</given-names></name><name><surname>Economides</surname><given-names>C.</given-names></name><name><surname>Rosenthal</surname><given-names>J.</given-names></name></person-group><article-title>Clinical development success rates for investigational drugs</article-title><source>Nat. Biotechnol.</source><year>2014</year><volume>32</volume><fpage>40</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/nbt.2786</pub-id><?supplied-pmid 24406927?><pub-id pub-id-type="pmid">24406927</pub-id></element-citation></ref><ref id="B287-ijms-19-01578"><label>287.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Loong</surname><given-names>H.H.</given-names></name><name><surname>Siu</surname><given-names>L.L.</given-names></name></person-group><article-title>Selecting the best drugs for phase I clinical development and beyond</article-title><source>American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting</source><publisher-name>American Society of Clinical Oncology</publisher-name><publisher-loc>Alexandria, VA, USA</publisher-loc><year>2013</year><fpage>469</fpage><lpage>473</lpage></element-citation></ref><ref id="B288-ijms-19-01578"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavan</surname><given-names>S.</given-names></name><name><surname>Nicholls</surname><given-names>I.A.</given-names></name><name><surname>Karlsson</surname><given-names>B.C.</given-names></name><name><surname>Rosengren</surname><given-names>A.M.</given-names></name><name><surname>Ballabio</surname><given-names>D.</given-names></name><name><surname>Consonni</surname><given-names>V.</given-names></name><name><surname>Todeschini</surname><given-names>R.</given-names></name></person-group><article-title>Towards global qsar model building for acute toxicity: Munro database case study</article-title><source>Int. J. Mol. Sci.</source><year>2014</year><volume>15</volume><fpage>18162</fpage><lpage>18174</lpage><pub-id pub-id-type="doi">10.3390/ijms151018162</pub-id><?supplied-pmid 25302621?><pub-id pub-id-type="pmid">25302621</pub-id></element-citation></ref><ref id="B289-ijms-19-01578"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherkasov</surname><given-names>A.</given-names></name><name><surname>Muratov</surname><given-names>E.N.</given-names></name><name><surname>Fourches</surname><given-names>D.</given-names></name><name><surname>Varnek</surname><given-names>A.</given-names></name><name><surname>Baskin</surname><given-names>I.I.</given-names></name><name><surname>Cronin</surname><given-names>M.</given-names></name><name><surname>Dearden</surname><given-names>J.</given-names></name><name><surname>Gramatica</surname><given-names>P.</given-names></name><name><surname>Martin</surname><given-names>Y.C.</given-names></name><name><surname>Todeschini</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Qsar modeling: Where have you been? Where are you going to?</article-title><source>J. Med. Chem.</source><year>2014</year><volume>57</volume><fpage>4977</fpage><lpage>5010</lpage><pub-id pub-id-type="doi">10.1021/jm4004285</pub-id><?supplied-pmid 24351051?><pub-id pub-id-type="pmid">24351051</pub-id></element-citation></ref><ref id="B290-ijms-19-01578"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devillers</surname><given-names>J.</given-names></name></person-group><article-title>Methods for building QSARs</article-title><source>Methods Mol. Biol.</source><year>2013</year><volume>930</volume><fpage>3</fpage><lpage>27</lpage><?supplied-pmid 23086835?><pub-id pub-id-type="pmid">23086835</pub-id></element-citation></ref><ref id="B291-ijms-19-01578"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>K.M.</given-names></name><name><surname>Manuppello</surname><given-names>J.R.</given-names></name><name><surname>Willett</surname><given-names>C.E.</given-names></name></person-group><article-title>Building on a solid foundation: SAR and QSAR as a fundamental strategy to reduce animal testing</article-title><source>SAR QSAR Environ. Res.</source><year>2014</year><volume>25</volume><fpage>357</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1080/1062936X.2014.907203</pub-id><?supplied-pmid 24773450?><pub-id pub-id-type="pmid">24773450</pub-id></element-citation></ref><ref id="B292-ijms-19-01578"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchmair</surname><given-names>J.</given-names></name><name><surname>Goller</surname><given-names>A.H.</given-names></name><name><surname>Lang</surname><given-names>D.</given-names></name><name><surname>Kunze</surname><given-names>J.</given-names></name><name><surname>Testa</surname><given-names>B.</given-names></name><name><surname>Wilson</surname><given-names>I.D.</given-names></name><name><surname>Glen</surname><given-names>R.C.</given-names></name><name><surname>Schneider</surname><given-names>G.</given-names></name></person-group><article-title>Predicting drug metabolism: Experiment and/or computation?</article-title><source>Nat. Rev. Drug Discov.</source><year>2015</year><volume>14</volume><fpage>387</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1038/nrd4581</pub-id><?supplied-pmid 25907346?><pub-id pub-id-type="pmid">25907346</pub-id></element-citation></ref><ref id="B293-ijms-19-01578"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>G.</given-names></name><name><surname>Lal Gupta</surname><given-names>P.</given-names></name><name><surname>Jayaram</surname><given-names>B.</given-names></name></person-group><article-title>Predicting the binding modes and sites of metabolism of xenobiotics</article-title><source>Mol. BioSyst.</source><year>2015</year><volume>11</volume><fpage>1914</fpage><lpage>1924</lpage><pub-id pub-id-type="doi">10.1039/C5MB00118H</pub-id><?supplied-pmid 25913019?><pub-id pub-id-type="pmid">25913019</pub-id></element-citation></ref><ref id="B294-ijms-19-01578"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>X.</given-names></name><name><surname>Min</surname><given-names>J.L.</given-names></name><name><surname>Lin</surname><given-names>W.Z.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Chou</surname><given-names>K.C.</given-names></name></person-group><article-title>Idrug-target: Predicting the interactions between drug compounds and target proteins in cellular networking via benchmark dataset optimization approach</article-title><source>J. Biomol. Struct. Dyn.</source><year>2015</year><volume>33</volume><fpage>2221</fpage><lpage>2233</lpage><pub-id pub-id-type="doi">10.1080/07391102.2014.998710</pub-id><?supplied-pmid 25513722?><pub-id pub-id-type="pmid">25513722</pub-id></element-citation></ref><ref id="B295-ijms-19-01578"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Luo</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Predicting drug side effects by multi-label learning and ensemble learning</article-title><source>BMC Bioinform.</source><year>2015</year><volume>16</volume><elocation-id>365</elocation-id><pub-id pub-id-type="doi">10.1186/s12859-015-0774-y</pub-id><?supplied-pmid 26537615?><pub-id pub-id-type="pmid">26537615</pub-id></element-citation></ref><ref id="B296-ijms-19-01578"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastian</surname><given-names>L.</given-names></name><name><surname>Hof</surname><given-names>J.</given-names></name><name><surname>Pfau</surname><given-names>M.</given-names></name><name><surname>Fichtner</surname><given-names>I.</given-names></name><name><surname>Eckert</surname><given-names>C.</given-names></name><name><surname>Henze</surname><given-names>G.</given-names></name><name><surname>Prada</surname><given-names>J.</given-names></name><name><surname>von Stackelberg</surname><given-names>A.</given-names></name><name><surname>Seeger</surname><given-names>K.</given-names></name><name><surname>Shalapour</surname><given-names>S.</given-names></name></person-group><article-title>Synergistic activity of bortezomib and hdaci in preclinical models of b-cell precursor acute lymphoblastic leukemia via modulation of p53, pi3k/akt, and nf-kappab</article-title><source>Clin. Cancer Res.</source><year>2013</year><volume>19</volume><fpage>1445</fpage><lpage>1457</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-1511</pub-id><?supplied-pmid 23357978?><pub-id pub-id-type="pmid">23357978</pub-id></element-citation></ref><ref id="B297-ijms-19-01578"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanciu-Herrera</surname><given-names>C.</given-names></name><name><surname>Morgan</surname><given-names>C.</given-names></name><name><surname>Herrera</surname><given-names>L.</given-names></name></person-group><article-title>Anti-cd19 and anti-cd22 monoclonal antibodies increase the effectiveness of chemotherapy in pre-b acute lymphoblastic leukemia cell lines</article-title><source>Leukemia Res.</source><year>2008</year><volume>32</volume><fpage>625</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2007.07.002</pub-id><?supplied-pmid 17706771?><pub-id pub-id-type="pmid">17706771</pub-id></element-citation></ref><ref id="B298-ijms-19-01578"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzobo</surname><given-names>K.</given-names></name><name><surname>Senthebane</surname><given-names>D.A.</given-names></name><name><surname>Rowe</surname><given-names>A.</given-names></name><name><surname>Thomford</surname><given-names>N.E.</given-names></name><name><surname>Mwapagha</surname><given-names>L.M.</given-names></name><name><surname>Al-Awwad</surname><given-names>N.</given-names></name><name><surname>Dandara</surname><given-names>C.</given-names></name><name><surname>Parker</surname><given-names>M.I.</given-names></name></person-group><article-title>Cancer stem cell hypothesis for therapeutic innovation in clinical oncology? Taking the root out, not chopping the leaf</article-title><source>Omics</source><year>2016</year><volume>20</volume><fpage>681</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1089/omi.2016.0152</pub-id><?supplied-pmid 27930094?><pub-id pub-id-type="pmid">27930094</pub-id></element-citation></ref><ref id="B299-ijms-19-01578"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzobo</surname><given-names>K.</given-names></name><name><surname>Senthebane</surname><given-names>D.A.</given-names></name><name><surname>Thomford</surname><given-names>N.E.</given-names></name><name><surname>Rowe</surname><given-names>A.</given-names></name><name><surname>Dandara</surname><given-names>C.</given-names></name><name><surname>Parker</surname><given-names>M.I.</given-names></name></person-group><article-title>Not everyone fits the mold: Intratumor and intertumor heterogeneity and innovative cancer drug design and development</article-title><source>Omics</source><year>2018</year><volume>22</volume><fpage>17</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1089/omi.2017.0174</pub-id><?supplied-pmid 29356626?><pub-id pub-id-type="pmid">29356626</pub-id></element-citation></ref><ref id="B300-ijms-19-01578"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baselga</surname><given-names>J.</given-names></name><name><surname>Cortes</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>S.B.</given-names></name><name><surname>Im</surname><given-names>S.A.</given-names></name><name><surname>Hegg</surname><given-names>R.</given-names></name><name><surname>Im</surname><given-names>Y.H.</given-names></name><name><surname>Roman</surname><given-names>L.</given-names></name><name><surname>Pedrini</surname><given-names>J.L.</given-names></name><name><surname>Pienkowski</surname><given-names>T.</given-names></name><name><surname>Knott</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer</article-title><source>N. Engl. J. Med.</source><year>2012</year><volume>366</volume><fpage>109</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1113216</pub-id><?supplied-pmid 22149875?><pub-id pub-id-type="pmid">22149875</pub-id></element-citation></ref><ref id="B301-ijms-19-01578"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawajiri</surname><given-names>H.</given-names></name><name><surname>Takashima</surname><given-names>T.</given-names></name><name><surname>Kashiwagi</surname><given-names>S.</given-names></name><name><surname>Noda</surname><given-names>S.</given-names></name><name><surname>Onoda</surname><given-names>N.</given-names></name><name><surname>Hirakawa</surname><given-names>K.</given-names></name></person-group><article-title>Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer</article-title><source>Expert Rev. Anticancer Ther.</source><year>2015</year><volume>15</volume><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1586/14737140.2015.992418</pub-id><?supplied-pmid 25494663?><pub-id pub-id-type="pmid">25494663</pub-id></element-citation></ref><ref id="B302-ijms-19-01578"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swain</surname><given-names>S.M.</given-names></name><name><surname>Baselga</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>S.B.</given-names></name><name><surname>Ro</surname><given-names>J.</given-names></name><name><surname>Semiglazov</surname><given-names>V.</given-names></name><name><surname>Campone</surname><given-names>M.</given-names></name><name><surname>Ciruelos</surname><given-names>E.</given-names></name><name><surname>Ferrero</surname><given-names>J.M.</given-names></name><name><surname>Schneeweiss</surname><given-names>A.</given-names></name><name><surname>Heeson</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>724</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1413513</pub-id><?supplied-pmid 25693012?><pub-id pub-id-type="pmid">25693012</pub-id></element-citation></ref><ref id="B303-ijms-19-01578"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swain</surname><given-names>S.M.</given-names></name><name><surname>Baselga</surname><given-names>J.</given-names></name><name><surname>Miles</surname><given-names>D.</given-names></name><name><surname>Im</surname><given-names>Y.H.</given-names></name><name><surname>Quah</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>L.F.</given-names></name><name><surname>Cortes</surname><given-names>J.</given-names></name></person-group><article-title>Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: Results from the randomized phase iii study cleopatra</article-title><source>Ann. Oncol.</source><year>2014</year><volume>25</volume><fpage>1116</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu133</pub-id><?supplied-pmid 24685829?><pub-id pub-id-type="pmid">24685829</pub-id></element-citation></ref><ref id="B304-ijms-19-01578"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swain</surname><given-names>S.M.</given-names></name><name><surname>Kim</surname><given-names>S.B.</given-names></name><name><surname>Cortes</surname><given-names>J.</given-names></name><name><surname>Ro</surname><given-names>J.</given-names></name><name><surname>Semiglazov</surname><given-names>V.</given-names></name><name><surname>Campone</surname><given-names>M.</given-names></name><name><surname>Ciruelos</surname><given-names>E.</given-names></name><name><surname>Ferrero</surname><given-names>J.M.</given-names></name><name><surname>Schneeweiss</surname><given-names>A.</given-names></name><name><surname>Knott</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (cleopatra study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study</article-title><source>Lancet Oncol.</source><year>2013</year><volume>14</volume><fpage>461</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70130-X</pub-id><pub-id pub-id-type="pmid">23602601</pub-id></element-citation></ref><ref id="B305-ijms-19-01578"><label>305.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Academy of Sciences (US)</collab></person-group><article-title>The national academies collection: Reports funded by national institutes of health</article-title><source>Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease</source><publisher-name>National Academies Press (US), National Academy of Sciences</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2011</year></element-citation></ref><ref id="B306-ijms-19-01578"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debouck</surname><given-names>C.</given-names></name></person-group><article-title>Integrating genomics across drug discovery and development</article-title><source>Toxicol. Lett.</source><year>2009</year><volume>186</volume><fpage>9</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2008.09.011</pub-id><?supplied-pmid 18930125?><pub-id pub-id-type="pmid">18930125</pub-id></element-citation></ref><ref id="B307-ijms-19-01578"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debouck</surname><given-names>C.</given-names></name><name><surname>Metcalf</surname><given-names>B.</given-names></name></person-group><article-title>The impact of genomics on drug discovery</article-title><source>Ann. Rev. Pharmacol. Toxicol.</source><year>2000</year><volume>40</volume><fpage>193</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.40.1.193</pub-id><?supplied-pmid 10836133?><pub-id pub-id-type="pmid">10836133</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-19-01578-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Two examples of successful stories of plant natural products that are being used in hospitals and clinics for disease treatment. (<bold>A</bold>) Morphine is isolated from <italic>Papaver somniferum</italic> also called opium poppy (<bold>B</bold>) Paclitaxel is isolated from <italic>Taxus brevifolia</italic> also called pacific yew. (Images credit: <uri xlink:href="https://en.wikipedia.org/wiki">https://en.wikipedia.org/wiki</uri>).</p></caption><graphic xlink:href="ijms-19-01578-g001"/></fig><fig id="ijms-19-01578-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Innovative technologies for natural product drug discovery. Application of these technologies can potentially lead to novel drug candidates from natural products.</p></caption><graphic xlink:href="ijms-19-01578-g002"/></fig><fig id="ijms-19-01578-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Exploiting the properties of plant extracts in the development of novel medicines inspired by compounds found in medicinal plant extracts.</p></caption><graphic xlink:href="ijms-19-01578-g003"/></fig><fig id="ijms-19-01578-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Precision therapies in oncology can be designed to only affect cancer cells. Biomarkers can be identified through next generation sequencing, gene expression profiling and proteomics. Drivers and regulators of important pathways involved in cancer cell proliferation, survival and chemoresistance can be identified. Only with this knowledge can the development of novel drugs be achieved.</p></caption><graphic xlink:href="ijms-19-01578-g004"/></fig></floats-group></article>